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Abstract 
 
Mycobacterium tuberculosis stably adapts to respiratory limited environments by 
entering into a nongrowing but metabolically active state termed quiescence. 
This state is inherently tolerant to antibiotics due to a reduction in growth and 
activity of associated biosynthetic pathways. Understanding the physiology of the 
quiescent state, therefore, may be useful in developing new strategies to improve 
drug efficiency. Here, we used an established in vitro model of respiratory stress, 
hypoxia, to induce quiescence. We utilized metabolomic and genetic approaches 
to identify essential and active pathways associated with nongrowth. Our 
metabolomic profile of hypoxic M. tuberculosis revealed an increase in several 
free fatty acids, metabolite intermediates in the oxidative pathway of the 
tricarboxylic acid (TCA) cycle, as well as, the important chemical messenger, 
cAMP. In tandem, a high-throughput transposon mutant library screen (TnSeq) 
revealed that a cAMP-regulated protein acetyltransferase, MtPat, was 
conditionally essential for survival in the hypoxic state. Via 13C-carbon flux tracing 
we show an MtPat mutant is deficient in re-routing hypoxic metabolism away 
from the oxidative TCA cycle and that MtPat is involved in inhibiting fatty-acid 
catabolism in hypoxia. Additionally, we show that reductive TCA metabolism is 
required for survival of hypoxia by depletion of an essential TCA enzyme, malate 
dehydrogenase (Mdh) both in in vitro hypoxia and in vivo mouse infection. 
  vi 
Inhibition of Mdh with a novel compound resulted in a significantly greater killing 
efficiency than the first-line anti-M. tuberculosis drug isoniazid (INH). In 
conclusion, we show that understanding the physiology of the quiescent state 
can lead to new drug targets for M. tuberculosis. 
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All microorganisms are exposed to periodic stresses that inhibit growth. Many 
bacteria and fungi weather these periods by entering a hardy, nonreplicating 
state, often termed quiescence or dormancy. When this occurs during an 
infection, the resulting slowly growing pathogen is able to tolerate both immune 
insults and prolonged antibiotic exposure. While the stresses encountered in a 
free-living environment may differ from those imposed by host immunity, these 
growth-limiting conditions impose common pressures, and many of the 
corresponding microbial responses appear to be universal. In this review, we 
discuss the common features of these growth-limited states, which suggest new 
approaches for treating chronic infections such as tuberculosis.  




A defining feature of Mycobacterium tuberculosis, the causative agent of 
tuberculosis, is its slow growth. The maximal doubling time of this bacterium is 
approximately 20 hours and is significantly slower when exposed to stresses 
such as those encountered in the host. Indeed, the bacterial population found in 
chronically infected animals replicates only once every 100 hours or more (Gill et 
al., 2009; Muñoz-Elías et al., 2005), and subpopulations of bacteria are thought 
to cease growth entirely for significant periods. The importance of this relatively 
quiescent behavior is difficult to overstate, as it likely underlies the chronicity of 
the infection as well as the requirement for extended antibiotic therapy.  
Dormancy, latency, and persistence are conceptually related terms used to 
describe the propensity of M. tuberculosis to arrest its growth in response to 
host-imposed stress. Because this behavior is very different from well-studied 
model organisms or agents of acute infection, it is sometimes considered an 
unusual selective adaptation specific to the pathogenic mycobacteria. While this 
trait is likely adaptive, it is by no means unusual. In fact, slow to negligible 
replication is the norm in the microbial world, where organisms often inhabit 
environments that are incompatible with rapid growth. In this review, we will 
consider mycobacterial dormancy in this broader ecological context.  
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Three Strategies to Weather the Storm  
 
All microbes are subjected to changing environments, and the basic 
requirements for growth (carbon, nitrogen, phosphorus, water, etc.) are not 
always available. The evolutionary success of virtually all microbial species 
requires the ability to weather these periods, and the spectrum of survival 
strategies used by different microbial species has been studied for decades 
(Steinhaus and Birkeland, 1939). In general, these strategies can be described 
as variations of three general themes (Figure 1.1).  
Bust and Boom  
 
The physiology of organisms that evolved in consistently nutrient-rich 
environments, such as the bacteria Escherichia coli, are tuned to maximize 
growth rate (Neidhardt, 1999). Under nutrient-replete conditions in which 
bacterial metabolism is often studied, these organisms maximize their growth at 
the expense of economy by using relatively inefficient fermentative pathways to 
generate energy (Wolfe, 2005). Upon nutrient exhaustion the majority of these 
bacterial populations die, leaving a few viable organisms that subsist on the 
corpses of their siblings. Slow growth and cell death are balanced during this 
period (Finkel, 2006). When environmental conditions become more favorable, 
the few survivors resume growth. The ability to replicate rapidly is likely to be an 
essential component of this strategy, as these organisms must outcompete 
neighboring microbes to consume the newly introduced nutrients.  
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Figure 1.1. Strategies to Overcome Growth-Limiting Stress  
 
All microorganisms encounter periods during which growth is impossible. 
Three fundamental themes describe the strategies used to weather these 
periods. ‘‘Bust and boom’’ describes a strategy that relies on the dynamic 
persistence of a small subpopulation, ‘‘sporulation’’ is defined by the 
production of metabolically inactive spores, and ‘‘quiescence’’ describes a 
metabolically active nonreplicating cell that is resistant to many environmental 
insults. These strategies differ in several important respects including the 
population density of persistent organisms, the sensitivity of these cells to 
toxins and antibiotics, and the differential dependence on rapid growth to 
repopulate the niche.  
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A distinct strategy for surviving periods of growth-limiting stress appears to be 
favored by both M. tuberculosis (Betts et al., 2002; Mitchison and Coates, 2004; 
Wayne, 1976) and many environmental bacteria (Lewis and Gattie, 1991). When 
these organisms are exposed to growth-limiting stress, the bulk of the bacterial 
population slows or arrests its growth and can persist in a viable nonreplicating 
state for months or even years (Corper and Cohn, 1933). These ‘‘quiescent’’ cells 
can be differentiated from truly dormant spore-like forms because they display 
nominal metabolic capacity, maintain their membrane potential, and do not 
undergo obvious morphological differentiation (Gengenbacher et al., 2010; Rao 
et al., 2008). This strategy allows the viable bacterial population size to be 
maintained throughout the period of stress (Jones and Lennon, 2010), relieving 
the emphasis for rapid growth seen in the bust-and-boom model.  
True Dormancy  
 
Sporulation is the purest form of microbial dormancy. When exposed to growth-
restricting stress, some bacteria undergo an asymmetric cell division to produce 
a hardy metabolically inactive daughter cell called a spore (Stragier and Losick, 
1996). Upon exposure to favorable environmental conditions, a fraction of spores 
germinate and initiate rapid growth to reestablish the population. This strategy 
could be viewed as a combination of the first two. The spore, while fundamentally 
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distinct, shares many structural and biochemical features with quiescent cells, 
which promote long-term survival. Upon germination, however, rapid growth may 
be advantageous to repopulate the niche. Indeed, the 10 min replication time of 
some spore-forming species of the clostridia bacteria are among the fastest 
known (Kreidl et al., 2002).  
Historically, the strategies at either end of this spectrum have been most heavily 
studied. This is due to the experimental tractability of rapidly growing organisms, 
not because these strategies are more common or important. Indeed, it has been 
estimated that 60% of the microbial biomass on earth exists in a quiescent state 
(Cole, 1999; Lewis and Gattie, 1991). Despite its ubiquity, we still know relatively 
little about the regulatory mechanisms and physiological changes that define 
microbial quiescence. While these cellular adaptations are not exactly the same 
for all organisms or under all conditions, common themes can be defined (Figure 
1-2). In this review, we will consider the general adaptations that are required for 
quiescence in diverse microorganisms and discuss how these insights might be 
used to develop more effective therapies for chronic infections such as 
tuberculosis.  
Common Features of Quiescent Cells  
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Figure 1.2. Common Themes in Microbial Quiescence  
 
Growth arrest can be induced by many stimuli and can have a variety of 
consequences on the cell. Shown are common growth-limiting stresses 
encountered by environmental microbes and pathogens. With a few notable 
exceptions, most of the growth-limiting stresses encountered in these envi- 
ronments are similar. Some responses to these insults are linked to a 
particular stress. For example, specific DNA repair pathways are necessary to 
resist oxidative and nitrosative stress, and the remodeling of carbon 
metabolism will be different in hypoxic versus normoxic conditions. In contrast, 
other re- sponses appear to be secondary to growth arrest per se. For 
example, a wide variety of growth-inhibiting stresses trigger carbon storage 
and cell wall re- modeling, and the maintenance of energy homeostasis is 
universally required for viability. PMF, proton motive force; ROS, reactive 
oxygen species; RNI, reactive nitrogen intermediate.  
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Carbon Storage  
 
An almost universal property of quiescent cells is the accumulation of carbon 
stores, although the chemical structure of the storage form can differ. During low 
growth states, the yeast Saccharomyces cerevisiae accumulates glycogen, 
trehalose, and triglycerides as the main forms of metabolizable carbon (Gray et 
al., 2004). The bacterial pathogen Vibrio cholerae accumulates glycogen in 
preparation for survival in nutrient-poor environments (Bourassa and Camilli, 
2009). Additionally, many bacteria store fatty acids in the form of triglycerides 
(Daniel et al., 2004; Kalscheuer et al., 2007) and wax esters (Sirakova et al., 
2012). Both triglycerides and wax esters also accumulate in plant seeds (Radunz 
and Schmid, 2000), indicating that this mode of storage is advantageous for 
organisms that represent vastly separated domains of life. In addition, linear 
plastic polymers like polyhydroxyalkanoates and poly-b-hydroxybutyric acid can 
serve as a carbon repository in a variety of bacteria living in the soil and the 
rhizosphere (Kadouri et al., 2005).  
What is the purpose of carbon storage? The most intuitive answer is that these 
cells are simply ‘‘storing nuts for winter,’’ and these nutritional stores can be 
rapidly mobilized to fuel growth when environmental conditions improve. This role 
has been most clearly demonstrated in the S. cerevisiae cell, where the trehalose 
stores that accumulate in stationary cultures are immediately consumed upon 
addition of fresh media to fuel rapid regrowth (Shi et al., 2010). Glycogen may 
serve a similar role in V. cholerae, a bacterium whose life cycle relies on periodic 
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switches from the nutrient-replete mammalian gut to nutrient- poor aquatic 
environments (Bourassa and Camilli, 2009).  
Carbon storage has also been found to play an important role in remodeling 
cellular carbon fluxes and facilitating entry into the quiescent state. Diverse 
stresses, such as low oxygen, low pH, or low iron, all induce a storage response 
in M. tuberculosis through the activation of a common sensor-kinase system, 
DosRST (Bacon et al., 2007; Baek et al., 2011; Daniel et al., 2011). The DosS 
sensor likely responds to alterations in cellular redox state in these contexts 
(Honaker et al., 2010), and triggers the synthesis of triglycerides that are stored 
in large cytosolic inclusions (Garton et al., 2002). The impact of this response 
appears to extend beyond the generation of nutrient stores. That is, disruption of 
the triglyceride biosynthesis pathway in M. tuberculosis reverses the growth 
arrest that is normally caused by these stresses, but has little effect on the 
subsequent recovery of growth when the stress is relieved (Baek et al., 2011). 
This inverse relationship between growth and triglyceride production appears to 
result from the redirection of acetyl-CoA from the TCA cycle, where it is used to 
generate energy during aerobic respiration, into lipid synthesis, where acetyl CoA 
serves as a building block for fatty acids. The growth-limiting effect of carbon 
storage is unlikely to be restricted to mycobacteria. For example, S. cerevisiae 
mutants that are unable to produce glycogen or trehalose consume more CO2 
than the wild-type strain during slow growth (Silljé et al., 1999), indicating higher 
TCA flux in the absence of carbon storage. The almost universal propensity of 
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microorganisms to accumulate acetyl CoA-derived carbon stores under growth-
limiting stresses suggests that this may represent a common strategy for 
reducing growth and metabolic rate.  
Cell Wall Modification  
 
Virtually all bacteria are surrounded by an elastic meshwork of peptidoglycan that 
maintains cellular integrity under changing environmental conditions. This 
structure is composed of glycan chains, consisting of N-acetylglucosamine 
(NAG) and N-acetyl-muramic acid (NAM), crosslinked through short peptide 
moieties. Not surprisingly, the long-term survival of both spores and quiescent 
cells depends on specific alterations in the composition of this structure. For 
example, in stationary phase cultures, the Gram-positive bacteria 
Staphylococcus aureus generates a cell wall that is structurally different from the 
peptidoglycan found during exponential phase growth, in that it contains fewer 
pentaglycine bridges, which crosslink the glycan chains, and is significantly 
thicker (Zhou and Cegelski, 2012). Similarly, the level and gradient of 
crosslinking are important for the formation of bacterial spores. In the spore 
peptidoglycan layer of the soil-dwelling bacteria Bacillus subtilis, the peptide side 
chains serving as crosslinkers are completely or partially removed from the NAM 
residues and replaced by muramic-d-lactam, a specificity determinant for 
germination autolytic enzymes, at every second NAM position in the cortex 
glycan strands. As a consequence, overall levels of crosslinking are markedly 
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decreased in the spore cortex as compared to the vegetative cell wall (Atrih et 
al., 1996). Thus, common features of the peptidoglycan in both quiescent cells 
and spores are reduced crosslinks and increased peptidoglycan mass.  
The regulation of these modifications is likely complex, but recent observations 
suggest that extracellular D-amino acids, such as D-methionine and D-leucine, 
could play an important role. D-amino acids accumulate to millimolar levels in the 
supernatants of stationary phase bacterial culture, where they regulate cell wall 
synthetic enzymes and are incorporated into the peptidoglycan polymer. The 
increased abundance of D-amino acids in cultures of nongrowing cells and their 
ability to alter the osmotic sensitivity of V. cholerae (Lam et al., 2009) suggests a 
likely role in remodeling the cell wall for quiescence.  
Like many other bacteria, M. tuberculosis may vary the cross- linking of its 
peptidoglycan in slow growth states (Lavollay et al., 2008). During exponential 
growth, M. tuberculosis peptidoglycan is cross-linked largely via linkages 
between the third and fourth amino acids in the stem peptide, the chain of amino 
acids in peptidoglycan that crosslinks adjacent strands (i.e., 4/3 linkages). 
However, in stationary phase the cell wall primarily consists of 3/3 crosslinks. 
While not all investigators have observed these changes (Kumar et al., 2012), 
altered crosslinking could significantly change the physical characteristics of the 
cell wall. In addition, 3/3 crosslinks are made by transpeptidases that are 
insensitive to b-lactam antibiotics that inhibit cell wall synthesis, suggesting the 
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reduction in 4/3 linkages may reduce antibiotic susceptibility. Indeed, when the 
L,D-transpeptidase (MT2594/Rv2518c) responsible for making the 3/3 link- ages 
in M. tuberculosis was inactivated, the bacteria became more susceptible to the 
b-lactam antibiotic amoxicillin, and persistence in animals was attenuated (Gupta 
et al., 2010).  
The mycobacterial cell wall is much more complex than those surrounding the 
organisms discussed above, and the full complement of alterations that 
accompany quiescence have yet to be defined. Mycobacterial peptidoglycan is 
conjugated to an additional glycan layer and finally to a functional outer 
membrane composed of very long chain fatty acids called mycolic acids. 
Surrounding this hydrophobic layer is a capsule that is largely comprised of the 
polysaccharide α-glucan. Thickening of the mycobacterial cell wall upon hypoxia-
induced stasis was first demonstrated more than 30 years ago (Wayne, 1976). 
More recently, a computational model of the M. tuberculosis response to hypoxia 
was used to predict a large increase in production of cell wall components like 
mycolic acids and peptidoglycan (Fang et al., 2012). This prediction is consistent 
with electron microscopy studies that demonstrate thickening of the outer mycolic 
acid and/or capsule layers of the cell wall (Cunningham and Spreadbury, 1998). 
A major physiological outcome of these changes is decreased permeability of the 
cell wall, and the uptake of several classes of antibiotics into quiescent M. 
tuberculosis is significantly decreased relative to replicating cells (Sarathy et al., 
2013).  
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In addition to its structural roles, cell wall metabolism also appears to play an 
important role in generating signals that regulate the germination of spores and 
the exit from quiescence. In B. subtilis, the PrkC Ser/Thr kinase responds to the 
presence of extracellular peptidoglycan fragments and induces spore 
germination (Shah et al., 2008). These fragments are released by growing cells, 
providing a mechanism by which the spore can sense the presence of a 
favorable growth environment using cues from neighboring bacteria. M. 
tuberculosis expresses a similar Ser/Thr kinase, PknB, which is also capable of 
binding extracellular peptidoglycan fragments (Mir et al., 2011) and regulates cell 
wall synthesis and growth (Gee et al., 2012). Activation of this kinase could 
explain the ability of spent culture medium to promote the regrowth of quiescent 
mycobacteria, as this activity depends on secreted lysozyme-like proteins 
(Mukamolova et al., 1998) that could act by liberating peptidoglycan-derived 
PknB ligands.  
Macromolecular Synthesis and Stability  
 
It may seem intuitive that RNA and protein synthesis will proceed at negligible 
rates in the quiescent cell. However, the dynamics of macromolecular synthesis 
are more complicated than they appear and vary during the entry, maintenance, 
and exit from quiescence. During entry and exit, protein synthesis accelerates. 
Protein turnover increases 5-fold in famished E. coli cells due to proteases that 
are produced in early stationary phase. This enhanced protein turnover during 
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the transition to the growth- limited state facilitates de novo protein synthesis in 
the absence of an exogenous carbon source (Shaikh et al., 2010), and the 
required amino acids are provided by peptidase-dependent autophagy, in which 
amino acids are produced via protein hydrolysis and degradation (Reeve et al., 
1984). Similarly, increased protein turnover may also be required for exiting the 
quiescent state. Regrowth of M. tuberculosis from hypoxia- induced stasis is 
accompanied by an increase of the ClgR regulatory protein, which induces 
expression of the ClpXP protease that uses ATP hydrolysis to unfold proteins for 
subsequent degradation (Sherrid et al., 2010). Here, increased protein turn- over 
is a likely indicator of the wholesale metabolic remodeling necessary to shift 
between growth states.  
Once quiescence is established, however, it is reasonable to assume that the 
synthesis of RNA and protein will slow considerably. Indeed, quiescence in S. 
cerevisiae is accompanied by a 3- to 5-fold decrease in overall transcription rate 
(Choder, 1991), and a 20-fold decrease in protein synthesis (Fuge et al., 1994). 
The mechanisms underlying the reduction of macromolecular synthesis in slowly 
growing E. coli have been explored in great detail. While the rate of nascent RNA 
and polypeptide chain elongation remains relatively constant, the number of 
synthetic sites decreases (Pedersen, 1986). As approximately half of the mass of 
the rapidly growing E. coli cell is comprised of protein synthesis machinery, the 
economy realized by this strategy is evident (Neidhardt, 1999). The same 
analysis has not been performed on nonreplicating cells, and it remains likely that 
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both initiation and elongation rate slow. This could be the result of specific 
regulatory systems, such as the stringent response, which controls ribosomal 
RNA transcription during stress (Stallings et al., 2009), and is critical for M. 
tuberculosis survival in both hypoxia- and starvation-induced stasis (Primm et al., 
2000). In addition, low levels of nucleotide triphosphates and amino acids could 
nonspecifically limit elongation rate. This would be consistent with the proposed 
mechanism by which the drug pyrazinamide kills nonreplicating M. tuberculosis 
by inhibiting trans-translation, a mechanism for recycling stalled ribosomes (Shi 
et al., 2011).  
The apparent reduction in RNA synthesis upon mycobacterial entry into 
quiescence is coupled to a 15-fold increase in mRNA stability (Rustad et al., 
2013), and these stable mRNAs are required to sustain pools of essential 
proteins (Rao and Li, 2009). This phenomenon is not unique to mycobacteria. In 
both S. aureus and S. cerevisiae, mRNA transcripts are globally stabilized in 
response to stationary phase and stress (Anderson et al., 2006; Jona et al., 
2000). In addition, slow growth induces the preferential stabilization of a set of 
transcripts in E. coli (Georgellis et al., 1993), indicating that survival requires the 
continual synthesis of select proteins. In support of this model, studies have 
shown that stationary phase E. coli requires the continual expression of a subset 
of genes that are controlled by the σS subunit of the RNA polymerase, including 
many genes involved in cellular stress responses (Talukder et al., 1996). 
Additionally, a subset of mRNAs is strongly induced in quiescent S. cerevisiae 
  33 
(Werner-Washburne et al., 1996). In sum, while the rate of macromolecular 
synthesis clearly decreases in quiescent cells, continual transcription and 
translation occurs. The ability of RNA polymerase and DNA gyrase inhibitors to 
kill non- replicating mycobacteria indicates that these activities may also be 
required for survival (Betts et al., 2002; Sala et al., 2010). Energetics and 
Metabolism during Quiescence Maintenance of membrane potential and ATP 
synthesis is not required for sustaining the viability of spores, even though a 
repertoire of ATPases and ATP-dependent regulatory proteins is utilized during 
the initiation of germination (Errington, 2003). In contrast, quiescent bacteria 
maintain their membrane potential (Pernthaler and Amann, 2004; Rao et al., 
2008), and energy homeostasis appears to be critical for survival. In 
nonreplicating M. tuberculosis cells starved for oxygen or nutrients, ATP levels 
are maintained at a steady level, which is only 5-fold lower than replicating cells 
(Gengenbacher et al., 2010; Rao et al., 2008). This maintenance of ATP 
homeostasis is clearly important, as disruption of the proton motive force or 
chemical inhibition of the F0F1 ATP synthase involved in ATP synthesis induces 
cell death in nutrient-starved or hypoxic cultures (Rao et al., 2008; Sala et al., 
2010). Diverse strategies can be used to maintain energy homeostasis. Both 
respiratory and fermentative path- ways can support the long-term survival of 
bacteria in stationary phase (Duwat et al., 2001). Similarly, M. tuberculosis 
harbors a number of respiratory systems utilizing both oxygen and nitrate as 
terminal electron acceptors (Boshoff and Barry, 2005). When respiration is not 
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possible, recent data suggest that fermentation can lead to succinate secretion, 
which plays an important role in maintaining membrane potential (Watanabe et 
al., 2011; Eoh and Rhee, 2013). This general strategy is used by a number of 
Gram-positive and Gram-negative organisms under respiration-limited conditions 
(Engel et al., 1994; Schnorpfeil et al., 2001).  
While the overall rate of carbon utilization decreases in quiescence, a few 
metabolic pathways display enhanced flux (Sauer et al., 1999; Zhang et al., 
2009). The specific pathways used to maintain the quiescent cell are diverse, 
and their relative importance depends on the peculiarities of both the organism 
and the environment. However, common themes have emerged, such as a 
central role for the glyoxylate shunt in adapting to the growth- limited state. This 
pathway consists of isocitrate lyase and malate synthase and is responsible for 
the conversion of isocitrate and acetyl-CoA into malate and succinate. This 
bypasses a segment of the TCA cycle that is normally siphoned to produce 
biosynthetic precursors. While initially considered simply as an anapleurotic 
system that is used to replenish TCA intermediates during growth on 
nonglycolytic carbon sources such as lipids (Muñoz-Elías and McKinney, 2005), 
recent studies indicate that these reactions are an essential component of 
metabolic cycles that sustain diverse bacterial species in slowly growing states. 
The glyoxylate shunt is an essential component of the phosphoenolpyruvate-
glyoxylate cycle in E. coli (Fischer and Sauer, 2003) and the ‘‘GAS’’ pathway in 
mycobacteria (Beste et al., 2011). These pathways are important for the 
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utilization of glucose, in contrast to the canonical role for the glyoxylate shunt in 
lipid catabolism. In both cases, these cycles are used to uncouple glucose 
oxidation from the production of reducing equivalents, and may function to 
maintain the redox state of the cytosol. In the mycobacterial case, inhibition of 
isocitrate lyase causes cell death in both hypoxia- and starvation-induced 
quiescence, supporting the importance of these pathways in nongrowing states 
(Gengenbacher et al., 2010; Eoh and Rhee, 2013).  
Preservation of Genome Integrity  
 
Maintaining genome fidelity when little or no metabolic capacity is available for 
canonical DNA repair mechanisms is a challenge faced by both quiescent cells 
and dormant spores. One strategy common to both types of cells is altering 
chromosomal structure to a more chemically stable form. The chromosome of 
stationary phase E. coli assumes an extremely compact structure. A nucleoid-
associated protein called Dps, which is expressed only in stationary phase, 
mediates biocrystallization of the nucleoid and protects DNA from damage 
(Martinez and Kolter, 1997). This compaction of DNA can be very dynamic as 
bacteria enter and exit different growth states. In the photosynthetic 
cyanobacterium, Synechococcus elongates, a circadian clock- controlled 
mechanism induces periodic chromosome compaction during the night (Smith 
and Williams, 2006), and the resulting alterations in DNA supercoiling control 
global gene expression patterns (Vijayan et al., 2009). M. tuberculosis might use 
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a similar mechanism to protect its chromosome. A mycobacterial histone-like 
protein, Lsr2, mediates chromosome compaction and protection from reactive 
oxygen and nitrogen species (Summers et al., 2012). The mechanisms 
underlying this protective ability are unclear but could be related to the reported 
association between Lsr2 and a FAD-binding flavoprotein that mediates general 
oxidative stress resistance (Du et al., 2012). The compact packaging of bacterial 
DNA can be also facilitated by cationic metabolites, such as polyamines, which 
have been implicated in the protection of DNA from chemical damage (Baeza et 
al., 1991). M. tuberculosis synthesizes a repertoire of polyamines that facilitate 
transcription and DNA replication (Marton and Pegg, 1995), although the roles of 
these compounds during cellular quiescence remain unknown.  
Truly dormant spores are not able to actively maintain their chromosome but 
depend on the induction of DNA repair systems upon exit from the dormant state. 
While the nominal metabolic capacity of the quiescent cell likely allows a subset 
of DNA repair mechanisms to operate continuously, the relative activity of 
different systems in growing and nongrowing states remains uncertain, and 
distinct organisms favor different strategies. Some microorganisms arrest growth 
with a single chromosome (Valcourt et al., 2012), while others, such as M. 
tuberculosis, exits the cell cycle with two chromosomal copies (Wayne, 1977). 
Thus, high-fidelity recombinational repair mechanisms, which often dominate in 
growing cells, are only available to a subset of quiescent organisms. Despite the 
apparent presence of a recombinational template in nonreplicating M. 
  37 
tuberculosis, this organism still appears to utilize more error-prone repair 
systems. For example, error-prone translesion polymerases, which replicate past 
DNA damage lesions, are important for the survival of slowly growing M. 
tuberculosis in chronically infected animals (Boshoff et al., 2003). Similarly, 
mycobacteria rely on nonhomologous end-joining (NHEJ), in which double strand 
breaks are imprecisely rejoined, to repair double-stranded breaks in quiescent 
states (Shuman and Glickman, 2007). The use of the low- fidelity NHEJ system 
under these conditions could be due to its dependence on ribonucleotides as 
opposed to deoxyribonucleotide triphosphates, which may be limiting in 
nonreplicating cells (Gong et al., 2005).  
The particular DNA repair pathways used by quiescent organ- isms have 
significant implications for genome evolution. While the mutation rate of rapidly 
growing organisms is largely deter- mined by the error rate of the replisome 
(Kunkel, 2004), the fidelity of DNA repair systems might dominate in organisms 
that spend a significant portion of their existence in slowly growing states. 
Consistent with this model, it was recently estimated that the M. tuberculosis 
genome accumulates mutations at a similar rate in active and latent infection 
states (Ford et al., 2011), and mutations accumulate in a time-dependent and not 
replication-dependent manner (Ford et al., 2013). As drug resistance in M. 
tuberculosis is the product of spontaneous mutation, the specific DNA repair 
pathways that are operational in the quiescent state could determine the rate at 
which resistance emerges.  
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Strategies to Eradicate Quiescent Bacteria  
 
Arguably, the most important factor limiting tuberculosis control efforts is the 
exceptionally long treatment course that is required to prevent relapse. While the 
standard regimen of antitubercular drugs rapidly kills replicating bacteria in vitro, 
the same drugs must be administered for at least 6 months to effectively treat an 
active TB infection. The reduced activity of antibiotics in the in vivo environment 
is not specific to mycobacteria and is often attributed to slowly replicating or 
quiescent populations of the pathogen (Eagle, 1952; McDermott, 1958). The 
antibiotic sensitivity of quiescent bacterial populations has been investigated 
extensively in the context of environmentally induced stasis in M. tuberculosis 
(Mitchison and Coates, 2004; Rao et al., 2008; Xie et al., 2005), drug-tolerant 
populations found in biofilms (Brown et al.,1988), and nonreplicating ‘‘persister’’ 
subpopulations that exist even in rapidly growing cultures (Balaban et al., 2004). 
In all situations, quiescent bacterial populations are less sensitive to existing 
antibiotics that target functions necessary for cell growth. In principle, the 
identification of cellular functions that are important for the regulation or 
maintenance of quiescence should suggest new strategies for eliminating 
nonreplicating bacterial populations and could be used to accelerate the 
treatment of chronic infections. The following three general approaches have 
been pursued to this end.  
Inhibit Pathways that Are Essential in the Quiescent State 
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In the case of M. tuberculosis there is an anecdotal correlation between drugs 
that retain activity against nonreplicating cells in vitro and those that have the 
strongest sterilizing activity in vivo (Mitchison and Coates, 2004), although this 
correlation is not absolute. As a result, new drug candidates are generally tested 
for their ability to kill quiescent bacteria. Among the several new regimens under 
development, a combination that includes drugs retaining activity against 
nonreplicating cells, bedaquiline, PA-824, and moxifloxacin, showed the highest 
early bactericidal activity in a recent human trial (Diacon et al., 2012). While none 
of these drugs were developed specifically to kill in a growth rate- independent 
manner, all three might have been predicted to have this ability based on their 
mechanism of action. Bedaquiline inhibits the F0F1 ATP synthase, a function 
required for energy maintenance (Andries et al., 2005), PA-824 is a 
nitroimidazole that kills via nonspecific nitrosative (nitrogen radical-mediated) 
damage (Singh et al., 2008), and moxifloxacin produces DNA breaks at sites of 
ongoing transcription (Drlica et al., 2008). These observations suggest that 
specifically targeting other functions necessary for survival, such as those 
maintaining carbon flux, energy generation, or redox maintenance, might 
represent a productive strategy to produce more effective therapies (Table 1). 
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Table 1.1. Strategies to Eradicate Quiescent Bacterial Populations 
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Sensitize the Quiescent Cell to Existing Antibiotics 
 
 
As an alternative to targeting what is likely a restricted set of pathways that are 
necessary for maintaining viability in the absence of replication, it may also be 
possible to alter the physiology of the quiescent cell to render it more antibiotic 
susceptible. Two recent studies have focused on increasing antibiotic activity by 
altering flux through central carbon metabolism. In M. tuberculosis, antibiotic 
efficacy is reduced as a result of carbon storage responses that lower TCA flux. 
Genetic mutations or nutritional supplements that inhibit triglyceride production, 
and thus drive activity of the TCA cycle, or directly enhance TCA flux were found 
to enhance antibiotic activity in quiescent cells in vitro and in animal models 
(Baek et al., 2011). A similar approach for enhancing TCA-dependent antibiotic 
activity by metabolite supplementation was subsequently found to enhance 
aminoglycoside activity in E. coli and S. aureus (Allison et al., 2011). Another 
promising approach is inhibiting the stringent response. This system coordinates 
cellular physiology during slow growth states in many bacteria, and genetic 
inhibition of the stringent response sensitizes Pseudomonas aeruginosa biofilms 
to antibiotics (Nguyen et al., 2011). While metabolite supplementation might not 
be practical for many infections of the deep tissues, and small molecule 
modulators of these pathways are not currently avail- able, these studies provide 
proof for the concept that quiescent cells can be rendered antibiotic susceptible.  
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Alter the Growth-Limiting Stress  
 
 
Instead of directly modulating bacterial metabolism, it may be possible to 
enhance drug efficacy by removing the specific environmental pressures that 
induce quiescence. For example, nonreplicating, antibiotic-tolerant cells are 
found in relatively high numbers in bacterial biofilms (Lewis, 2007), and the 
disruption of the biofilm architecture increases antibiotic activity at least in part by 
reversing this differentiation (Musk and Hergenrother, 2006). Similarly, it may be 
possible to modulate the host immune pressures that induce the antibiotic 
tolerant state. Overt immunosuppression can enhance antibiotic activity in a 
number of models (Assfalg et al., 2010; Lenaerts et al., 2003). Even more subtle 
chemical modulation of tumor necrosis factor (TNF) signaling, which plays central 
roles in the inflammatory response, has been shown to accelerate 
antituberculosis therapy in animals (Bourigault et al., 2013).  
Thus, both the host and the pathogen can be manipulated to increase antibiotic 
efficacy. A more detailed understanding of the specific pressures that limit growth 
during infection and the pathogen’s adaptations to these stresses could lead to 
the rational development of new synergistic therapies that accelerate 
antibacterial treatment.  
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Conclusion and Specific Aims 
 
The aim of this work was to better understand the physiology of the quiescent 
state in M. tuberculosis in order to identify new strategies for drug treatment. As 
detailed above, while there are many pathways that are down-regulated or 
inactive in the nongrowing quiescent state, there are also active processes 
involved in maintaining viability that require further study. Our approach to 
identifying these active pathways was to harness the power of global and high-
throughput screens, metabolomics and TnSeq, to identify active pathways and 
enzymes involved in the stable adaptation and survival of hypoxia. Specifically, 
we wished to accomplish the following goals: 
I. Identify metabolic alterations in hypoxic M. tuberculosis 
II. Identify conditionally essential genes in hypoxic M. tuberculosis 
III. Understand the role of MtPat in hypoxic metabolic regulation 
IV. Identify new targets for drug treatment in hypoxic M. tuberculosis 
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Upon inhibition of respiration, which occurs in hypoxic or nitric oxide-containing 
host microenvironments, M. tuberculosis adapts a non-replicating ‘quiescent’ 
state and becomes relatively unresponsive to antibiotic treatment. In this study, 
we utilized a combination of metabolite profiling in tandem with comprehensive 
mutant fitness analysis to identify regulatory or metabolic pathways that could be 
targeted to kill quiescent cells under hypoxic conditions. Quantification of total 
metabolite pools revealed alterations in the abundance of tricarboxylic acid (TCA) 
cycle intermediates that correlated with increased cyclic AMP (cAMP). A parallel 
genetic study identified a cAMP-controlled protein acetyl-transferase 
(MtPat/Rv0998) that was essential for survival in hypoxia. MtPat promoted 
survival by coordinately inhibiting both fatty acid catabolism and oxidative TCA 
reactions, and favoring flux through reductive TCA reactions that maintain the 
redox state of the cell. In the absence of this regulatory system, beta-oxidation 
and continued flux through oxidative TCA reactions lead to reduction of the 
NAD+/NADH pool and reduced viability. Genetic inhibition of TCA enzymes 
verified the relative importance of reductive reactions in hypoxic cultures and 
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murine lung, and established a specific role for malate dehydrogenase (Mdh) in 
survival. Chemical inhibition of Mdh caused more rapid cell death in hypoxia than 
did isoniazid, suggesting a new strategy for eradication of quiescent bacteria.  





Tuberculosis (TB) has proven difficult or impossible to control throughout much of 
the world. The resilience of this disease can be attributed to the huge reservoir of 
asymptomatic Mycobacterium tuberculosis (Mtb) infection, which is estimated to 
include as many as one billion individuals, and the remarkably long and complex 
treatment regimen that is necessary to prevent or cure infection. Despite the 
availability of drugs that rapidly kill (Mtb) in vitro, treatment of active TB disease 
still requires the administration of these agents for at least six months. This long 
and complex regimen is difficult to deliver and incomplete treatment is both 
ineffective and contributes to the selection of drug-resistant strains.   
 
A defining feature of Mtb that limits antibiotic efficacy is its relatively slow growth 
rate and propensity to exit the cell cycle and adopt a hardy nonreplicating state 
during times of stress (Gengenbacher et al., 2010; Hett and Rubin, 2008; Voskuil 
et al., 2003; Wayne and Sohaskey, 2001). While Mtb does not replicate in this 
“quiescent” state it remains metabolically active (Baek et al., 2011; Eoh and 
Rhee, 2013; Watanabe et al., 2011), distinguishing quiescence from true 
microbial “dormancy” responses, such as sporulation. Despite this continual 
metabolic activity, quiescent Mtb becomes relatively tolerant to existing 
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antibiotics that target bacterial functions, such as transcription, translation, and 
cell wall synthesis, which are required primarily during active replication. 
Understanding which metabolic pathways remain necessary for the survival of 
quiescent Mtb could lead to the rational design of new drugs that are more 
effective in eradicating these cells.  
 
A wide variety of stresses encountered during infection, such as low oxygen, low 
pH, iron starvation, and exposure to nitric oxide (NO), are capable of reducing 
mycobacterial growth and antibiotic efficacy. While the specific adaptation to 
each of these stresses is likely to differ, they all initially trigger the DosRST 
regulatory system that senses respiratory capacity by responding to the reduction 
state of the quinone pool (Voskuil et al., 2003). This response to respiratory 
limitation has been most thoroughly studied using a well-defined in vitro model in 
which hypoxia is used to arrest the growth of this obligate aerobe (Wayne and 
Hayes 1996; Rustad et al., 2008; Boshoff et al., 2004; Eoh and Rhee, 2013). 
Upon oxygen depletion, DosRST rapidly induces a 48-gene regulon that includes 
the Tgs1-encoded triglyceride synthase (Voskuil et al., 2003). The resulting 
carbon storage response redirects acetyl-CoA from growth promoting pathways 
into the formation of cytosolic lipid bodies, which correlates with the arrest of  
bacterial replication (Baek et al., 2011). This initial response is followed by more 
stable transcriptional and metabolic changes that promote long-term survival 
(Rustad et al., 2008; Watanabe et al., 2011; Eoh and Rhee, 2013; Galagan et al., 
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2013; Baek et al., 2011). The outcome of this adaptation is a remodeling of the 
TCA cycle from the oxidative reactions that occur during respiration to a 
reductive pathway that regenerates NAD+ and produces succinate to sustain 
membrane potential, ATP synthesis, and anaplerosis. Indeed, these dual 
responses to respiration limitation serve to maintain cellular redox balance, since 
both lipid anabolism and reductive TCA consume NADH and regenerate NAD+.  
 
These studies describe important responses to respiratory limitation and suggest 
pathways that might be important for the survival of quiescent Mtb. However, it 
remains unclear how metabolic alterations are regulated and which of these 
remodeled pathways are most important for survival of the quiescent cell. To 
understand the consequences of perturbing individual metabolic pathways in 
quiescent cells, we combined a comprehensive metabolite analysis of hypoxic 
Mtb with a parallel genome-wide genetic screen for mutants that were unable to 
survive under this condition. This combination of approaches identified a cAMP-
dependent regulatory pathway that coordinates the switch from oxidative to 
reductive metabolism, and defined bacterial functions that can be targeted to kill 
quiescent Mtb. Inhibiting one such function, a non-redundant component of the 
reductive TCA pathway, resulted in rapid Mtb death in hypoxia and during 
infection. We conclude that this insight into the physiology of quiescent cells can 
inform the development of more effective TB therapies. 
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Materials and Methods 
 
Mycobacterium tuberculosis H37Rv (ATCC 27294) was used. Cultures were 
grown using Middlebrook 7H9 media supplemented with 0.05% Tween-80 and 
OADC (Becton Dickinson) enrichment, or on 7H10 agar with OADC enrichment 
at 37˚C. For fatty acid-free media, 7H9 was supplemented with ADC, using fatty-
acid free BSA (Sigma) and 0.05% tyloxapol (Sigma). For 13C flux experiments, 
7H10 media was supplemented with ADC using 0.05% D-Glucose-2-13C (Sigma) 
and 0.05% acetate.  
 
Hypoxic cultures were grown in 17 mL cultures in sealed glass vials (as 
described in Baek et al., 2011), or in 31 mL cultures in 45 ml glass serum vials 
(Wheaton) sealed with 20 mm rubber stoppers (Wheaton) and 20 mm aluminum 
crimp caps (Supelco). At indicated time points, 3 vials were opened and viable 
bacterial numbers were enumerated on 7H10 agar plates. Redox ratios were 
determined using the NAD/NADH Quantitation Kit (Sigma). 
 
For metabolite abundance, metabolites were extracted from hypoxic (day 10) and 
aerobic cultures in quadruplicate. Cells were lysed in chloroform:methanol (2:1), 
dried and subjected to analysis via GC/MS and LC/MS as described in Griffin et 
al., 2012. 
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Transposon mutagenesis of H37Rv was carried out as described in Long et al. 
(2015). Three independent libraries were generated and mixed together at equal 
ratios based on optical density (A600). Hypoxic vials (31 mL) were inoculated in 
replicates of eight with approximately 107 mutants at day zero. At day 21 and day 
42, eight vials were opened per time point and approximately 50,000 mutant CFU 
were spread onto each of three 7H10 petri plates (245mm x 245mm) including 25 
µg/mL Kanamycin and 0.05% Tween-80 for an approximate total of 150,000 
mutant CFU per replicate. Input library (control) was plated in replicates of eight 
as described above for hypoxic samples. 7H10 agar plates were incubated for 28 
days at 37ºC, after which genomic DNA was extracted independently from all 
replicates. Sample preparation, sequencing and analysis were performed as 
described in Nambi et al., 2015.  
 
Genetic knockout of MtPat was achieved by hygromycin-marker replacement via 
suicide vector pJM1 as previously described (Baek et al., 2011). For 13C flux 
experiments, bacteria were inoculated onto 0.45 µm HVLP membrane filters 
(Millipore) and placed on top of 7H10 agar, and grown at 37˚C for 7-10 days, at 
which point the filters were acclimated to room temperature and transferred to 
7H10 agar plates including 0.05% D-Glucose-2-13C and placed inside an 
anaerobic chamber (BBL) with a GasPak (Beckton Dickinson) to deplete oxygen. 
After two hours at RT, anaerobic chamber was placed at 37˚C for 7-10 days. 
Filters containing bacteria were removed an added to 2 mL screw-capped tubes 
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with silica beads (pre-washed with HPLC-grade methanol) and 1 mL HPLC-
grade acetonitrile:methanol:water (2:2:1). Lysis and quenching of metabolites 
was performed by bead-beating three times at 6.5 m/s for 30 seconds each. The 
supernatant was filtered using a 0.22 µm HVLP filter and kept at -80˚C until 
further use. HPLC analysis was performed using an Agilent 6520 Accurate-Mass 
QTOF LC/MS system (Agilent Technologies Inc, Marshfield, MA, USA) with a 
Cogent Diamond Hydride TYPE-C Silica HPLC Column (100Å Pore Size) 
(MicroSolv, 70000-15P-2) and isocratic gradient as described in Eoh and Rhee, 
2013. Peak area was measured for each metabolite of interest and flux ratio was 
determined by comparison of peak area for standard metabolite mass and peak 
area of metabolite mass +1 (i.e. 13C labeled-form). 
 
For mouse infections, C57BL/6 mice were infected with approximately 200-300 
CFU/lung of WT (H37Rv) or ∆MtPat via the aerosol route using a Glas-col 
aerosol exposure system. After approximately four weeks, isoniazid (INH) 
treatment was initiated and delivered via drinking water (100 µg/ml INH). Mice 
were sacrificed at weeks four and twelve and organs were extracted and CFU 
was enumerated as described in Baek et al., 2011.  
 
Genetic knockdown constructs (Mdh-DAS, SucD-DAS) were made as described 
previously (Kim et al., 2013, Schnappinger et al., 2015). Knockdowns were 
induced with ATc (1 µg/mL) added to cultures in vitro or with doxycycline chow 
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for mouse infections. Knockdowns were confirmed in hypoxia using multiple-
reaction-mode (MRM) Mass Spectrometry to detect the presence of specific 
target peptides. For hypoxic and aerobic cultures, ATc was added every seven 
days using a non-coring gas-tight syringe (Hamilton) with 1 µg/mL as the initial 
dose and 0.5 µg/mL as the subsequent doses. Pooled mouse infection 
(C57BL/6), qTag strain construction, and qPCR analysis were performed as 
described in Blumenthal et al., 2010.  
 
The Sacchettini Lab at TAMU carried out the Mdh inhibitory compound screen. 
Inhibition of Mdh was measured by the conversion of s-malate to oxaloacetate 
and the decrease of reaction cofactor NADH (ex:340nm, em:460nm). Assay 
conditions were as follows: 100mM HEPES, 50mM KCl, pH7.5, 100 µM OAA, 
250 µM NADH and 0.25nM Mdh. 3653 compounds were screened, of which 
3321 have been shown to have whole-cell activity in Mycobacteria. Three active 
compounds were identified, and the most effective compound (Compound A) 
was selected for further testing. For hypoxic drug testing, Compound A (CHEM 
ID # 5104073) was solubilized in DMSO and filtered using PMSF sterile filters. 40 
µM of Compound A, or 2 µg/ml of isoniazid (INH), or both, was added to hypoxic 
cultures every seven days after the initial 10 day stable adaptation to hypoxia. 
Compound A sensitivity assay was carried out in the presence of 1µg/mL ATc 
and differing concentrations of the compound as described in Franzblau et al., 
1998. Viability was measured by the addition of alamarBlue Dye (Thermo Fisher) 
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and monitoring fluorescence excitation (ex: 570nm, em: 585nm). 
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Results 
 
Quantifying total metabolite pools in quiescent M. tuberculosis reveals 
coordinated alterations in carbon metabolism and increased cAMP 
 
 
The ultimate rationale for this study was to apply parallel metabolomic and 
genetic profiling to associate metabolic changes with the genes that regulate 
them. To accomplish this, we first utilized high-throughput metabolomics to 
identify metabolic pathways that are regulated during the adaptation to hypoxia. 
Mtb was cultured in sealed vials in which the bacterium gradually depletes the 
available oxygen over an initial growth period of five to seven days. Once the 
oxygen is consumed, Mtb ceases replication but maintains viability for several 
weeks. To capture the initial adaptation to the hypoxic condition, we extracted 
total metabolites from 10-day-old non-replicating cultures, and compared these to 
metabolites extracted from log-phase aerobic cultures. Approximately 200 
distinct metabolites were quantified via a combination of gas and liquid phase 
chromatography coupled with mass spectrometry. 
 
A clear change in metabolic state was apparent between the two conditions 
(Figure 2.1). In general, the abundance of biosynthetic precursors was 
decreased, reflecting the lack of necessity to increase biomass. This change was 
apparent in amino acid pools and also in the pentose phosphate pathway, which 
generates nucleotides. In contrast, we noted a general increase in abundance of 
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free fatty acids (linoleate, oleate, methylstearate, margarate, arachidate), sugar 
alcohols (malitol, sorbitol) and glycogen precursors (maltose oligomers) (Figure 
2.2).  The accumulation of these compounds is consistent with a general shift 
from carbon catabolism to storage. This observation is consistent with the known 
accumulation of triglycerides under these conditions and suggests the presence 
of diverse carbon storage programs in hypoxic M. tuberculosis.  
 
A second notable effect was the differential abundance of some TCA 
intermediates. Citrate, cis-aconitate, alpha-ketoglutarate, and acetyl-CoA were all 
more abundant in the hypoxic extracts when compared with the aerobic extracts.  
In contrast, the abundance of malate, fumarate, and succinate were unchanged 
or less abundant in hypoxic extracts (Figure 2.3), indicating that these distinct 
TCA reactions were uncoupled in hypoxic Mtb. These observations are generally 
consistent with the bifurcated TCA pathway that has been previously described in 
hypoxic Mtb, in which the oxidation of acetyl-CoA to 2-ketoglytarate occurs 
independently from the reduction of malate to succinate (Watanabe et al., 2011; 
Eoh and Rhee, 2013). Together, both carbon storage and TCA remodeling 
observed in hypoxia correlate with growth arrest and redox maintenance.  
 
This remodeling of metabolic state was accompanied by a five-fold increase in 
the abundance of 3’,5’-cyclic-AMP (cAMP) in hypoxic Mtb (Figure 2.4). cAMP is a 
second messenger that is synthesized by adenylate cyclase enzymes and 
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involved in regulation of carbon catabolism in many systems in response to 
extra- or intra-cellular stimuli. While cAMP was relatively increased in hypoxic 
cells, the abundance of adenosine and AMP were similar in aerobic and hypoxic 
conditions suggesting that the increase in abundance of cAMP is not a byproduct 
of altered of precursor pools, but likely reflected an increased rate of production. 
These results confirmed and extended previous characterizations of the 
metabolic adaptation to hypoxia and implicated cAMP as a possible regulator of 
this response.  




Figure 2.1. Metabolite abundance in hypoxic vs. aerobic Mtb. 
 
M. tuberculosis was grown in either hypoxic or aerobic conditions and GC/MS 
and LC/MS were used to quantify the relative abundance of each metabolite. 
A fold-change ratio of 1 indicates no chance in metabolite abundance. A 
dotted line representing statistical significance (p ≤ 0.05) was determined 
using student’s t test on quadruplicate replicates. A complete list of 
metabolites profiled is included in Table 4.1. 
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Figure 2.2. Abundances of free fatty acids increase in hypoxic Mtb. 
 
Condition-specific abundances of free fatty acids (highlighted in Figure 2.1). M. 
tuberculosis was grown in hypoxic and aerobic conditions and metabolite 
abundance was determined by GC/MS and LC/MS. Metabolites were 
measured in quadruplicate.  
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Figure 2.3. Abundance of TCA metabolites in hypoxic and aerobic Mtb. 
 
Condition-specific abundances of TCA cycle intermediates (highlighted in 
Figure 2.1). M. tuberculosis was grown in hypoxic and aerobic conditions and 
metabolite abundance was determined by GC/MS and LC/MS. Metabolites 
were measured in quadruplicate. Oxidative (Ox.) and reductive (Red.) 
branches of the TCA cycle are indicated. 
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Figure 2.4. Abundance of 3’,5’-cAMP increases in hypoxic Mtb. 
 
Condition-specific abundance of 3’,5’-cAMP (highlighted in Figure 2.1). M. 
tuberculosis was grown in hypoxic and aerobic conditions and metabolite 
abundance was determined by GC/MS and LC/MS. Metabolites were 
measured in quadruplicate. Ratio p value < 0.005 (Table 4.1). 
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Genome-wide mutant fitness profiling identifies redox maintenance and 
cAMP pathways that are essential for the adaptation to hypoxia 
 
To associate the observed metabolic changes with the responsible bacterial 
genes, we quantified the relative fitness of Mtb mutants under hypoxic conditions. 
A highly saturated library of random transposon mutants was generated, in which 
55,000 of the possible 76,000 TA dinucleotide insertion sites were represented. 
In this complex library, an insertion is present every 80 bases on average and 
virutally every nonessential gene is represented by multiple individual 
clones (Sassetti et al., 2003; Griffin et al., 2011). The transposon library was 
subjected to hypoxic culture for either three or six weeks, and the relative 
abundance of each mutant in the input pool and selected pools was compared 
using next generation sequencing (Figure 2.5). This “transposon sequencing” 
(TNseq) strategy allows relative fitness of each Mtb mutant to be estimated over 
the period of selection. The multiple time points included in this experimental 
design allowed us to differentiate between three distinct phenotype classes 
(Figure 2.6). 30 mutants were found to be relatively underrepresented after three 
weeks of hypoxia (“early hypoxia”), when compared to the input library. These 
mutants likely include both those with defects in growth during the period of 
oxygen depletion and in initial survival in hypoxia. All but two of these mutants 
were among the 101 that were significantly underrepresented when the input was 
compared to the libraries selected for 6 weeks (“late hypoxia”). To specifically 
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define the mutants that were unable to survive in the quiescent state, we 
compared the composition of libraries that were selected for 3 versus 6 weeks of 
hypoxia. This latter set of 32 mutants represents genes that are specifically 
required for maintaining viability in the absence of replication (Figure 2.7, Table 
4.2 – 4.7). 
 
While the majority of genes found to be conditionally essential in hypoxia had no 
annotated function, a number of known pathways were identified. As expected, a 
number of the conditionally essential genes are part of the DosR dormancy 
regulon, including dosR (rv3133c) and acr/hspX (rv2031c), which were essential 
in both early and late hypoxia. Other DosR regulon genes dosS (rv3132c), otsB1 
(rv2006) and unknown genes rv2030c, and rv2623 were found to be conditionally 
essential in late hypoxia. The DosR regulon consists of 48 genes that are 
transcriptionally upregulated upon exposure to hypoxic conditions and, 
furthermore, acr/hspX has been shown to be the most strongly upregulated 
transcript by DosR in hypoxic conditions (Sherman et al., 2001; Voskuil et al., 
2003). The activity of DosR is involved in maintaining the redox state of the cell in 
the absence of oxygen (Leistikow et al., 2010) facilitated at least in part by 
induction of tgs1 and accumulation of triacylglyceride (Baek et al., 2011). 
Consistent with a redox regulation as a critical adaptation to hypoxia, a number 
of genes predicted to be involved in F420 biosynthesis/metabolism were identified 
as conditionally essential: fbiA (rv3261) and fgd1 (rv0407). F420 is a rare 
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prokaryotic coenzyme present in Mycobacterial species that is involved in 
protecting the bacterium from nitrosative damage (Purwantini and 
Mukhopadhyay, 2009) and has a role in maintaining viability in hypoxia 
(Gurumurthy et al., 2013). Indeed, the mycobacterial Fgd1, an F420-dependent 
glucose-6-phosphate dehydrogenase, has been shown to respond to oxidative 
stress by metabolizing glucose-6-phosphate (G6P) in order to maintain redox 
balance (Hasan et al., 2010). Thus, our hypoxic genetic screen confirms 
maintenance of redox balance as a central theme in the adaptive response to 
hypoxia.  
 
The observed increase in cAMP during the adaptation to hypoxia (Figure 2.4) led 
us to investigate the behavior of mutants lacking predicted cAMP-associated 
genes under these conditions. The Mtb genome encodes sixteen proteins with 
predicted adenylate cyclase (AC) domains; of which ten have been biochemically 
characterized as active cAMP producing enzymes (Shenoy and Visweswariah, 
2006). Only one of these adenylate cyclases met our significance threshold in the 
hypoxic transposon mutant library screen, Rv1625c/Cya (Figure 2.8). Despite the 
statistical significance of this phenotype, mutants lacking this enzyme displayed a 
modest fitness defect and were underrepresented by 1.5-fold after 6 weeks of 
hypoxia. 
 
cAMP acts by interacting with effector proteins that contain nucleotide binding 
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domains (NBD). To identify potential the downstream targets of cAMP signals in 
Mtb, we specifically assessed the relative fitness of mutants lacking each of the 
nine predicted cAMP-binding proteins encoded in the genome. Only one of these 
mutants, lacking the rv0998 gene, was significantly underrepresented in our 
hypoxic transposon library screen (Figure 2.9). Indeed, the abundance of this 
mutant decreased by more than 20-fold between 3 and 6 weeks of hypoxia, 
representing the most profound survival defect identified during this period of 
quiescence. rv0998 encodes a cAMP-regulated protein lysine acetyltransferase, 
known as MtPat (Nambi et al., 2010; Lee et al., 2012; Nambi et al., 2013). This 
two-domain protein is homologous to a large family of protein acetyltransferase 
(Pat) proteins. The mycobacterial Pat ortholog also contains an additional 
nucleotide-binding domain that is structurally similar to the cAMP responsive 
region of protein kinase A, and has been shown to increase acetylation activity 
upon cAMP binding. To confirm the predicted essentiality of MtPat in hypoxia, 
this gene was deleted in Mtb. The ∆MtPat deletion mutant grew normally in 
aerobic conditions and reached a similar cell density as wild type Mtb in hypoxic 
vials. However, unlike wild type Mtb or a complemented strain, the ∆MtPat 
mutant progressively lost viability once hypoxia was achieved (Figure 2.10). 
Notably, the ∆MtPat did not display a survival defect in starvation conditions 
(Figure 2.12), but did have a hypersensitivity to streptomycin treatment (Figure 
2.11), which suggests MtPat’s role is specific to stress from respiration limitation. 
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Together, this comprehensive mutant fitness profiling confirmed the importance 
of redox maintenance systems in survival under hypoxic conditions.  
Furthermore, this study specifically implicated a cAMP-mediated pathway, 
consisting of Cya and MtPat, in this adaptation.  
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Figure 2.5. Hypoxia TnSeq experimental model to predict conditionally 
essential genes. 
 
A mutagenized M. tuberculosis transposon library was inoculated into hypoxic 
vials and plated for surviving mutants (CFU) at the indicated time points (zero, 
three and six weeks). Stable adaptaion to hypoxia occurs at approximately 
week one. Surviving mutants from week three and week six were compared to 
the input (time zero) to determine which mutants increased or decreased in 
abundance. The comparison of week three versus week six allows for the 
prediction of essential genes specifically required after the stable adaptation to 
hypoxia. 
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Figure 2.6. TnSeq in hypoxic Mtb identifies conditionally essential genes.  
 
Non-essential genes with >4 TAs hit are plotted by their log2 change fold ratio 
Individual genes are represented by blue dots. A ratio in the range of 1 to -1 
indicates no significant change in the fitness of the transposon-interrupted 
gene between the two conditions, while a ratio of |1.5| or greater (red dotted 
lines) indicates a significant change in the gene in hypoxic conditions. 
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Figure 2.7. Hypoxic conditonally essential genes are consistent across 
timepoints. 
 
A Venn Diagram compares the underrepresented genes identified from each 
time point comparison: input vs. hypoxia week 3 (IvH3), input vs. hypoxia 
week 6 (IvH6), and hypoxia week 3 vs. hypoxia week 6 (H3vH6). The 
conditionally essential underrepresented genes identified were largely 
consistent across datasets. Conditionally essential genes were defined as: p 
value ≤ 0.005, TAs hit >4, log2 fold change ≤ -1.5.  
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Figure 2.8. Comparison of Mtb Adenylate Cyclase (AC) predicted 
essentiality in hypoxia. 
 
Comparison of the log2 fold change of the predicted Adenylace Cyclase (AC) 
enzymes of M. tuberculosis (TAs hit >4) at week three vs week six. Rv1625c is 
the only AC with a p value ≤ 0.05 (denoted by asterisk), and no AC has a log2 
fold change greater than |1.5|.  
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Figure 2.9. Comparison of Mtb cyclic nucleotide binding proteins (cNMP) 
predicts essentiality of MtPat in hypoxia. 
 
Comparison of the log2 fold change of the predicted cyclic nucleotide binding 
proteins (cNMP) of M. tuberculosis (TAs hit >4) at week three vs week six. 
Rv0998 (MtPat) is the only statistically significant cNMP with a p value ≤ 0.05 
(denoted by asterisk), and log2 fold change greater than |1.5|.  
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Figure 2.10. Reduced survival of ∆MtPat in hypoxia.  
 
Hypoxic survival in an ∆MtPat deletion strain is significantly impared. Cultures 
were grown in triplicate in hypoxic vials. Viability was measured by CFU/mL at 
the indicated time points. 
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Figure 2.11. ∆MtPat is hypersensitive to streptomycin treatment. 
 
Survival of streptomycin treatment (2µg/mL streptomycin) in an ∆MtPat 
deletion strain is significantly impared. Viability was measured by CFU at the 
indicated time points and percent survival was determined for each strain 
based on pre-treatment CFU.  
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Figure 2.12. ∆MtPat survives starvation stress. 
 
No survival defect was observed in starvation conditions (PBS+tyloxapol) in an 
∆MtPat deletion strain. Viability was measured by CFU at the indicated time 
points. 
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cAMP induced protein lysine acetylation is required to remodel central 
metabolism and maintain redox homeostasis 
 
Because cAMP and Pat orthologs have been shown to regulate carbon 
metabolism in other systems (Wang et al., 2010; Castaño-Cerezo et al., 2011), 
we hypothesized that MtPat may be involved in regulating the pathways known to 
be altered in hypoxia (Watanabe et al., 2011; Eoh and Rhee, 2013). To 
specifically quantify the effect of MtPat on carbon metabolism, we used stable 
isotope labeling to measure the relative flux through each metabolite pool. Wild 
type, ∆MtPat, and complemented strains were independently grown on media 
containing a mixture of substrates for glycolysis and beta-oxidation, and 2-[13C]-
labeled glucose was added to track the fate of each carbon source in aerobic or 
hypoxic conditions. After nine days of hypoxic culture, total metabolites were 
extracted and analyzed via HPLC-LC/MS. Relative flux was measured via the 
level of conversion of each metabolite to the 13C labeled form. 
 
Under aerobic conditions wild-type incorporated 2-[13C]-glucose into all TCA 
metabolites, consistent with the use of a canonical TCA cycle. Under hypoxic 
conditions, however, flux of 2-[13C]-glucose indicated branched TCA metabolism 
(Figure 2.13). Flux of glycolytic carbon was concentrated primarily into malate 
and succinate, while flux through citrate/isocitrate and alpha-ketoglutarate was 
barely detectable. This pattern of labeling indicated that accumulation of citrate 
and alpha-ketoglutarate in our initial metabolomic screen was due to a reduction 
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in flux through these reactions. These data are consistent with branched TCA 
metabolism in hypoxia, with a preferential use of reductive branch that converts 
malate to succinate and an almost complete absence of activity in the oxidative 
branch that converts citrate to alpha-ketoglutarate (Eoh and Rhee, 2013; 
Watanabe et al., 2011). 
 
In contrast with wild-type Mtb and the complemented ∆MtPat mutant, the ∆MtPat 
strain continued to incorporate 2-[13C]-glucose into the oxidative branch of TCA 
under hypoxic conditions. Whereas there was no detectable flux through 
citrate/isocitrate in wild type hypoxic Mtb, the mutant incorporated 13C -labeled 
carbon into this dedicated first step of oxidative TCA, and ultimately had 13C -flux 
patterns similar to aerobically growing bacteria.  
 
The preferential use of reductive TCA reactions in hypoxia has been 
hypothesized be important for the regeneration of NAD+, which is expected to 
become reduced to NADH in the absence of an efficient electron acceptor, such 
as oxygen (Eoh and Rhee, 2013; Watanabe et al., 2011).  As a result, the 
continued flux through the oxidative branch of TCA in ∆MtPat might impair 
survival in hypoxia by limiting NAD+ regeneration from NADH. To test this 
hypothesis, we measured the redox state of the NAD+/NADH pool (Figure 2.14). 
Under aerobic conditions, both wild type and the ∆MtPat mutant maintained a 
balance of NADH and NAD+, with this cofactor primarily in the oxidized form. 
  88 
While wild type bacteria were able to maintain NADH/NAD+ balance in hypoxia, 
the ratio of NADH/NAD+ increased by more than 10-fold in the ∆MtPat deletion 
mutant upon oxygen limitation. The observed redox imbalance in the mutant is 
consistent with the increased flux through oxidative reactions inferred by 13C-
carbon tracing, and implies that depletion of NAD+ could underlie the impaired 
survival of this strain in hypoxia. 
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Figure 2.13. Hypoxic metabolism utilizes reductive TCA, while ∆MtPat 
continues oxidative TCA flux. 
 
M. tuberculosis grown on 2-[13C] glucose in aerobic conditions incorporates 
13C into all metabolites of the TCA cycle (blue bars) as measured by 
HPLC/MS. Anaylsis of M. tuberculosis in hypoxic conditions (red bars) 
identifies a reduction in flux through oxidative TCA metabolites 
(citrate/isocitrate, α-ketoglutarate), while maintaining flux through reductive 
TCA metabolites (malate, succinate). Unlike hypoxic WT, hypoxic ∆MtPat 
continues to incorporate 13C into oxidative branch metabolites (green bars). 
Metabolites were quantitated by HPLC/MS and flux was determined by the 
change (∆) in peak area of M (metabolite mass) to M+1 (metabolite mass + 1, 
i.e. 13C-labeled). 
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Figure 2.14. ∆MtPat is overreduced in hypoxia. 
 
The ratio of NADH and NAD+ was quantified for each strain in aerobic and 
hypoxic conditions. Values were normalized to CFU for each strain in each 
condition.  
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Coordinated regulation of oxidative metabolic reactions via MtPat is 
necessary for hypoxic survival 
 
 
While many substrates have been proposed for Pat orthologs, based largely on 
acetyl-proteomic approaches, biochemical studies have implicated predominantly 
acetyl- and acyl-CoA ligases as targets of Pat-mediated regulation (Crosby et al, 
2012). Indeed, MtPat acetylates both the acetyl-CoA ligase (Acs) and 10 different 
acyl-CoA ligases (FadD paralogs) in a cAMP-dependent manner (Xu et al., 2011; 
Nambi et al., 2013). These FadD proteins are involved in fatty acid catabolism 
through beta-oxidation. Like the oxidative branch of TCA, beta-oxidation 
consumes NAD+ and produces NADH. Furthermore, catabolism of fatty acids 
ultimately ends in the production of acetyl-CoA, which is readily incorporated the 
oxidative branch of the TCA cycle. Based on these similarities between beta-
oxidation and oxidative TCA cycle reactions and the known effect of MtPat on 
acyl-CoA ligase activity, we hypothesized that coordinated repression of these 
pathways may be important for survival in hypoxia. 
 
To test whether the MtPat-mediated inhibition of fatty acid catabolism to acetyl-
CoA is important for hypoxic survival, we determined whether the survival of the 
∆MtPat mutant was altered by abundance of fatty acid in the medium. While the 
presence of oleate had no effect on the viability of wild type Mtb or the ∆MtPat 
complemented strain, the omission of fatty acid from the medium effectively 
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ameliorated the viability defect of the ∆MtPat mutant (Figure 2.15). Together 
these results indicate that the coordinated inhibition of fatty acid catabolism and 
oxidative TCA reactions by MtPat contributes to the survival of Mtb in hypoxia. 
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Figure 2.15. Fatty Acid-free media rescues hypoxic ∆MtPat. 
 
Hypoxic ∆MtPat has a survival defect in standard 7H9 media (mixed carbon 
including glucose, oleate and glycerol). Survival of hypoxic ∆MtPat is no longer 
impared in fatty-acid free (glucose and glycerol) media. Viability was 
measured by CFU at indicated time points.  
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Targeting components of the reductive branch of the TCA cycle in 
quiescent M. tuberculosis increases the efficacy of existing drug therapies 
 
The redox state of the cell correlates with antibiotic sensitivity (Dwyer et al., 
2014). Since the reductive branch of the TCA cycle is actively utilized during the 
hypoxic state, we hypothesized that targeting components of this branch would 
make effective targets for drug treatment in vivo. C57BL/6 mice were infected 
with ∆MtPat and treated with isoniazid (INH) starting at four weeks post infection. 
After eight weeks of treatment, the bacterial burden in mice infected with the 
∆MtPat deletion strain was significantly reduced in the lung and complete 
sterilization achieved in the spleen (Figure 2.16). Thus, targeting an enzyme 
involved in metabolic switch to the reductive branch of the TCA cycle is effective 
in sensitizing quiescent M. tuberculosis to INH in vivo. 
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Figure 2.16. ∆MtPat is hypersensitive to INH treatment in vivo. 
 
Aerosol mouse (C57BL/6) infection with WT (H37Rv) and ∆MtPat strains. Mice 
were started on isoniazid (INH) treatment at week four (pre-treatment, blue 
bars) and treatment was continued for eight weeks (week twelve, red bars). 
Mouse lungs and spleen were plated on 7H10 agar for CFU at weeks four and 
eight. Limit of detection = 100 CFU. 
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Utilization of the reductive branch of the TCA cycle is critical for survival of 
quiescent M. tuberculosis in vitro and in vivo 
 
The impaired survival of the ∆MtPat mutant in hypoxia indicated that preferential 
utilization of reductive TCA reactions was important for maintaining viability in 
hypoxia. In order to directly assess the importance of these reactions, we 
constructed a mutant in which the only non-redundant step in the predicted 
reductive pathway, malate dehydrogenase (Mdh), could be inducibly depleted. 
The mdh gene was fused in situ with a DAS+4 tag. This tag directs the 
proteolysis of the fusion protein by the ClpXP system upon the induction of the 
SspB adapter by anhydrotetracycline (ATc) addition. To verify that protein 
depletion was efficient in quiescent cells, ATc was added to the Mdh-DAS mutant 
after ten days of hypoxic culture. Eight days later, 97.83 % depletion of Mdh was 
confirmed by targeted mass spectrometry (Figure 2.17). 
 
To assess the relative contribution of Mdh to Mtb survival, the protein was 
depleted in either aerobic or hypoxic cultures and viability was assessed over 
time (Figure 2.18).  Mdh depletion arrested the growth of the Mdh-DAS mutant 
when ATc was added to exponentially growing aerobic cultures, confirming the 
predicted essentiality of this gene under these conditions. When Mdh was 
depleted in non-growing cells, the relative effect depended on the presence of 
oxygen. In stationary phase aerobic cultures, Mdh depletion only modestly 
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increased the rate of cell death (Figure 2.19). In contrast, Mdh depletion in 
hypoxia resulted in a significant increase in cell death. Within four weeks of ATc 
addition, the viability of Mdh-DAS mutant cultures had fallen below the limit of 
detection (Figure 2.19). To determine if Mdh depletion had a similar effect on 
central carbon metabolism as ∆MtPat deletion, we traced the fate of 2-[13C]-
glucose in the Mdh-DAS mutant in the presence and absence of ATc. Under 
hypoxic conditions, we found that inhibiting reductive TCA activity via Mdh 
depletion increased flux through the oxidative branch of TCA, as measured by 
the increased conversion of citrate/isocitrate to the 13C-labeled form (Figure 
2.20). These data further support the conclusion that the preferential utilization of 
reductive TCA reactions is critical for survival during hypoxia-induced 
quiescence. 
 
While the induction of the DosR regulon during growth in the lungs of C57BL/6 
mice (Voskuil et al., 2003; Rustad et al., 2008) suggests that respiration is limited 
at this site, overtly hypoxic lesions are not observed in this model. To determine if 
Mdh is necessary for Mtb survival in the mouse lung despite the absence of 
hypoxic lesions, we infected mice with a mixture of wild type Mtb and the Mdh-
DAS mutant, and the relative abundance of these strains was quantified in lung 
homogenates by quantitative PCR (Blumenthal et al., 2010). Depletion of Mdh 
was initiated either 1 week or 6 weeks after infection by the administration of 
doxycycline. In either treatment regime, the viability of the Mdh-DAS strain was 
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reduced 105-106 fold upon protein depletion (Figure 2.21).   
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Figure 2.17. Depletion of targeted knockdown constructs in hypoxia. 
 
Conditional depletion of Mdh and SucD was initiated at day ten of hypoxia 
using anhydrotetracycline (ATc), and lysates obtained at day eighteen of 
hypoxia were analyzed via MS multiple-reaction-monitoring (MRM) mode. 
Abundance of target peptides from Mdh (knockdown), SucD (knockdown) and 
Icd2 (knockout) strains at day eighteen were normalized to SigA levels and 
expressed as a percentage of peptide abundance in a control sample. 
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Figure 2.18. Inducible depletion of knockdown targets is sufficient to 
inhibit the essential activity of the enzymes. 
 
Growth inhibition of induced delpletion of target enzymes was measured by 
optical density (OD) over eight days. Depletion was initiated by addition of ATc 
(1 µg/mL) to culture media at day zero. Cultures were grown and measured in 
triplicate.  
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Figure 2.19. Mdh is required for survival in hypoxia.  
 
Knockdown of target enzymes was induced at day ten in hypoxic and aerobic 
conditions. CFU was enumerated at indicated time points. Limit of detection = 
100 CFU (dotted line). Cultures were grown and plated in triplicate for each 
strain and condition. 
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Figure 2.20. Mdh-DAS exhibits oxidative branch cycling in hypoxia. 
 
Metabolic flux tracing of 13C-labeled glucose is incorporated into oxidative 
branch metabolites (citrate/isocitrate) in hypoxic Mdh-DAS. Ratio is 
determined by percent of 13C labeled carbon (natural abundance of 13C-
citrate/isocitrate is approximately 6%). 



















  111 
 
Figure 2.21. Mdh is required in in vivo mouse infection. 
 
Aerosol mouse infection (C57BL/6) of pooled, barcoded (“qtag”) M. 
tuberculosis strains. Induced depletion of knockdown strains (Mdh-DAS, 
SucD-DAS) was initiated at week one and week six via doxy chow. For 
delpletion initiated at week one, lungs were harvested at week three, plated for 
CFU, and abundance was determined for each strain (WT1, WT2, Mdh-DAS, 
SucdD-DAS) via qPCR of unique “qtag” barcoded regions (constant:variable). 
For delpletion initiated at week six, lungs were harvested at week fourteen, 
plated for CFU, and abundance was determined for each strain (WT1, WT2, 
Mdh-DAS, SucdD-DAS) via qPCR of unique “qtag” barcoded regions 
(constant:variable). 
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Chemical inhibition of Mdh kills hypoxic M. tuberculosis  
 
While the requirement for Mdh in quiescent cells in vitro and in the mouse lung 
suggest that Mdh inhibition could be therapeutically useful, chemical inhibition of 
TCA enzymes has proven difficult (Lee et al., 2015). To determine if the Mtb Mdh 
enzyme is ‘druggable’ we performed a high-throughput screen for inhibitors. To 
focus the screen on compounds that are likely to have access to the 
mycobacterial cytosol, we used a curated library of 3600 compounds that have 
been shown to inhibit mycobacterial growth in a variety of high-throughput 
screening efforts (Figure 2.22). We identified three Mdh inhibitors with the 
properties listed in Table 2.1. The most potent Mdh inhibitor, Compound A 
(CHEM ID # 5104073), was selected for further testing in intact Mtb (Figure 
2.23).  
 
To determine if this compound’s growth inhibitory activity was related to Mdh 
inhibition in the intact cell, we determined if genetic depletion of Mdh altered 
susceptibility to this compound (Franzblau et al., 1998). Since Mdh knockdown is 
lethal by itself, we performed a ‘checkerboard’ analysis in which doses of the 
putative Mdh inhibitor and ATc were cross-titered to allow the effect of partial 
inhibition to be assessed. Using this scheme, we identified synergy between ATc 
and the Mdh inhibitor, such that the Mdh-depleted strain was hypersensitive to a 
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0.5x MIC concentration of Mdh inhibitor (Figure 2.24).  Both the in vitro inhibition 
of Mdh by this compound and the chemical-genetic synergy observed between it 
and Mdh-depletion, suggest that Mtb growth inhibition is at least partially 
dependent upon Mdh inhibition. 
 
To determine if chemical Mdh inhibition could mimic genetic Mdh depletion we 
compared the activity of the Mdh inhibitor with the mycolic acid inhibitor, 
isoniazid, in hypoxic culture. Each compound was added after 10 days of hypoxic 
culture and every seven days thereafter. Over the treatment period, isoniazid had 
a minimal effect on the viability of quiescent Mtb, as previously shown for this 
compound and other cell wall inhibitors. In contrast, Mdh inhibition had a similar 
effect as Mdh protein depletion, killing 99% of Mtb after 21 days of treatment and 
reducing viability beyond the limit of detection after 35 days (Figure 2.25). 
Furthermore, compound treated cells were overreduced (Figure 2.26). These 
data indicate that chemical inhibition of reductive TCA in general, and Mdh in 
particular, may be an effective strategy for killing quiescent bacteria and 
accelerating TB therapy (Figure 2.27).  
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Figure 2.22. High throughput screen for Mdh inhibition assay. 
 
Assay condition: 100mM HEPES, 50mM KCl, pH7.5, 100 µM OAA, 250 µM 
NADH and 0.25nM Mdh. Read fluorescent decrease of NADH (Ex: 340nm Em: 
460nm). Screened compounds: 3653 (i3321 of them have showed in vitro 
whole cell activity). Active compounds identified: 3. 












Km of OAA=49µM; Km of NADH=48.8 µM 
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Table 2.1. Potential inhibitors of Mdh  
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Compound A B C 
IC50 (uM) 15 15 37.5 
MIC99 for M. Smegmatis in 7H9 dextrose (uM) ND >100 >100 
MIC99 for M. Smegmatis in 7H9 acetate (uM) ND 25 >100 
MIC99 for mc
2
 7000 in 7H9 dextrose (uM) ND ND >100 
MIC99 for mc
2
 7000 in M9 acetate (uM) 20* 25 >100 
* Dual carbon sources: acetate and dextrose 
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Figure 2.23. Structure of “Compound A” (CHEM ID #5104073). 
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Figure 2.24. Mdh-DAS is hypersensitive to sub-MIC “Compound A”. 
 
WT, Mdh-DAS, and SucD-DAS strains were treated with 0 µM, 10 µM (0.5x 
MIC), 20 µM (1x MIC), or 40 µM (2x MIC) in the presence of ATc in triplicate. 
Viability was determined by reduction of alamarBlue measured via 
fluorescence intensity. 
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Figure 2.25. “Compound A” reduces hypoxic CFU in vitro. 
 
Compound A (40 µM), isoniazid (INH) (2 µg/mL), and Compound A and INH in 
combination were added to hypoxic cultures of WT H37Rv every seven days 
starting at day ten as indicated. Cultures were grown in triplicate and CFU 
were enumerated at indicated time points. Limit of detection = 100 CFU 
(dotted line). 
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Figure 2.26. “Compound A” treated hypoxic cells are overreduced. 
 
NADH was quantified from WT and treated lysates at day twenty-four of 
hypoxia (i.e. fourteen days of drug treatment). Cultures were measured in 
triplicate and values were normalized to CFU at the indicated time point. 
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Chapter III. Discussion 
 
Our study confirms and extends the metabolic changes that occur as Mtb adapts 
to the quiescent state under hypoxic conditions. We show that MtPat is 
responsible for the coordinated inhibition of both oxidative TCA and beta-
oxidation, and that this is critical for regeneration of NAD+ in the absence of 
oxidative phosphorylation. In conjunction with previous studies, these results 
suggest the presence of a multi-step metabolic adaption that is necessary for 
long-term survival in hypoxia (Figure 3.1). 
 
The immediate response to hypoxia is DosR induction and triglyceride (TG) 
synthesis, which was shown to be important for the initial growth arrest of the 
bacterium. Inhibiting TG synthesis by deleting Tgs1 resulted in continued growth 
and metabolic activity in hypoxia and increased sensitivity to a number of 
antibiotics (Baek et al., 2011). In this study, we found a number of metabolites 
accumulate in hypoxia that suggest additional carbon storage pathways. The 
accumulated fatty acids may be a component of the same cytosolic lipid bodies 
that harbor TG, and the maltose oligomers indicate the accumulation of 
glycogen. While inhibiting Tgs1 does potentiate antibiotic activity somewhat 
(Baek et al., 2011), the presence of multiple carbon storage pathways may 
undermine efforts to target characterized carbon storage pathways to accelerate 
drug treatment. 
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Both DosR activation and Tgs1 expression is transient, and the subsequent 
adaptation to hypoxia depends, at least in part, on cAMP. The cAMP system in 
mycobacteria is complex and poorly understood (McDonough and Rodriguez, 
2011). M. tuberculosis is predicted to encode sixteen adenylate cyclases in its 
genome, while E. coli, for comparison, only has one (Shenoy and Visweswariah, 
2006). Additionally, M. tuberculosis is predicted to have ten cNMP-binding 
proteins, and a recent report suggests even more may exist that contain non-
canonical cNMP-binding domains (Bai et al., 2011; Banerjee et al., 2015). In this 
study, we identified one cAMP-binding protein, MtPat that was important for 
surviving the hypoxic state. It is likely that M. tuberculosis relies on its abundance 
of adenylate cyclases to sense and produce a cAMP signal depending on a 
variety of stresses encountered in the host, such as hypoxia, pH, low iron, 
nutritional limitation, etc. For example, one characterized adenylate cyclase, 
Rv1626, is activated by low pH (Tews et al., 2005). Mutations in one AC, 
Rv1625c/Cya caused a significant survival defect, but this phenotype was much 
less severe than that seen for MtPat. We speculate that the multitude of ACs 
encoded by M. tuberculosis may be able to compensate for one another. 
Alternatively, alterations in free cAMP levels may also be controlled by the 
amount of cAMP bound to or released by Rv1636, a recently described cAMP 
“buffer” protein (Banerjee et al., 2015).  
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MtPat has previously been shown to acetylate acetyl-CoA synthase (Acs) and 
ten beta-oxidative fatty acid ligases (FadDs) in vitro (Xu et al., 2011; Nambi et al., 
2013). Both Acs and beta-oxidative FadDs produce acetyl-CoA as end products, 
which suggest a cohesive role for MtPat in regulating acetyl-CoA availability and 
metabolism. Furthermore, we have shown that restricting fatty acid metabolism 
rescues hypoxic ∆MtPat, which suggests MtPat inhibits beta-oxidation in hypoxia 
and that the maintenance of NAD+/NADH homeostasis via the coordinated 
control of oxidative reactions is important for survival. While MtPat mediated 
inhibition of fatty acid catabolism can be attributed to known targets, such as 
FadD proteins and Acs, the mechanism by which it controls oxidative TCA 
activity remains unclear. Acetyl-proteomic studies in other bacteria have 
identified a number of potential targets for regulatory acetylation that could 
mediate these effects, such as pyruvate dehydrogenase complex, isocitrate 
dehydrogenase and alpha-ketoglutarate dehydrogenase (Zhang et al., 2009).  
 
The result of MtPat activation is an inhibition of oxidative carbon metabolism, and 
preferential use of the reductive TCA reactions described previously (Watanabe 
et al., 2011; Eoh and Rhee, 2013). While all of the enzymes necessary for the 
conversion of glycolytic carbon to succinate via this fermentation pathway have 
not been defined, the one clearly non-redundant reaction is mediated by Mdh. 
Depletion of Mdh killed Mtb within hypoxia and mouse lung. While there is no 
hypoxia in mouse lung, we think the combination of NO, CO, low pH, and low 
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iron is likely creating a similarly respiratory limited environment. 
 
We were able to show that a small molecule compound could chemically inhibit 
Mdh and this inhibition led to robust depletion of CFU. These studies provide 
proof of the concept that interfering with the pathways necessary for survival in 
the absence of replication could accelerate the eradication of Mtb. The structure 
for M. tuberculosis Mdh has been solved (Ferraris et al., 2015), and while it is 
similar to the human Mdh ortholog, there are sufficient structural differences that 
can be exploited in order to engineer a compound that is specific to M. 
tuberculosis Mdh (Figure 3.2). Therefore, we have shown that understanding 
active components of quiescence metabolism -- MtPat, Mdh -- are effective 
targets for treating this heretofore difficult to treat disease state.  
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Figure 3.1. Summary. 
 
An increase in cAMP in hypoxic M. tuberculosis activates a cAMP-protein 
lysine acetyltransferase, MtPat (Rv0998), which inhibits fatty acid catabolism 
resulting in reduced availability of acetyl-CoA to oxidative TCA. Flux through 
the reductive branch of TCA is essential in hypoxia, and genetic and chemical 
inhibition of Mdh in hypoxia results in cell death.  
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Figure 3.2. Structural comparison of Mtb Mdh and Human Mdh. 
 
M. tuberculosis Mdh (top query) and human Mdh (bottom query) share a 
17.56% structural identity and 27.98% structural similarity. Alignment based on 
the jFATCAT_rigid algorithm (Ye and Godzik, 2003; Prlić et al., 2010). 
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Table 4.1. Hypoxic-dependent metabolomic profiling.  
 
“Ratio Hypoxic/Aerobic” = relative abundance of metabolite in hypoxia / relative 
abundance of metabolite in aerobic conditions 
“P-Value” = calculated using student t-test on quadruplicate samples  
 
BIOCHEMICAL	   Ratio	  Hypoxic/Aerobic	   P-­‐Value	  
1-­‐octadecanol	   1.2750	   0.010004593	  
1-­‐palmitoylglycerophosphoinositol*	   0.1927	   0.000813584	  
1-­‐stearoylglycerol	  (1-­‐monostearin)	   1.2555	   0.645006280	  
2-­‐aminoadipate	   1.2373	   0.162577251	  
2-­‐aminobutyrate	   1.1605	   0.429311377	  
2-­‐isopropylmalate	   0.1075	   0.000001267	  
2-­‐pyrrolidinone	   0.7050	   0.092559601	  
2'-­‐deoxyadenosine	   1.0000	   	  
3-­‐phosphoglycerate	   4.4313	   0.055642110	  
4-­‐acetamidobutanoate	   2.2282	   0.053012805	  
4-­‐hydroxybutyrate	  (GHB)	   8.0364	   0.007474693	  
5-­‐methylthioadenosine	  (MTA)	   0.2077	   0.000004099	  
5-­‐oxoproline	   0.4524	   0.000586128	  
7-­‐alpha-­‐hydroxycholesterol	   1.0745	   0.141148658	  
7-­‐beta-­‐hydroxycholesterol	   1.0000	   	  
acetyl	  CoA	   1.9494	   0.008398702	  
adenine	   0.3450	   0.000858261	  
adenosine	   0.1596	   0.000573986	  
adenosine	  3'-­‐monophosphate	  (3'-­‐AMP)	   0.6697	   0.103490198	  
adenosine	  3',5'-­‐cyclic	  monophosphate	  (cAMP)	   3.8423	   0.004831917	  
adenosine	  5'-­‐monophosphate	  (AMP)	   0.3167	   0.000115237	  
adenosine	  5'diphosphoribose	   1.0000	   	  
adenosine-­‐5'-­‐diphosphoglucose	   0.3467	   0.023085001	  
alanine	   0.4819	   0.000138738	  
alanylalanine	   1.2840	   0.387935532	  
alpha-­‐ketoglutarate	   2.9152	   0.086027272	  
alpha-­‐tocopherol	   1.3516	   0.335355311	  
arachidate	  (20:0)	   1.4392	   0.003514474	  
arginine	   0.2404	   0.000010581	  
asparagine	   1.0000	   	  
aspartate	   0.4004	   0.000004328	  
beta-­‐alanine	   0.7247	   0.278815341	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beta-­‐hydroxyisovalerate	   1.1444	   0.278244812	  
beta-­‐methyllevulinate	   1.1392	   0.294965515	  
betaine	   0.1241	   0.000000001	  
cadaverine	   1.0000	   	  
caproate	  (6:0)	   1.4186	   0.248645108	  
caprylate	  (8:0)	   1.0195	   0.905932890	  
cholesterol	   1.0000	   	  
cis-­‐aconitate	   6.5739	   0.000002728	  
citrate	   33.7999	   0.000000473	  
citrulline	   0.2886	   0.000005208	  
cysteine	   0.8226	   0.639627073	  
diaminopimelate	   0.2369	   0.000040453	  
dihydroxyacetone	  phosphate	  (DHAP)	   0.3184	   0.157122942	  
diisopropanolamine	   1.6753	   0.158475072	  
eicosenoate	  (20:1n9	  or	  11)	   8.1845	   0.007320390	  
flavin	  adenine	  dinucleotide	  (FAD)	   0.2979	   0.000046093	  
flavin	  mononucleotide	  (FMN)	   0.7714	   0.000164632	  
fructose	   0.7926	   0.415201016	  
fructose-­‐6-­‐phosphate	   0.4033	   0.000146366	  
fumarate	   0.8344	   0.064609902	  
gamma-­‐aminobutyrate	  (GABA)	   0.7544	   0.139379235	  
gamma-­‐glutamyl-­‐2-­‐aminobutyrate	   0.3569	   0.000186826	  
gamma-­‐glutamylalanine	   0.3720	   0.000189911	  
gamma-­‐glutamylglutamate	   1.1399	   0.445853510	  
gamma-­‐glutamylglutamine	   0.2965	   0.000112181	  
gamma-­‐glutamylisoleucine*	   0.3167	   0.000088186	  
gamma-­‐glutamylleucine	   0.3550	   0.000202000	  
gamma-­‐glutamylmethionine	   0.1724	   0.000002573	  
gamma-­‐glutamylphenylalanine	   0.5084	   0.013786352	  
gamma-­‐glutamylthreonine*	   0.2777	   0.000018177	  
gamma-­‐glutamyltyrosine	   0.6930	   0.114399161	  
gamma-­‐glutamylvaline	   0.1807	   0.000000561	  
GDP-­‐mannose	   2.9603	   0.022401943	  
glucose	   1.1367	   0.218631151	  
glucose	  1-­‐phosphate	   0.5113	   0.021943436	  
glucose-­‐6-­‐phosphate	  (G6P)	   0.3128	   0.000057624	  
glutamate	   0.2231	   0.000001958	  
glutamate,	  gamma-­‐methyl	  ester	   0.4239	   0.002668751	  
glutamine	   0.3374	   0.000038355	  
glycerate	   0.9804	   0.917806752	  
glycerol	   1.4817	   0.028428205	  
glycerol	  2-­‐phosphate	   0.2149	   0.000001564	  
glycerol	  3-­‐phosphate	  (G3P)	   0.1340	   0.000000008	  
glycerophosphorylcholine	  (GPC)	   0.2254	   0.000042091	  
glycine	   0.2814	   0.000143861	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glycolate	  (hydroxyacetate)	   1.1467	   0.409844006	  
guanosine	   1.3437	   0.212345834	  
guanosine	  5'-­‐	  monophosphate	  (GMP)	   0.3916	   0.095694729	  
histidine	   1.0264	   0.916443983	  
homoserine	   0.3413	   0.015010320	  
inosine	   1.0845	   0.588772492	  
inositol	  1-­‐phosphate	  (I1P)	   0.5126	   0.001615975	  
Isobar:	  fructose	  1,6-­‐diphosphate,	  glucose	  1,6-­‐
diphosphate	  
1.0127	   0.938953105	  
Isobar:	  ribulose	  5-­‐phosphate,	  xylulose	  5-­‐phosphate	   0.3295	   0.002534627	  
isoleucine	   0.4402	   0.000064794	  
leucine	   0.4848	   0.000528007	  
linoleamide	  (18:2n6)	   0.2548	   0.086201203	  
linoleate	  (18:2n6)	   1.9745	   0.000001287	  
lysine	   0.5299	   0.001020144	  
malate	   1.1058	   0.302271196	  
malitol	   4.6168	   0.006547860	  
maltose	   2.9322	   0.009397942	  
maltotetraose	   0.5551	   0.046188245	  
maltotriose	   1.1812	   0.414358832	  
mannose	   0.3816	   0.000299511	  
mannose-­‐1-­‐phosphate	   0.2129	   0.000000773	  
mannose-­‐6-­‐phosphate	   0.3399	   0.000099249	  
margarate	  (17:0)	   1.4893	   0.006515264	  
methylphosphate	   0.1155	   0.119725771	  
methylsuccinate	   0.4694	   0.015492167	  
mycothione	  (MSSM)*	   0.4294	   0.000284995	  
myo-­‐inositol	   0.4310	   0.000046217	  
myristate	  (14:0)	   0.9411	   0.502310756	  
N-­‐6-­‐trimethyllysine	   1.6970	   0.086106062	  
N-­‐acetylglutamate	   0.1915	   0.001173212	  
N-­‐acetylornithine	   13.9076	   0.001563377	  
n-­‐Butyl	  Oleate	   0.6577	   0.258382263	  
N2-­‐acetyllysine	   1.4292	   0.084569726	  
N6-­‐acetyllysine	   1.0263	   0.866137067	  
nicotinamide	  adenine	  dinucleotide	  (NAD+)	   0.2486	   0.000001676	  
nicotinate	   0.2762	   0.000224946	  
nicotinate	  ribonucleoside*	   0.3350	   0.005414823	  
nicotinic	  acid	  mononucleotide	  (NaMN)	   0.2110	   0.000011843	  
O-­‐acetylhomoserine	   0.4415	   0.000274634	  
oleamide	   0.2969	   0.066537598	  
oleate	  (18:1n9)	   2.2505	   0.000025901	  
ornithine	   0.5867	   0.001865578	  
palmitate	  (16:0)	   0.9616	   0.377259423	  
pantothenate	   0.2161	   0.000028308	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pentadecanoate	  (15:0)	   1.1171	   0.086609671	  
phenylalanine	   1.1129	   0.592178077	  
phosphate	   1.7699	   0.001973597	  
pipecolate	   0.7986	   0.494987747	  
proline	   0.2410	   0.000005216	  
pyruvate	   1.5097	   0.028969869	  
ribose	  5-­‐phosphate	   1.4781	   0.355917684	  
S-­‐adenosylhomocysteine	  (SAH)	   0.2035	   0.000001464	  
sedoheptulose-­‐7-­‐phosphate	   0.4571	   0.000177267	  
serine	   0.3686	   0.000044288	  
sorbitol	   3.5214	   0.023860615	  
stearate	  (18:0)	   0.9900	   0.865386426	  
succinate	   0.2874	   0.000036198	  
succinyl	  CoA	   1.7079	   0.140596777	  
threonine	   0.1294	   0.000000291	  
thymidine	  5'-­‐monophosphate	   0.2599	   0.000308292	  
trehalose	   1.0891	   0.541711278	  
trehalose	  6-­‐phosphate	   0.1628	   0.006365764	  
triethyleneglycol	   0.9731	   0.789545082	  
tryptophan	   0.5933	   0.005209362	  
tyrosine	   0.6995	   0.077677710	  
valine	   0.3018	   0.000005388	  
X	  -­‐	  02973	   0.5506	   0.003283806	  
X	  -­‐	  03094	   0.8145	   0.043294197	  
X	  -­‐	  04033	   8.7237	   0.015157693	  
X	  -­‐	  04044	  	   0.8697	   0.058128617	  
X	  -­‐	  04768	   1.8307	   0.012026906	  
X	  -­‐	  05407	  -­‐	  retired	  for	  2,3-­‐dihydroxyisovalerate	   1.2072	   0.086218191	  
X	  -­‐	  05437	   0.5604	   0.005968419	  
X	  -­‐	  06346	  -­‐	  retired	  for	  isoproturon	   1.2426	   0.346685166	  
X	  -­‐	  07887-­‐	  retired	  for	  p-­‐toluic	  acid	  	   1.0585	   0.573374023	  
X	  -­‐	  08754	   0.2044	   0.000006017	  
X	  -­‐	  08889	   1.2427	   0.485254859	  
X	  -­‐	  08988	   0.8283	   0.734434555	  
X	  -­‐	  10821	  -­‐	  retired	  for	  gamma-­‐glutamylmethionine	   0.0433	   0.000007111	  
X	  -­‐	  10889	   0.2303	   0.000107866	  
X	  -­‐	  11011	  -­‐	  retired	  for	  2-­‐methylcitrate	   0.7148	   0.330074809	  
X	  -­‐	  11251	   1.2961	   0.011463773	  
X	  -­‐	  11297	   0.6385	   0.097424806	  
X	  -­‐	  11391	   1.1097	   0.092179609	  
X	  -­‐	  11394	   1.0339	   0.378431842	  
X	  -­‐	  11395	   0.9593	   0.689867241	  
X	  -­‐	  11404	   1.0246	   0.712704435	  
X	  -­‐	  11406_200	   0.4812	   0.355917684	  
X	  -­‐	  11453	   1.2121	   0.314669108	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X	  -­‐	  11455	   1.3597	   0.112664688	  
X	  -­‐	  11456	  -­‐	  retired	  for	  tetraethylene	  glycol	   1.1740	   0.184916742	  
X	  -­‐	  11457	   1.1592	   0.044274550	  
X	  -­‐	  11461	   1.3061	   0.004517783	  
X	  -­‐	  11509	   3.0601	   0.000066355	  
X	  -­‐	  11533	   0.9282	   0.153747050	  
X	  -­‐	  11550	   0.5011	   0.000027172	  
X	  -­‐	  11568	  -­‐	  retired	  for	  ergothioneine	   0.0278	   0.000000013	  
X	  -­‐	  11687_200	   2.8933	   0.023689277	  
X	  -­‐	  11730-­‐	  retired	  for	  17-­‐methylstearate	   3.1402	   0.000279737	  
X	  -­‐	  11795	   11.5222	   0.002818278	  
X	  -­‐	  11809	   0.5619	   0.015358099	  
X	  -­‐	  11840	   0.9875	   0.918523786	  
X	  -­‐	  11875	   0.8357	   0.139495515	  
X	  -­‐	  11910	   1.1954	   0.081907611	  
X	  -­‐	  12051	   0.1579	   0.000041817	  
X	  -­‐	  12660	   0.1208	   0.000012793	  
X	  -­‐	  12776	   1.2209	   0.046586001	  
X	  -­‐	  12805	   0.9535	   0.667743217	  
X	  -­‐	  12889_201	   0.0722	   0.000000000	  
X	  -­‐	  13005	   0.6470	   0.017832251	  
X	  -­‐	  13093	   1.5596	   0.574092317	  
X	  -­‐	  13149	   1.3345	   0.003093639	  
X	  -­‐	  13168	   1.0000	   	  
X	  -­‐	  13183	  -­‐	  retired	  for	  stearamide	   0.5912	   0.217364956	  
X	  -­‐	  13548	   1.0990	   0.285006083	  
X	  -­‐	  13549	   1.0507	   0.609667748	  
X	  -­‐	  13645	   1.0000	   	  
X	  -­‐	  13672	   1.2742	   0.053370122	  
X	  -­‐	  13737	   0.4223	   0.000321245	  
X	  -­‐	  13828	   0.8855	   0.495973254	  
X	  -­‐	  13872	   0.5563	   0.004082046	  
X	  -­‐	  14318	   1.0000	   	  
X	  -­‐	  14359	   0.1788	   0.000020884	  
X	  -­‐	  14568	   1.3020	   0.004982376	  
X	  -­‐	  14575	   4.1950	   0.000343660	  
X	  -­‐	  14588	   2.2485	   0.004081221	  
X	  -­‐	  14955	   1.7146	   0.066359291	  
X	  -­‐	  15138	   0.7239	   0.012575161	  
X	  -­‐	  15177	   0.3538	   0.000331370	  
X	  -­‐	  15261	  -­‐	  retired	  for	  2-­‐methylcitrate	   1.0000	   	  
X	  -­‐	  15279	   0.8442	   0.235179536	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Table 4.2. Conditionally Essential Genes Underrepresented at Week Three 
of Hypoxia Versus Input Library (IvH3). 
  
Gene	  Number	   Gene	  Name	   Log2	  Fold	  Change	   P	  Val.	  (resampling)	  
Rv1069c	   -­‐	   -­‐4.8575	   0.0004	  
Rv3680	   -­‐	   -­‐4.7476	   0.0004	  
Rv3133c	   dosR	   -­‐4.5473	   0.0004	  
Rv2179c	   -­‐	   -­‐3.8493	   0.0004	  
Rv3720	   -­‐	   -­‐3.0884	   0.0004	  
Rv0204c	   -­‐	   -­‐2.7567	   0.0004	  
Rv2869c	   rip	   -­‐2.7228	   0.0004	  
Rv3849	   espR	   -­‐2.6390	   0.0004	  
Rv3270	   ctpC	   -­‐2.4333	   0.0004	  
Rv1432	   -­‐	   -­‐2.3675	   0.0004	  
Rv2381c	   mbtD	   -­‐2.1842	   0.0004	  
Rv3810	   pirG	   -­‐2.0850	   0.0004	  
Rv2386c	   mbtI	   -­‐2.0843	   0.0032	  
Rv2535c	   pepQ	   -­‐2.0603	   0.0004	  
Rv3210c	   -­‐	   -­‐1.9555	   0.0004	  
Rv3024c	   trmU	   -­‐1.9549	   0.0004	  
Rv1170	   mshB	   -­‐1.9153	   0.0004	  
Rv0135c	   -­‐	   -­‐1.8953	   0.0004	  
Rv2115c	   mpa	   -­‐1.8819	   0.0032	  
Rv2384	   mbtA	   -­‐1.8679	   0.0004	  
Rv0821c	   phoY2	   -­‐1.8580	   0.0004	  
Rv2383c	   mbtB	   -­‐1.8315	   0.0004	  
Rv0361	   -­‐	   -­‐1.8253	   0.0004	  
Rv2379c	   mbtF	   -­‐1.8236	   0.0004	  
Rv0470c	   pcaA	   -­‐1.8152	   0.0004	  
Rv2031c	   hspX	   -­‐1.8005	   0.0004	  
Rv2380c	   mbtE	   -­‐1.6252	   0.0004	  
Rv2051c	   ppm1	   -­‐1.6009	   0.0004	  
Rv1178	   -­‐	   -­‐1.5796	   0.0004	  
Rv0344c	   lpqJ	   -­‐1.5436	   0.0004	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Table 4.3. Conditionally Essential Genes Overrepresented at Week Three of 
Hypoxia Versus Input Library (IvH3). 
 
Gene	  Number	   Gene	  Name	   Log2	  Fold	  Change	   P	  Val.	  (resampling)	  
Rv3484	   cpsA	   1.5272	   0.0004	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Table 4.4. Conditionally Essential Genes Underrepresented at Week Six of 
Hypoxia Versus Input Library (IvH6). 
 
Gene	  Number	   Gene	  Name	   Log2	  Fold	  Change	   P	  Val.	  (resampling)	  
Rv1069c	   -­‐	   -­‐5.9379	   0.0002	  
Rv0361	   -­‐	   -­‐5.7894	   0.0002	  
Rv2031c	   hspX	   -­‐5.3831	   0.0002	  
Rv2869c	   rip	   -­‐4.9620	   0.0002	  
Rv3133c	   dosR	   -­‐4.8122	   0.0002	  
Rv1712	   cmk	   -­‐4.7855	   0.0002	  
Rv2384	   mbtA	   -­‐4.6212	   0.0002	  
Rv3261	   fbiA	   -­‐4.3418	   0.0002	  
Rv2179c	   -­‐	   -­‐4.2293	   0.0002	  
Rv2383c	   mbtB	   -­‐4.0530	   0.0002	  
Rv2115c	   mpa	   -­‐4.0384	   0.0002	  
Rv1432	   -­‐	   -­‐3.8820	   0.0002	  
Rv0561c	   -­‐	   -­‐3.8623	   0.0002	  
Rv0007	   -­‐	   -­‐3.8120	   0.0002	  
Rv3274c	   fadE25	   -­‐3.7889	   0.0002	  
Rv2379c	   mbtF	   -­‐3.7030	   0.0002	  
Rv3193c	   -­‐	   -­‐3.6257	   0.0002	  
Rv3849	   espR	   -­‐3.5857	   0.0017	  
Rv2381c	   mbtD	   -­‐3.5797	   0.0002	  
Rv2563	   -­‐	   -­‐3.5323	   0.0002	  
Rv2382c	   mbtC	   -­‐3.5236	   0.0002	  
Rv0248c	   -­‐	   -­‐3.4902	   0.0002	  
Rv0127	   mak	   -­‐3.4007	   0.0002	  
Rv0204c	   -­‐	   -­‐3.3985	   0.0002	  
Rv0998	   MtPat	   -­‐3.3748	   0.0002	  
Rv2623	   TB31.7	   -­‐3.3700	   0.0002	  
Rv3160c	   -­‐	   -­‐3.3584	   0.0002	  
Rv1791	   PE19	   -­‐3.3413	   0.0002	  
Rv3283	   sseA	   -­‐3.2967	   0.0002	  
Rv0247c	   -­‐	   -­‐3.2641	   0.0002	  
Rv3574	   kstR	   -­‐3.2366	   0.0002	  
Rv0407	   fgd1	   -­‐3.2079	   0.0002	  
Rv2241	   aceE	   -­‐3.0503	   0.0002	  
Rv0470c	   pcaA	   -­‐3.0423	   0.0002	  
Rv3680	   -­‐	   -­‐3.0312	   0.0002	  
Rv1626	   -­‐	   -­‐3.0307	   0.0002	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Rv2553c	   -­‐	   -­‐3.0126	   0.0017	  
Rv3270	   ctpC	   -­‐3.0037	   0.0002	  
Rv2386c	   mbtI	   -­‐2.9984	   0.0002	  
Rv2989	   -­‐	   -­‐2.8756	   0.0002	  
Rv2140c	   TB18.6	   -­‐2.8731	   0.0002	  
Rv0436c	   pssA	   -­‐2.8724	   0.0002	  
Rv2380c	   mbtE	   -­‐2.8710	   0.0002	  
Rv3720	   -­‐	   -­‐2.8691	   0.0002	  
Rv1823	   -­‐	   -­‐2.8633	   0.0002	  
Rv0757	   phoP	   -­‐2.8460	   0.0002	  
Rv2170	   -­‐	   -­‐2.8368	   0.0002	  
Rv3810	   pirG	   -­‐2.8106	   0.0002	  
Rv2051c	   ppm1	   -­‐2.7740	   0.0002	  
Rv3220c	   -­‐	   -­‐2.7419	   0.0002	  
Rv0249c	   -­‐	   -­‐2.7103	   0.0002	  
Rv1287	   -­‐	   -­‐2.6170	   0.0002	  
Rv1592c	   -­‐	   -­‐2.6134	   0.0002	  
Rv2091c	   -­‐	   -­‐2.5880	   0.0002	  
Rv0821c	   phoY2	   -­‐2.5782	   0.0002	  
Rv1212c	   glgA	   -­‐2.5432	   0.0002	  
Rv1908c	   katG	   -­‐2.5380	   0.0002	  
Rv2535c	   pepQ	   -­‐2.5360	   0.0002	  
Rv0554	   bpoC	   -­‐2.5128	   0.0002	  
Rv0994	   moeA1	   -­‐2.4421	   0.0002	  
Rv1824	   -­‐	   -­‐2.4131	   0.0002	  
Rv3433c	   -­‐	   -­‐2.4048	   0.0002	  
Rv3256c	   -­‐	   -­‐2.3736	   0.0002	  
Rv3207c	   -­‐	   -­‐2.3405	   0.0002	  
Rv0758	   phoR	   -­‐2.3014	   0.0002	  
Rv2030c	   -­‐	   -­‐2.2870	   0.0002	  
Rv0135c	   -­‐	   -­‐2.2643	   0.0002	  
Rv2404c	   lepA	   -­‐2.1605	   0.0002	  
Rv1860	   apa	   -­‐2.1522	   0.0002	  
Rv3024c	   iscS	   -­‐2.1400	   0.0002	  
Rv1345	   mbtM	   -­‐2.0732	   0.0002	  
Rv3600c	   -­‐	   -­‐2.0541	   0.0002	  
Rv2859c	   -­‐	   -­‐2.0054	   0.0002	  
Rv1473	   -­‐	   -­‐1.9806	   0.0002	  
Rv2378c	   mbtG	   -­‐1.9773	   0.0031	  
Rv3236c	   kefB	   -­‐1.9225	   0.0002	  
Rv1078	   pra	   -­‐1.8989	   0.0002	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Rv0324	   -­‐	   -­‐1.8914	   0.0002	  
Rv2171	   lppM	   -­‐1.8815	   0.0002	  
Rv3132c	   dosS	   -­‐1.8678	   0.0002	  
Rv3664c	   dppC	   -­‐1.8552	   0.0002	  
Rv0066c	   icd2	   -­‐1.8224	   0.0031	  
Rv2672	   -­‐	   -­‐1.7974	   0.0002	  
Rv1170	   mshB	   -­‐1.7955	   0.0002	  
Rv1178	   -­‐	   -­‐1.7671	   0.0002	  
Rv3068c	   pgmA	   -­‐1.7581	   0.0002	  
Rv0945	   -­‐	   -­‐1.7542	   0.0017	  
Rv2737c	   recA	   -­‐1.7461	   0.0002	  
Rv1538c	   ansA	   -­‐1.7320	   0.0002	  
Rv1112	   -­‐	   -­‐1.7141	   0.0002	  
Rv0472c	   -­‐	   -­‐1.7054	   0.0002	  
Rv1013	   pks16	   -­‐1.7018	   0.0002	  
Rv1070c	   echA8	   -­‐1.6732	   0.0002	  
Rv2733c	   -­‐	   -­‐1.6574	   0.0002	  
Rv2363	   amiA2	   -­‐1.5768	   0.0002	  
Rv2006	   otsB1	   -­‐1.5561	   0.0002	  
Rv1565c	   -­‐	   -­‐1.5550	   0.0002	  
Rv2795c	   -­‐	   -­‐1.5277	   0.0002	  
Rv3223c	   sigH	   -­‐1.5209	   0.0002	  
Rv2583c	   relA	   -­‐1.5203	   0.0002	  
Rv2224c	   caeA	   -­‐1.5047	   0.0002	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Table 4.5. Conditionally Essential Genes Overrepresented at Week Six of 
Hypoxia Versus Input Library (IvH6). 
 
Gene	  Number	   Gene	  Name	   Log2	  Fold	  Change	   P	  Val.	  (resampling)	  
Rv1339	   -­‐	   4.2622	   0.0002	  
Rv0019c	   fhaB	   3.9590	   0.0002	  
Rv3484	   cpsA	   3.7325	   0.0002	  
Rv3696c	   glpK	   3.6015	   0.0002	  
Rv0018c	   pstP	   2.9401	   0.0002	  
Rv0466	   -­‐	   2.5168	   0.0002	  
Rv2691	   ceoB	   2.2263	   0.0002	  
Rv1421	   -­‐	   2.0087	   0.0017	  
Rv0644c	   mmaA2	   2.0018	   0.0017	  
Rv1336	   cysM	   1.9908	   0.0002	  
Rv0642c	   mmaA4	   1.9764	   0.0002	  
Rv1244	   lpqZ	   1.9558	   0.0002	  
Rv1780	   -­‐	   1.7776	   0.0002	  
Rv2694c	   -­‐	   1.7487	   0.0002	  
Rv1058	   fadD14	   1.6854	   0.0002	  
Rv1543	   -­‐	   1.6729	   0.0002	  
Rv1640c	   lysX	   1.6584	   0.0002	  
Rv3779	   -­‐	   1.6512	   0.0002	  
Rv3200c	   -­‐	   1.6057	   0.0002	  
Rv0199	   -­‐	   1.5736	   0.0002	  
Rv0877	   -­‐	   1.5478	   0.0002	  
Rv3130c	   tgs1	   1.5349	   0.0002	  
Rv3818	   -­‐	   1.5207	   0.0002	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Table 4.6. Conditionally Essential Genes Underrepresented at Week Six of 
Hypoxia Versus Week Three of Hypoxia (H3vH6). 
 
Gene	  Number	   Gene	  Name	   Log2	  Fold	  Change	   P	  Val.	  (resampling)	  
Rv0998	   MtPat	   -­‐4.5415	   0.0004	  
Rv0361	   -­‐	   -­‐3.7876	   0.0004	  
Rv2031c	   hspX	   -­‐3.5242	   0.0004	  
Rv3261	   fbiA	   -­‐3.0411	   0.0004	  
Rv0007	   -­‐	   -­‐2.7064	   0.0004	  
Rv2384	   mbtA	   -­‐2.6587	   0.0004	  
Rv2170	   -­‐	   -­‐2.6194	   0.0032	  
Rv0561c	   -­‐	   -­‐2.6041	   0.0004	  
Rv1791	   PE19	   -­‐2.5614	   0.0004	  
Rv0248c	   -­‐	   -­‐2.5165	   0.0004	  
Rv2241	   aceE	   -­‐2.3929	   0.0004	  
Rv0066c	   icd2	   -­‐2.3862	   0.0004	  
Rv1212c	   glgA	   -­‐2.3151	   0.0004	  
Rv0247c	   -­‐	   -­‐2.2883	   0.0004	  
Rv2563	   -­‐	   -­‐2.2569	   0.0004	  
Rv2383c	   mbtB	   -­‐2.2311	   0.0004	  
Rv0407	   fgd1	   -­‐2.1537	   0.0004	  
Rv1823	   -­‐	   -­‐2.1288	   0.0004	  
Rv1908c	   katG	   -­‐2.1165	   0.0004	  
Rv3574	   kstR	   -­‐1.9883	   0.0032	  
Rv3283	   sseA	   -­‐1.9553	   0.0004	  
Rv0758	   phoR	   -­‐1.9516	   0.0004	  
Rv2379c	   mbtF	   -­‐1.9279	   0.0004	  
Rv2989	   -­‐	   -­‐1.9163	   0.0004	  
Rv0757	   phoP	   -­‐1.8225	   0.0004	  
Rv2091c	   -­‐	   -­‐1.7524	   0.0004	  
Rv3236c	   kefB	   -­‐1.7129	   0.0004	  
Rv0249c	   -­‐	   -­‐1.6799	   0.0004	  
Rv2672	   -­‐	   -­‐1.5389	   0.0004	  
Rv1626	   -­‐	   -­‐1.5278	   0.0004	  
Rv1592c	   -­‐	   -­‐1.5179	   0.0004	  
Rv2171	   lppM	   -­‐1.5079	   0.0004	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Table 4.7. Conditionally Essential Genes Overrepresented at Week Six of 
Hypoxia Versus Week Three of Hypoxia (H3vH6). 
 
Gene	  Number	   Gene	  Name	   Log2	  Fold	  Change	   P	  Val.	  (resampling)	  
Rv0019c	   fhaB	   3.2926	   0.0004	  
Rv3696c	   glpK	   3.0174	   0.0004	  
Rv2691	   ceoB	   2.8478	   0.0004	  
Rv1339	   -­‐	   2.8166	   0.0004	  
Rv1099c	   glpX	   2.3801	   0.0032	  
Rv2694c	   -­‐	   2.2676	   0.0004	  
Rv0018c	   pstP	   2.2675	   0.0004	  
Rv3484	   cpsA	   2.1723	   0.0004	  
Rv0642c	   mmaA4	   2.0369	   0.0004	  
Rv0466	   -­‐	   1.8434	   0.0004	  
Rv0820	   phoT	   1.8234	   0.0004	  
Rv1925	   fadD31	   1.8029	   0.0004	  
Rv0668	   rpoC	   1.7847	   0.0004	  
Rv1543	   -­‐	   1.6703	   0.0004	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Global profiling of protein modifications in bacteria has identified a number of 
post-translational acetylations on enzymatic proteins. This reversible acetylation 
of a lysine residue is a regulatory event capable of altering the activity of the 
acetylated enzyme. In Mycobacterium tuberculosis we sought to identify 
acetylated enzymes that may be involved in the metabolic switch to reductive 
TCA. We cultured WT, ∆MtPat, and ∆CobB strains in hypoxic and normoxic 
conditions to identify what acetylations are dependent on hypoxia and MtPat. 
While a number of acetylated peptides were identified, none could be confidently 




Protein lysine acetylation is a post-translational modification recently described in 
bacteria (Zhang et al., 2009). Reversible lysine acetylation of substrate proteins 
carried out by a protein acetyltransferase (Pat) enzyme and cognate deacetylase 
(CobB) can serve as a regulatory mechanism for controlling enzymatic activity of 
acetylated proteins (Crosby et al., 2010; Nambi et al., 2010). The Pat ortholog in 
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M. tuberculosis, MtPat (Rv0998), was shown to acetylate a number of proteins 
controlling acetyl-CoA availability (Nambi et al., 2013; Xu et al., 2011). Other 
bacterial proteomic studies have identified acetylations of central metabolic 
enzymes involved in the TCA cycle (Zhang et al, 2009, Wang et al., 2010). In 
order to identify any potential acetylations, and therefore regulations, of 
metabolic enzymes in M. tuberculosis, in both aerobic and hypoxic conditions, we 
utilized an acetyl-peptide enrichment technique coupled with mass spectrometry.  
 
Materials and Methods 
 
Acetyl-enriched peptides were obtained from WT, ∆MtPat, and ∆CobB (Rv1151 - 
deactylase) strains from aerobic and hypoxic conditions. Strains were grown in 
triplicate in each condition, and at day 18 of hypoxic or aerobic culture cells were 
pelleted, washed and lysed. The resulting peptide extracts were digested with 
Trypsin (Promega) and incubated with an anti-acetyl-lysine antibody conjugated 
to beads (Immunechem Pharmaceuticals, ICP0388). 4 mg of digested protein 
was mixed with approximately 40 µL of washed beads and incubated overnight at 
4ºC. Beads were washed 4x and peptides eluted in 100 mM glycine pH 2. Eluted 
peptides were desalted and concentrated with ZipTips (Millipore) before MS 
analysis. Peptide analysis was done with the Mascot search engine (version 
2.4.1) using the Tuberculist_R27_050213 database. Scaffold software analysis 
was used with the following specificaitons: Protein Grouping Strategy: 
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Experiment-wide grouping with protein cluster analysis, Peptide Thresholds: 
80.0% minimum, Protein Thresholds: 90.0% minimum and 1 peptide minimum, 




Acetylated peptides identified from this enrichment strategy are listed in Tables 
4.8 – 4.13. As expected, deletion of the deacetylase, ∆CobB, resulted in the most 
acetyl-enriched peptides (153 in hypoxia, 128 in normoxia), while WT H37RV 
had the fewest (81 in hypoxia, 14 in normoxia). The acetyltransferase deletion 
strain ∆MtPat had a similar number of acetyl-enriched peptides between both 
coniditons (100 in hypoxia, 103 in normoxia). The increase in acetyl-peptides 
from normoxia to hypoxia in WT suggests that acetylation is upregulated upon 
sensing oxygen tension. Furthermore, a number of metabolic peptides are 
acetylated in hypoxic conditions in WT that are not present in normoxic 




A number of central metabolic enzymes were identified as acetylated (aceE, acn, 
gdh), however, since they were identified in ∆MtPat (hypoxic and normoxic 
conditions), we are unable to conclude whether their acetylation depends on 
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MtPat. It is possible that in the absence of MtPat another acetyltransferase is 
able to compensate, or that lysine acetylation occurs spontaneously when 
concetrations of acetyl-CoA are high. Indeed, the overall increase in acetyl-
enriched peptides from the ∆MtPat strain as compared to WT would suggest that 
in the absence of MtPat, acetylation is increased. We were unable to obtain 
peptides from known acetylation substrates of MtPat (Nambi et al., 2013; Xu et 
al., 2011), however this may be due to an excess of acetyl-peptides available to 
bind to the anti-acetyl-lysine antibody, or that the anti-acetyl-lysine antibody did 
not have the same affinity for all lysine acetylated peptides. Because of these 
issues, biochemical characterization of reversible acetylations by Pat proteins is 






Hypoxic cultures, protein extraction, peptide enrichment was done by Emily 
Rittershaus. MS analysis was done by John Lescyk. 
  154 
Table 4.8. Peptides Identified by Anti-Acetyl-Lysine Enrichment from WT (H37Rv) Normoxia 
Trypsinized Lysate. 
Protein	  name	   Total	  
spectrum	  
count	  
Peptide	  sequence	   Variable	  modifications	  
identified	  by	  spectrum	  
Rv3800c_pks13	   1	   GGYLkDIK	   k5:	  Acetyl	  (+42.01)	  
Rv0860_fadB	   2	   GYSEkLEAK	   k5:	  Acetyl	  (+42.01)	  
Rv0860_fadB	   2	   LEAkALER	   k4:	  Acetyl	  (+42.01)	  
Rv0685_tuf	   1	   TTLTAAITK	   	  
Rv1827_garA	   1	   LVFLTGPK	   	  
Rv0440_groEL2	   3	   GLNALADAVK	   	  
Rv0440_groEL2	   3	   LAGGVAVIK	   	  
Rv0440_groEL2	   3	   VALEAPLK	   	  
Rv2031c_hspX	   1	   DGQLTIkAER	   k7:	  Acetyl	  (+42.01)	  
Rv3520c_Rv3520c	   1	   ALkPITHPLR	   k3:	  Acetyl	  (+42.01)	  
Rv2605c_tesB2	   1	   ASQQQVWLR	   	  
Rv2241_aceE	   1	   TFkEVLR	   k3:	  Acetyl	  (+42.01)	  
Rv0815c_cysA2	   1	   VkLLDGGR	   k2:	  Acetyl	  (+42.01)	  
Rv3418c_groES	   1	   DVLAVVSK	   	  
Rv3131_Rv3131	   1	   TVLTLAVR	   	  
Rv3274c_fadE25	   1	   DDEGFTVGPkER	   k10:	  Acetyl	  (+42.01)	  
Rv3417c_groEL1	   1	   LAGGVAVIK	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Table 4.9. Peptides Identified by Anti-Acetyl-Lysine Enrichment from WT 
(H37Rv) Hypoxia Trypsinized Lysate. 
Protein	  name	   Total	  
spectrum	  
count	  
Peptide	  sequence	   Variable	  modifications	  
identified	  by	  spectrum	  
Rv3569c_hsaD	   1	   LSkFSVAPTR	   k3:	  Acetyl	  (+42.01)	  
Rv2145c_wag31	   1	   TYLESQLEELGQR	   	  
Rv2220_glnA1	   1	   DEkVEYVDVR	   k3:	  Acetyl	  (+42.01)	  
Rv0384c_clpB	   2	   HIEkDAALER	   k4:	  Acetyl	  (+42.01)	  
Rv0384c_clpB	   2	   HIEkDAALER	   k4:	  Acetyl	  (+42.01)	  
Rv0566c_Rv0566c	   1	   AAVDVFKEk	   k9:	  Acetyl	  (+42.01)	  
Rv1636_TB15.3	   1	   AADILkDESYK	   k6:	  Acetyl	  (+42.01)	  
Rv3800c_pks13	   2	   GGYLkDIK	   k5:	  Acetyl	  (+42.01)	  
Rv3800c_pks13	   2	   HSVYFTHGIR	   	  
Rv1390_rpoZ	   1	   YALVIYAAK	   	   	  
Rv2416c_eis	   1	   VDRTDLkLAR	   k7:	  Acetyl	  (+42.01)	  
Rv1310_atpD	   2	   TISLQPTDGLVR	   	  
Rv1310_atpD	   2	   TVLIQEmINR	   m7:	  Oxidation	  (+15.99)	  
Rv0707_rpsC	   1	   ADLEkLTGK	   k5:	  Acetyl	  (+42.01)	  
Rv1144_Rv1144	   1	   DLASkLIR	   k5:	  Acetyl	  (+42.01)	  
Rv3418c_groES	   4	   EKPQEGTVVAVGPGR	  
Rv3418c_groES	   4	   ILVQANEAETTTASGLVIPDTAK	  
Rv3418c_groES	   4	   VNIkPLEDK	   k4:	  Acetyl	  (+42.01)	  
Rv3418c_groES	   4	   YNGEEYLILSAR	   	  
Rv0350_dnaK	   4	   DAGQIAGLNVLR	   	  
Rv0350_dnaK	   4	   IQEGSGLSkEDIDR	   k9:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   4	   kYTAPEISAR	   k1:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   4	   NQAETLVYQTEK	   	  
Rv2429_ahpD	   2	   AALPEYAkDIK	   k8:	  Acetyl	  (+42.01)	  
Rv2429_ahpD	   2	   DIkLNLSSITR	   k3:	  Acetyl	  (+42.01)	  
Rv0503c_cmaA2	   1	   SHYDkSNEFFK	   k5:	  Acetyl	  (+42.01)	  
Rv0860_fadB	   3	   GAGFYEYADGkR	   k11:	  Acetyl	  (+42.01)	  
Rv0860_fadB	   3	   LEAkALER	   k4:	  Acetyl	  (+42.01)	  
Rv0860_fadB	   3	   LVAEkDSITGVVVASAK	   k5:	  Acetyl	  (+42.01)	  
Rv0282_eccA3	   1	   LVVIIAGYR	   	   	  
Rv0247c_Rv0247c	   1	   LQQTQTPDLAVR	   	  
Rv0569_Rv0569	   1	   FGAVQSAILHAR	   	  
Rv0652_rplL	   1	   EAkDLVDGAPKPLLEK	   k3:	  Acetyl	  (+42.01)	  
Rv1133c_metE	   1	   mRQEITEVIALQER	   m1:	  Oxidation	  (+15.99)	  
Rv1630_rpsA	   1	   DLQPYIGkEIEAK	   k8:	  Acetyl	  (+42.01)	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Rv2783c_gpsI	   6	   DGLVHISkLGK	   k8:	  Acetyl	  (+42.01)	  
Rv2783c_gpsI	   6	   IDEIkTQVVQR	   k5:	  Acetyl	  (+42.01)	  
Rv2783c_gpsI	   6	   IDEIkTQVVQR	   k5:	  Acetyl	  (+42.01)	  
Rv2783c_gpsI	   6	   VEDVVNVGDkLR	   k10:	  Acetyl	  (+42.01)	  
Rv2783c_gpsI	   6	   VEIADIDkR	   k8:	  Acetyl	  (+42.01)	  
Rv2783c_gpsI	   6	   VPVDkIGEVIGPK	   k5:	  Acetyl	  (+42.01)	  
Rv3628_ppa	   3	   HFFVHYkDLEPGK	   k7:	  Acetyl	  (+42.01)	  
Rv3628_ppa	   3	   HFFVHYkDLEPGK	   k7:	  Acetyl	  (+42.01)	  
Rv3628_ppa	   3	   HFFVHYkDLEPGK	   k7:	  Acetyl	  (+42.01)	  
Rv2460c_clpP2	   1	   DTDRDkILTAEEAK	   k6:	  Acetyl	  (+42.01)	  
Rv2185c_TB16.3	   1	   LIDGALkDLK	   k7:	  Acetyl	  (+42.01)	  
Rv1306_atpF	   1	   AEQQVASTLQTAHEQLkR	   k17:	  Acetyl	  (+42.01)	  
Rv2299c_htpG	   1	   VLSTIkDVQSSRPEDYR	   k6:	  Acetyl	  (+42.01)	  
Rv1932_tpx	   1	   DLPFAQkR	   k7:	  Acetyl	  (+42.01)	  
Rv2031c_hspX	   3	   DGQLTIkAER	   k7:	  Acetyl	  (+42.01)	  
Rv2031c_hspX	   3	   SEFAYGSFVR	   	  
Rv2031c_hspX	   3	   TVSLPVGADEDDIKATYDK	  
Rv3596c_clpC1	   3	   EFDEkIAEAR	   k5:	  Acetyl	  (+42.01)	  
Rv3596c_clpC1	   3	   VLkEINTR	   k3:	  Acetyl	  (+42.01)	  
Rv3596c_clpC1	   3	   YIEkDAALER	   k4:	  Acetyl	  (+42.01)	  
Rv1448c_tal	   1	   IVDRPNLFIkIPATK	   k10:	  Acetyl	  (+42.01)	  
Rv1521_fadD25	   1	   DLLIVYGR	   	   	  
Rv2534c_efp	   1	   VVDkTFNAGVK	   k4:	  Acetyl	  (+42.01)	  
Rv0971c_echA7	   1	   YYLTGEkFGAR	   k7:	  Acetyl	  (+42.01)	  
Rv1211_Rv1211	   1	   TGDGPLEATkEGR	   k10:	  Acetyl	  (+42.01)	  
Rv1201c_dapD	   1	   GPVTVYGVDkFPR	   k10:	  Acetyl	  (+42.01)	  
Rv1248c_Rv1248c	   2	   DFTEIkFR	   k6:	  Acetyl	  (+42.01)	  
Rv1248c_Rv1248c	   2	   VDGFAGAQYKk	   k11:	  Acetyl	  (+42.01)	  
Rv0824c_desA1	   1	   SVDPVELEkLR	   k9:	  Acetyl	  (+42.01)	  
Rv0706_rplV	   1	   TSHITVVVESR	   	  
Rv1925_fadD31	   2	   NIkYVGDLVAYR	   k3:	  Acetyl	  (+42.01)	  
Rv1925_fadD31	   2	   NIkYVGDLVAYR	   k3:	  Acetyl	  (+42.01)	  
Rv0685_tuf	   5	   AFDQIDNAPEER	   	  
Rv0685_tuf	   5	   GITINIAHVEYQTDKR	  
Rv0685_tuf	   5	   PGTTTPHTEFEGQVYILSkDEG
GR	  
k19:	  Acetyl	  (+42.01)	  
Rv0685_tuf	   5	   TTLTAAITK	   	   	  
Rv0685_tuf	   5	   VSALkALEGDAK	   k5:	  Acetyl	  (+42.01)	  
Rv3520c_Rv3520c	   1	   ALkPITHPLR	   k3:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   15	   AGAATEVELkER	   k10:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   15	   GLNALADAVK	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Rv0440_groEL2	   15	   GTFkSVAVK	   k4:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   15	   IGAELVkEVAK	   k7:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   15	   LAkLAGGVAVIK	   k3:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   15	   NVAAGANPLGLkR	   k12:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   15	   NVVLEKk	   k7:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   15	   QEIENSDSDYDREkLQER	   k14:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   15	   QEIENSDSDYDREkLQER	   k14:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   15	   qIAFNSGLEPGVVAEkVR	   n-­‐term:	  Gln-­‐>pyro-­‐Glu	  (-­‐
17.03),	  k16:	  Acetyl	  
(+42.01)	  
Rv0440_groEL2	   15	   VALEAPLK	   	   	  
Rv0440_groEL2	   15	   VSTVkDLLPLLEK	   k5:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   15	   VSTVkDLLPLLEK	   k5:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   15	   VTETLLkGAK	   k7:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   15	   VVVTkDETTIVEGAGDTDAIA
GR	  
k5:	  Acetyl	  (+42.01)	  
Rv3648c_cspA	   2	   TLEENQkVEFEIGHSPK	   k7:	  Acetyl	  (+42.01)	  
Rv3648c_cspA	   2	   VEFEIGHSPK	   	  
Rv3029c_fixA	   1	   TNIVVLIK	   	   	  
Rv3458c_rpsD	   1	   IkESEYLLQLQEK	   k2:	  Acetyl	  (+42.01)	  
Rv3846_sodA	   1	   GANDAVAkLEEAR	   k8:	  Acetyl	  (+42.01)	  
Rv0667_rpoB	   2	   LHHLVDDkIHAR	   k8:	  Acetyl	  (+42.01)	  
Rv0667_rpoB	   2	   LHHLVDDkIHAR	   k8:	  Acetyl	  (+42.01)	  
Rv3581c_ispF	   3	   HVVVLITQHGYR	   	  
Rv3581c_ispF	   3	   HVVVLITQHGYR	   	  
Rv3581c_ispF	   3	   HVVVLITQHGYR	   	  
Rv3274c_fadE25	   1	   GANGISAFmVHKDDEGFTVG
PkER	  
m9:	  Oxidation	  (+15.99),	  
k22:	  Acetyl	  (+42.01)	  
Rv2992c_gltS	   1	   DALIEGLALkPR	   k10:	  Acetyl	  (+42.01)	  
Rv0815c_cysA2	   1	   VkLLDGGR	   k2:	  Acetyl	  (+42.01)	  
Rv3285_accA3	   1	   NFLPAPGPVTkFHPPSGPGVR	   k11:	  Acetyl	  (+42.01)	  
Rv2703_sigA	   1	   AVEkFDYTK	   k4:	  Acetyl	  (+42.01)	  
Rv0831c_Rv0831c	   1	   LkDELLRQ	   k2:	  Acetyl	  (+42.01)	  
Rv3417c_groEL1	   1	   LAkLAGGVAVIK	   k3:	  Acetyl	  (+42.01)	  
Rv2882c_frr	   2	   EGEAGEDEVGRAEkDLDK	   k14:	  Acetyl	  (+42.01)	  
Rv2882c_frr	   2	   TTHQYVTQIDELVkHK	   k14:	  Acetyl	  (+42.01)	  
Rv0002_dnaN	   2	   ALPNkPVDVHVEGNR	   k5:	  Acetyl	  (+42.01)	  
Rv0002_dnaN	   2	   LLDAEFPkFR	   k8:	  Acetyl	  (+42.01)	  
Rv0489_gpm1	   1	   HYGALQGLDkAETK	   k10:	  Acetyl	  (+42.01)	  
Rv1463_Rv1463	   1	   YAESQHGGILLITHYTR	  
Rv3774_echA21	   1	   YASADAkFSVR	   k7:	  Acetyl	  (+42.01)	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Rv2211c_gcvT	   1	   AALLAEkAAGPR	   k7:	  Acetyl	  (+42.01)	  
Rv2244_acpM	   3	   IESENPDAVANVQAR	  
Rv2244_acpM	   3	   TVGDVVAYIQK	   	  
Rv2244_acpM	   3	   TVGDVVAYIQK	   	  
Rv1627c_Rv1627c	   1	   SFTEkHLGSVAGVPSVR	   k5:	  Acetyl	  (+42.01)	  
Rv3457c_rpoA	   1	   TESDLLDIR	   	   	  
Rv1308_atpA	   2	   HVLIIFDDLTK	   	  
Rv1308_atpA	   2	   LTEVIkNFK	   k6:	  Acetyl	  (+42.01)	  
Rv2241_aceE	   2	   GYALGkHFEGR	   k6:	  Acetyl	  (+42.01)	  
Rv2241_aceE	   2	   TFkEVLR	   k3:	  Acetyl	  (+42.01)	  
Rv2476c_gdh	   3	   ASGQkDLATLSVAAR	   k5:	  Acetyl	  (+42.01)	  
Rv2476c_gdh	   3	   ASGQkDLATLSVAAR	   k5:	  Acetyl	  (+42.01)	  
Rv2476c_gdh	   3	   LLPkVLADVQR	   k4:	  Acetyl	  (+42.01)	  
Rv3396c_guaA	   1	   LLFkDEVR	   k4:	  Acetyl	  (+42.01)	  
Rv1475c_acn	   1	   NYADVFkGDDR	   k7:	  Acetyl	  (+42.01)	  
Rv0281_Rv0281	   1	   TkYFDEYFR	   k2:	  Acetyl	  (+42.01)	  
Rv0462_lpdC	   2	   ALPNEDADVSkEIEK	   k11:	  Acetyl	  (+42.01)	  
Rv0462_lpdC	   2	   NAELVHIFTkDAK	   k10:	  Acetyl	  (+42.01)	  
Rv0668_rpoC	   1	   TFHQGGVGEDITGGLPR	  
Rv3105c_prfB	   1	   VLQAkLLER	   k5:	  Acetyl	  (+42.01)	  
Rv0716_rplE	   1	   SIAQFkLR	   k6:	  Acetyl	  (+42.01)	  
Rv0683_rpsG	   1	   TGTDPVITLkR	   k10:	  Acetyl	  (+42.01)	  
Rv2140c_TB18.6	   1	   YYVAVHAVkVEK	   k9:	  Acetyl	  (+42.01)	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Table 4.10. Peptides Identified by Anti-Acetyl-Lysine Enrichment from 
∆MtPat Normoxia Trypsinized Lysate. 
Protein	  name	   Total	  
spectrum	  
count	  
Peptide	  sequence	   Variable	  modifications	  
identified	  by	  spectrum	  
Rv2031c_hspX	   3	   DGQLTIkAER	   k7:	  Acetyl	  (+42.01)	  
Rv2031c_hspX	   3	   SEFAYGSFVR	   	  
Rv2031c_hspX	   3	   TVSLPVGADEDDIK	   	  
Rv2145c_wag31	   1	   ANAEQILGEAR	   	  
Rv2220_glnA1	   2	   DEkVEYVDVR	   k3:	  Acetyl	  (+42.01)	  
Rv2220_glnA1	   2	   TPDDVFkLAK	   k7:	  Acetyl	  (+42.01)	  
Rv0147_Rv0147	   1	   ITAALTkFR	   k7:	  Acetyl	  (+42.01)	  
Rv1636_TB15.3	   2	   LIIASAYLPQHEDAR	   	  
Rv1636_TB15.3	   2	   VDVLIVHTT	   	  
Rv0580c_Rv0580c	   1	   TQLmVVSFTGR	   m4:	  Oxidation	  (+15.99)	  
Rv3800c_pks13	   1	   GGYLkDIK	   k5:	  Acetyl	  (+42.01)	  
Rv1390_rpoZ	   1	   YALVIYAAK	   	  
Rv1310_atpD	   2	   TISLQPTDGLVR	   	  
Rv1310_atpD	   2	   TVLIQEmINR	   m7:	  Oxidation	  (+15.99)	  
Rv3274c_fadE25	   3	   DDEGFTVGPkER	   k10:	  Acetyl	  (+42.01)	  
Rv3274c_fadE25	   3	   EIAPHAAEVDEkAR	   k12:	  Acetyl	  (+42.01)	  
Rv3274c_fadE25	   3	   ITQIYEGTNQIQR	   	  
Rv0934_pstS1	   1	   VLAAmYQGTIK	   m5:	  Oxidation	  (+15.99)	  
Rv1037c_esxI	   1	   NFQVIYEQANAHGQK	  
Rv1388_mihF	   2	   GGTNLTQVLK	   	  
Rv1388_mihF	   2	   RGGTNLTQVLK	   	  
Rv2996c_serA1	   1	   TKPGVIIVNAAR	   	  
Rv1144_Rv1144	   1	   DLASkLIR	   k5:	  Acetyl	  (+42.01)	  
Rv2385_mbtJ	   1	   AmTYVAQFIR	   m2:	  Oxidation	  (+15.99)	  
Rv3528c_Rv3528c	   1	   ALDkYPVK	   k4:	  Acetyl	  (+42.01)	  
Rv1827_garA	   2	   FLLDQAITSAGR	   	  
Rv1827_garA	   2	   LVFLTGPK	   	  
Rv2605c_tesB2	   1	   ASQQQVWLR	   	  
Rv0350_dnaK	   4	   DAGQIAGLNVLR	   	  
Rv0350_dnaK	   4	   FkGTSGIDLTK	   k2:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   4	   IQEGSGLSkEDIDR	   k9:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   4	   kYTAPEISAR	   k1:	  Acetyl	  (+42.01)	  
Rv0896_gltA2	   1	   VYkNYDPR	   k3:	  Acetyl	  (+42.01)	  
Rv2429_ahpD	   1	   AALPEYAkDIK	   k8:	  Acetyl	  (+42.01)	  
Rv0503c_cmaA2	   1	   SHYDkSNEFFK	   k5:	  Acetyl	  (+42.01)	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Rv1391_dfp	   2	   kGcDLLVVNAVGEGR	   k1:	  Acetyl	  (+42.01),	  c3:	  
Carbamidomethyl	  (+57.02)	  
Rv1391_dfp	   2	   RkGcDLLVVNAVGEGR	   k2:	  Acetyl	  (+42.01),	  c4:	  
Carbamidomethyl	  (+57.02)	  
Rv0860_fadB	   1	   LEAkALER	   k4:	  Acetyl	  (+42.01)	  
Rv0282_eccA3	   1	   LVVIIAGYR	   	  
Rv0247c_Rv0247c	   1	   LQQTQTPDLAVR	   	  
Rv0569_Rv0569	   1	   FGAVQSAILHAR	   	  
Rv2785c_rpsO	   1	   GLLLLVGR	   	  
Rv1023_eno	   1	   VAkYNQLLR	   k3:	  Acetyl	  (+42.01)	  
Rv1133c_metE	   1	   WAVGAFR	   	  
Rv1630_rpsA	   4	   AWLEQTQSEVR	   	  
Rv1630_rpsA	   4	   DLQPYIGKEIEAk	   k13:	  Acetyl	  (+42.01)	  
Rv1630_rpsA	   4	   DLQPYIGKEIEAk	   k13:	  Acetyl	  (+42.01)	  
Rv1630_rpsA	   4	   RAWLEQTQSEVR	   	  
Rv2783c_gpsI	   3	   DGLVHISkLGK	   k8:	  Acetyl	  (+42.01)	  
Rv2783c_gpsI	   3	   IDEIkTQVVQR	   k5:	  Acetyl	  (+42.01)	  
Rv2783c_gpsI	   3	   VEIADIDkR	   k8:	  Acetyl	  (+42.01)	  
Rv2626c_hrp1	   2	   EHDIGALPIcGDDDR	   c10:	  Carbamidomethyl	  (+57.02)	  
Rv2626c_hrp1	   2	   HLPEHAIVQFVK	   	  
Rv2509_Rv2509	   1	   GSGVHVTVLAPGPVR	  
Rv3628_ppa	   2	   HFFVHYkDLEPGK	   k7:	  Acetyl	  (+42.01)	  
Rv3628_ppa	   2	   HFFVHYkDLEPGK	   k7:	  Acetyl	  (+42.01)	  
Rv0707_rpsC	   1	   ADLEkLTGK	   k5:	  Acetyl	  (+42.01)	  
Rv2185c_TB16.3	   1	   LIDGALkDLK	   k7:	  Acetyl	  (+42.01)	  
Rv3131_Rv3131	   1	   TVLTLAVR	   	  
Rv2524c_fas	   1	   GSQYAIAGTVR	   	  
Rv1058_fadD14	   1	   AFLADkVVR	   k6:	  Acetyl	  (+42.01)	  
Rv0222_echA1	   1	   ILIITINRPK	   	  
Rv3596c_clpC1	   1	   VLkEINTR	   k3:	  Acetyl	  (+42.01)	  
Rv1925_fadD31	   1	   NIkYVGDLVAYR	   k3:	  Acetyl	  (+42.01)	  
Rv1819c_bacA	   1	   NEkLNAAFR	   k3:	  Acetyl	  (+42.01)	  
Rv3676_crp	   2	   LYIIISGK	   	  
Rv3676_crp	   2	   QLLQLAQR	   	  
Rv0655_mkl	   1	   LALVGLGGDEKk	   k12:	  Acetyl	  (+42.01)	  
Rv0951_sucC	   1	   AGGVkYAATPQDAYEHAK	   k5:	  Acetyl	  (+42.01)	  
Rv1368_lprF	   1	   IYDPGIILDkDR	   k10:	  Acetyl	  (+42.01)	  
Rv1201c_dapD	   1	   GPVTVYGVDkFPR	   k10:	  Acetyl	  (+42.01)	  
Rv1521_fadD25	   1	   DLLIVYGR	   	  
Rv0702_rplD	   1	   QVLVVIGR	   	  
Rv0005_gyrB	   1	   LLKDkDPNLTGDDIR	   k5:	  Acetyl	  (+42.01)	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Rv1248c_Rv1248c	   1	   DFTEIkFR	   k6:	  Acetyl	  (+42.01)	  
Rv3051c_nrdE	   1	   IQFDkDR	   k5:	  Acetyl	  (+42.01)	  
Rv0824c_desA1	   1	   SVDPVELEkLR	   k9:	  Acetyl	  (+42.01)	  
Rv1079_metB	   1	   LIDkVFTR	   k4:	  Acetyl	  (+42.01)	  
Rv0701_rplC	   1	   VTVLNLLVHK	   	  
Rv1996_Rv1996	   1	   QVAmVVLGYR	   m4:	  Oxidation	  (+15.99)	  
Rv0685_tuf	   3	   TTLTAAITK	   	  
Rv0685_tuf	   3	   VLHDkFPDLNETK	   k5:	  Acetyl	  (+42.01)	  
Rv0685_tuf	   3	   VSALkALEGDAK	   k5:	  Acetyl	  (+42.01)	  
Rv3520c_Rv3520c	   1	   ALkPITHPLR	   k3:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   16	   AGAATEVELkER	   k10:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   16	   AGAATEVELkER	   k10:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   16	   AVEkVTETLLK	   k4:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   16	   DLLPLLEK	   	  
Rv0440_groEL2	   16	   GLNALADAVK	   	  
Rv0440_groEL2	   16	   GTFkSVAVK	   k4:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   16	   IGAELVkEVAK	   k7:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   16	   LAGGVAVIK	   	  
Rv0440_groEL2	   16	   LAkLAGGVAVIK	   k3:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   16	   NVAAGANPLGLK	   	  
Rv0440_groEL2	   16	   NVAAGANPLGLkR	   k12:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   16	   qEIENSDSDYDREkLQER	   n-­‐term:	  Gln-­‐>pyro-­‐Glu	  (-­‐17.03),	  
k14:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   16	   QEIENSDSDYDREkLQER	   k14:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   16	   QIAFNSGLEPGVVAEK	  
Rv0440_groEL2	   16	   VALEAPLK	   	  
Rv0440_groEL2	   16	   VTETLLkGAK	   k7:	  Acetyl	  (+42.01)	  
Rv3029c_fixA	   3	   AVEEALQIR	   	  
Rv3029c_fixA	   3	   FPSFkGImAAK	   k5:	  Acetyl	  (+42.01),	  m8:	  
Oxidation	  (+15.99)	  
Rv3029c_fixA	   3	   TNIVVLIK	   	  
Rv3846_sodA	   1	   GANDAVAkLEEAR	   k8:	  Acetyl	  (+42.01)	  
Rv1837c_glcB	   1	   DELQAQIDkWHR	   k9:	  Acetyl	  (+42.01)	  
Rv0462_lpdC	   2	   NAELVHIFTkDAK	   k10:	  Acetyl	  (+42.01)	  
Rv0462_lpdC	   2	   VAGVHFLmkK	   m8:	  Oxidation	  (+15.99),	  k9:	  
Acetyl	  (+42.01)	  
Rv3418c_groES	   1	   DVLAVVSk	   k8:	  Acetyl	  (+42.01)	  
Rv0815c_cysA2	   2	   SSHTWFVLR	   	  
Rv0815c_cysA2	   2	   VkLLDGGR	   k2:	  Acetyl	  (+42.01)	  
Rv3028c_fixB	   1	   AAVDSGYYPGQFQVGQTGK	  
Rv2889c_tsf	   1	   IGEkLELR	   k4:	  Acetyl	  (+42.01)	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Rv0873_fadE10	   1	   TEAFLVkLR	   k7:	  Acetyl	  (+42.01)	  
Rv2703_sigA	   1	   AVEkFDYTK	   k4:	  Acetyl	  (+42.01)	  
Rv0831c_Rv0831c	   1	   LkDELLR	   k2:	  Acetyl	  (+42.01)	  
Rv1259_udgB	   1	   PVPGWGSkR	   k8:	  Acetyl	  (+42.01)	  
Rv0231_fadE4	   1	   GVEkDTFFETVAR	   k4:	  Acetyl	  (+42.01)	  
Rv0933_pstB	   1	   LSGGQQQLLcLAR	   c10:	  Carbamidomethyl	  (+57.02)	  
Rv3417c_groEL1	   3	   LAGGVAVIK	   	  
Rv3417c_groEL1	   3	   LAkLAGGVAVIK	   k3:	  Acetyl	  (+42.01)	  
Rv3417c_groEL1	   3	   SDSDWDREkLGER	   k9:	  Acetyl	  (+42.01)	  
Rv0363c_fba	   1	   PLLAISAQR	   	  
Rv0002_dnaN	   2	   ALPNkPVDVHVEGNR	   k5:	  Acetyl	  (+42.01)	  
Rv0002_dnaN	   2	   LLDAEFPkFR	   k8:	  Acetyl	  (+42.01)	  
Rv3692_moxR2	   1	   GHVLLEGVPGVAK	   	  
Rv2986c_hupB	   1	   AELIDVLTQK	   	  
Rv2211c_gcvT	   1	   AALLAEkAAGPR	   k7:	  Acetyl	  (+42.01)	  
Rv1479_moxR1	   1	   GHVLLEGVPGVAK	   	  
Rv2238c_ahpE	   1	   DQNQQLVTLR	   	  
Rv2244_acpM	   3	   IESENPDAVANVQAR	  
Rv2244_acpM	   3	   TVGDVVAYIQK	   	  
Rv2244_acpM	   3	   TVGDVVAYIQK	   	  
Rv0066c_icd2	   1	   IFYKDAFAk	   k9:	  Acetyl	  (+42.01)	  
Rv2711_ideR	   1	   LDQSGPTVSQTVSR	  
Rv3248c_sahH	   1	   SIIVLSEGR	   	  
Rv3457c_rpoA	   3	   LHQLGLSLK	   	  
Rv3457c_rpoA	   3	   TESDLLDIR	   	  
Rv3457c_rpoA	   3	   TLVELFGLAR	   	  
Rv1308_atpA	   4	   AISLLLR	   	  
Rv1308_atpA	   4	   HVLIIFDDLTK	   	  
Rv1308_atpA	   4	   LTEVIkNFK	   k6:	  Acetyl	  (+42.01)	  
Rv1308_atpA	   4	   TAVcVDTILNQR	   c4:	  Carbamidomethyl	  (+57.02)	  
Rv0154c_fadE2	   1	   AAWTIDQHGNkEAR	   k11:	  Acetyl	  (+42.01)	  
Rv2241_aceE	   2	   GYALGkHFEGR	   k6:	  Acetyl	  (+42.01)	  
Rv2241_aceE	   2	   TFkEVLR	   k3:	  Acetyl	  (+42.01)	  
Rv2476c_gdh	   2	   LLPkVLADVQR	   k4:	  Acetyl	  (+42.01)	  
Rv2476c_gdh	   2	   LLVLAQAR	   	  
Rv3396c_guaA	   1	   LLFkDEVR	   k4:	  Acetyl	  (+42.01)	  
Rv1475c_acn	   1	   DHIEAIANWDPK	   	  
Rv3858c_gltD	   1	   ADPGGFLkYTHR	   k8:	  Acetyl	  (+42.01)	  
Rv0668_rpoC	   1	   TLKPEkDGLFcEK	   k6:	  Acetyl	  (+42.01),	  c11:	  
Carbamidomethyl	  (+57.02)	  
Rv0718_rpsH	   1	   LkANIAQILK	   k2:	  Acetyl	  (+42.01)	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Rv3105c_prfB	   1	   VLQAkLLER	   k5:	  Acetyl	  (+42.01)	  
Rv0683_rpsG	   1	   TGTDPVITLkR	   k10:	  Acetyl	  (+42.01)	  
Rv2572c_aspS	   1	   DHGGVIFIDLR	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Table 4.11. Peptides Identified by Anti-Acetyl-Lysine Enrichment from 
∆MtPat Hypoxia Trypsinized Lysate. 
Protein	  name	   Total	  
spectrum	  
count	  
Peptide	  sequence	   Variable	  modifications	  
identified	  by	  spectrum	  
Rv2145c_wag31	   1	   TYLESQLEELGQR	   	  
Rv2220_glnA1	   2	   DEkVEYVDVR	   k3:	  Acetyl	  (+42.01)	  
Rv2220_glnA1	   2	   TPDDVFkLAK	   k7:	  Acetyl	  (+42.01)	  
Rv0242c_fabG4	   1	   AALEkDYDLVGNNLGGR	   k5:	  Acetyl	  (+42.01)	  
Rv0271c_fadE6	   1	   AGQLIAEGHATkLLNLR	   k12:	  Acetyl	  (+42.01)	  
Rv1636_TB15.3	   2	   VTGTAPIYEILHDAkER	   k15:	  Acetyl	  (+42.01)	  
Rv1636_TB15.3	   2	   VTGTAPIYEILHDAkER	   k15:	  Acetyl	  (+42.01)	  
Rv3800c_pks13	   1	   GGYLkDIK	   k5:	  Acetyl	  (+42.01)	  
Rv1310_atpD	   1	   TISLQPTDGLVR	   	  
Rv3099c_Rv3099c	   1	   SQDVELGGDkELAGHILER	   k10:	  Acetyl	  (+42.01)	  
Rv2996c_serA1	   3	   AQGINLIIHYVDRPGALGK	  
Rv2996c_serA1	   3	   AQGINLIIHYVDRPGALGK	  
Rv2996c_serA1	   3	   TPETAGLIDkEALAK	   k10:	  Acetyl	  (+42.01)	  
Rv1144_Rv1144	   1	   DLASkLIR	   k5:	  Acetyl	  (+42.01)	  
Rv3417c_groEL1	   2	   HVVLAkAFGGPTVTNDGVTVAR	   k6:	  Acetyl	  (+42.01)	  
Rv3417c_groEL1	   2	   LAkLAGGVAVIK	   k3:	  Acetyl	  (+42.01)	  
Rv3248c_sahH	   1	   SIIVLSEGR	   	  
Rv3418c_groES	   5	   DVLAVVSk	   k8:	  Acetyl	  (+42.01)	  
Rv3418c_groES	   5	   IPLDVAEGDTVIYSkYGGTEIK	   k15:	  Acetyl	  (+42.01)	  
Rv3418c_groES	   5	   RIPLDVAEGDTVIYSkYGGTEIK	   k16:	  Acetyl	  (+42.01)	  
Rv3418c_groES	   5	   VNIkPLEDK	   k4:	  Acetyl	  (+42.01)	  
Rv3418c_groES	   5	   YNGEEYLILSAR	   	  
Rv3710_leuA	   1	   AIVHFYNSTSILQR	   	  
Rv0896_gltA2	   1	   mFTVLFALGR	   m1:	  Oxidation	  (+15.99)	  
Rv2429_ahpD	   2	   AALPEYAkDIK	   k8:	  Acetyl	  (+42.01)	  
Rv2429_ahpD	   2	   DIkLNLSSITR	   k3:	  Acetyl	  (+42.01)	  
Rv0860_fadB	   4	   GYSEkLEAK	   k5:	  Acetyl	  (+42.01)	  
Rv0860_fadB	   4	   LEAkALER	   k4:	  Acetyl	  (+42.01)	  
Rv0860_fadB	   4	   LVAEkDSITGVVVASAK	   k5:	  Acetyl	  (+42.01)	  
Rv0860_fadB	   4	   LVAEkDSITGVVVASAK	   k5:	  Acetyl	  (+42.01)	  
Rv0821c_phoY2	   1	   mGALALHVAkIAR	   m1:	  Oxidation	  
(+15.99),	  k10:	  Acetyl	  
(+42.01)	  
Rv0282_eccA3	   1	   LVVIIAGYR	   	  
Rv0569_Rv0569	   1	   FGAVQSAILHAR	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Rv1290c_Rv1290c	   1	   QmVDIALR	   m2:	  Oxidation	  (+15.99)	  
Rv0933_pstB	   1	   LTVIIVTHNLAQAAR	   	  
Rv1133c_metE	   2	   LHLPPLPTTTIGSYPQTSAIR	  
Rv1133c_metE	   2	   SELEAVAATLR	   	  
Rv1630_rpsA	   2	   DLQPYIGkEIEAK	   k8:	  Acetyl	  (+42.01)	  
Rv1630_rpsA	   2	   VRDLQPYIGkEIEAK	   k10:	  Acetyl	  (+42.01)	  
Rv2783c_gpsI	   3	   DGLVHISkLGK	   k8:	  Acetyl	  (+42.01)	  
Rv2783c_gpsI	   3	   LRVEIADIDkR	   k10:	  Acetyl	  (+42.01)	  
Rv2783c_gpsI	   3	   VEDVVNVGDkLR	   k10:	  Acetyl	  (+42.01)	  
Rv2606c_snzP	   2	   ATTFFDDPDVLAkVSR	   k13:	  Acetyl	  (+42.01)	  
Rv2606c_snzP	   2	   ATTFFDDPDVLAkVSR	   k13:	  Acetyl	  (+42.01)	  
Rv3628_ppa	   1	   HFFVHYkDLEPGK	   k7:	  Acetyl	  (+42.01)	  
Rv3029c_fixA	   2	   FPSFkGImAAK	   k5:	  Acetyl	  (+42.01),	  
m8:	  Oxidation	  (+15.99)	  
Rv3029c_fixA	   2	   TNIVVLIK	   	  
Rv2185c_TB16.3	   1	   LIDGALkDLK	   k7:	  Acetyl	  (+42.01)	  
Rv3001c_ilvC	   1	   LVADVEGGNkQLEELRR	   k10:	  Acetyl	  (+42.01)	  
Rv2928_tesA	   1	   QAAPTLYIFPHAGGTAkDYVAFSR	   k17:	  Acetyl	  (+42.01)	  
Rv2031c_hspX	   7	   AELPGVDPDkDVDImVR	   k10:	  Acetyl	  (+42.01),	  
m15:	  Oxidation	  
(+15.99)	  
Rv2031c_hspX	   7	   DGQLTIkAER	   k7:	  Acetyl	  (+42.01)	  
Rv2031c_hspX	   7	   GILTVSVAVSEGKPTEK	  
Rv2031c_hspX	   7	   SEFAYGSFVR	   	  
Rv2031c_hspX	   7	   TVSLPVGADEDDIK	   	  
Rv2031c_hspX	   7	   TVSLPVGADEDDIkATYDK	   k14:	  Acetyl	  (+42.01)	  
Rv2031c_hspX	   7	   TVSLPVGADEDDIkATYDK	   k14:	  Acetyl	  (+42.01)	  
Rv2780_ald	   1	   HGQILFTFLHLAASR	   	  
Rv2213_pepB	   1	   DLVNTPPSHLFPAEFAkR	   k17:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   8	   FkGTSGIDLTK	   k2:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   8	   IVNEPTAAALAYGLDKGEkEQR	   k19:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   8	   NQAETLVYQTEKFVk	   k15:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   8	   NQAETLVYQTEkFVK	   k12:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   8	   QATkDAGQIAGLNVLR	   k4:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   8	   qATkDAGQIAGLNVLR	   n-­‐term:	  Gln-­‐>pyro-­‐Glu	  
(-­‐17.03),	  k4:	  Acetyl	  
(+42.01)	  
Rv0350_dnaK	   8	   qATkDAGQIAGLNVLR	   n-­‐term:	  Gln-­‐>pyro-­‐Glu	  
(-­‐17.03),	  k4:	  Acetyl	  
(+42.01)	  
Rv0350_dnaK	   8	   VPEDTLNkVDAAVAEAK	   k8:	  Acetyl	  (+42.01)	  
Rv0248c_Rv0248c	   1	   HSYDVVVIGAGGAGLR	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Rv1448c_tal	   1	   IVDRPNLFIkIPATK	   k10:	  Acetyl	  (+42.01)	  
Rv1925_fadD31	   2	   NIkYVGDLVAYR	   k3:	  Acetyl	  (+42.01)	  
Rv1925_fadD31	   2	   NIkYVGDLVAYR	   k3:	  Acetyl	  (+42.01)	  
Rv1240_mdh	   1	   GRIDkSTAELADER	   k5:	  Acetyl	  (+42.01)	  
Rv1521_fadD25	   1	   DLLIVYGR	   	  
Rv1612_trpB	   1	   GAVIVVNLSGR	   	  
Rv2839c_infB	   1	   GLLkPIYEENQLGR	   k4:	  Acetyl	  (+42.01)	  
Rv0818_Rv0818	   1	   GRPLDLTYkEFELLK	   k9:	  Acetyl	  (+42.01)	  
Rv2949c_Rv2949c	   1	   LTQTNDPLGEVmAASHIETFKEEAk	   m12:	  Oxidation	  
(+15.99),	  k25:	  Acetyl	  
(+42.01)	  
Rv0652_rplL	   4	   EAkDLVDGAPKPLLEK	   k3:	  Acetyl	  (+42.01)	  
Rv0652_rplL	   4	   EAkDLVDGAPKPLLEK	   k3:	  Acetyl	  (+42.01)	  
Rv0652_rplL	   4	   EAkDLVDGAPKPLLEK	   k3:	  Acetyl	  (+42.01)	  
Rv0652_rplL	   4	   EIVSGLGLK	   	  
Rv1751_Rv1751	   1	   AGVQVTLLEkHGDFLR	   k10:	  Acetyl	  (+42.01)	  
Rv1192_Rv1192	   1	   DLLDkLHSR	   k5:	  Acetyl	  (+42.01)	  
Rv1201c_dapD	   1	   RGPVTVYGVDkFPR	   k11:	  Acetyl	  (+42.01)	  
Rv0005_gyrB	   1	   LLKDkDPNLTGDDIR	   k5:	  Acetyl	  (+42.01)	  
Rv3389c_htdY	   1	   LSVVTEVADIQDkGEGK	   k13:	  Acetyl	  (+42.01)	  
Rv1248c_Rv1248c	   1	   DFTEIkFR	   k6:	  Acetyl	  (+42.01)	  
Rv0824c_desA1	   1	   SVDPVELEkLR	   k9:	  Acetyl	  (+42.01)	  
Rv2572c_aspS	   1	   DHGGVIFIDLR	   	  
Rv0685_tuf	   11	   ELLAAQEFDEDAPVVR	  
Rv0685_tuf	   11	   GITINIAHVEYQTDK	   	  
Rv0685_tuf	   11	   GITINIAHVEYQTDK	   	  
Rv0685_tuf	   11	   GITINIAHVEYQTDkR	   k15:	  Acetyl	  (+42.01)	  
Rv0685_tuf	   11	   GQVVTKPGTTTPHTEFEGQVYILSkDEGGR	   k25:	  Acetyl	  (+42.01)	  
Rv0685_tuf	   11	   GQVVTKPGTTTPHTEFEGQVYILSkDEGGR	   k25:	  Acetyl	  (+42.01)	  
Rv0685_tuf	   11	   HTPFFNNYRPQFYFR	  
Rv0685_tuf	   11	   PGTTTPHTEFEGQVYILSkDEGGR	   k19:	  Acetyl	  (+42.01)	  
Rv0685_tuf	   11	   VLHDkFPDLNETK	   k5:	  Acetyl	  (+42.01)	  
Rv0685_tuf	   11	   VLHDKFPDLNETkAFDQIDNAPEER	   k13:	  Acetyl	  (+42.01)	  
Rv0685_tuf	   11	   VSALkALEGDAK	   k5:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   AGAATEVELkER	   k10:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   AGAATEVELkER	   k10:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   AVEkVTETLLK	   k4:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   DLLPLLEK	   	  
Rv0440_groEL2	   28	   EIELEDPYEkIGAELVK	   k10:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   FDkGYISGYFVTDPER	   k3:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   GLNALADAVK	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Rv0440_groEL2	   28	   GTFkSVAVK	   k4:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   GTFkSVAVK	   k4:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   GYISGYFVTDPER	   	  
Rv0440_groEL2	   28	   IGAELVkEVAK	   k7:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   KTDDVAGDGTTTATVLAQALVR	  
Rv0440_groEL2	   28	   KVVVTkDETTIVEGAGDTDAIAGR	   k6:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   LAkLAGGVAVIK	   k3:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   NVAAGANPLGLK	   	  
Rv0440_groEL2	   28	   NVAAGANPLGLkR	   k12:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   QEIENSDSDYDREkLQER	   k14:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   QIAFNSGLEPGVVAEK	  
Rv0440_groEL2	   28	   QIAFNSGLEPGVVAEkVR	   k16:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   QIAFNSGLEPGVVAEkVR	   k16:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   QIAFNSGLEPGVVAEkVR	   k16:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   qIAFNSGLEPGVVAEkVR	   n-­‐term:	  Gln-­‐>pyro-­‐Glu	  
(-­‐17.03),	  k16:	  Acetyl	  
(+42.01)	  
Rv0440_groEL2	   28	   TDDVAGDGTTTATVLAQALVR	  
Rv0440_groEL2	   28	   VALEAPLK	   	  
Rv0440_groEL2	   28	   VSTVkDLLPLLEK	   k5:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   VTETLLkGAK	   k7:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   VVVTkDETTIVEGAGDTDAIAGR	   k5:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   28	   VVVTkDETTIVEGAGDTDAIAGR	   k5:	  Acetyl	  (+42.01)	  
Rv3648c_cspA	   1	   TLEENQkVEFEIGHSPK	   k7:	  Acetyl	  (+42.01)	  
Rv1596_nadC	   1	   LGLGDAALIkDNHVAAAGSVVDALR	   k10:	  Acetyl	  (+42.01)	  
Rv1388_mihF	   2	   RGGTNLTQVLkDAESDEVLGK	   k11:	  Acetyl	  (+42.01)	  
Rv1388_mihF	   2	   RGGTNLTQVLkDAESDEVLGK	   k11:	  Acetyl	  (+42.01)	  
Rv2454c_Rv2454c	   1	   FPYYLETYGFHSIHGR	  
Rv3458c_rpsD	   2	   IkESEYLLQLQEK	   k2:	  Acetyl	  (+42.01)	  
Rv3458c_rpsD	   2	   IkESEYLLQLQEK	   k2:	  Acetyl	  (+42.01)	  
Rv1658_argG	   1	   GFVYVHGLSSkLAAR	   k11:	  Acetyl	  (+42.01)	  
Rv3846_sodA	   1	   GANDAVAkLEEAR	   k8:	  Acetyl	  (+42.01)	  
Rv1837c_glcB	   3	   GDLAAAVDkDGTAFLR	   k9:	  Acetyl	  (+42.01)	  
Rv1837c_glcB	   3	   GDLAAAVDkDGTAFLR	   k9:	  Acetyl	  (+42.01)	  
Rv1837c_glcB	   3	   GDLAAAVDkDGTAFLR	   k9:	  Acetyl	  (+42.01)	  
Rv0667_rpoB	   1	   STLEkDNTVGTDEALLDIYRK	   k5:	  Acetyl	  (+42.01)	  
Rv3274c_fadE25	   2	   DDEGFTVGPkER	   k10:	  Acetyl	  (+42.01)	  
Rv3274c_fadE25	   2	   EIAPHAAEVDEkAR	   k12:	  Acetyl	  (+42.01)	  
Rv0815c_cysA2	   1	   VkLLDGGR	   k2:	  Acetyl	  (+42.01)	  
Rv3285_accA3	   1	   NFLPAPGPVTkFHPPSGPGVR	   k11:	  Acetyl	  (+42.01)	  
Rv2889c_tsf	   1	   IGEkLELR	   k4:	  Acetyl	  (+42.01)	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Rv0873_fadE10	   1	   TEAFLVkLR	   k7:	  Acetyl	  (+42.01)	  
Rv2703_sigA	   2	   AVEkFDYTK	   k4:	  Acetyl	  (+42.01)	  
Rv2703_sigA	   2	   IPVHmVEVINkLGR	   m5:	  Oxidation	  
(+15.99),	  k11:	  Acetyl	  
(+42.01)	  
Rv0270_fadD2	   2	   FKPALVLEDIEkHK	   k12:	  Acetyl	  (+42.01)	  
Rv0270_fadD2	   2	   ILDQLEkTEPKPDLSSLK	   k7:	  Acetyl	  (+42.01)	  
Rv0009_ppiA	   1	   TVANFVGLAQGTK	   	  
Rv0231_fadE4	   1	   GVEkDTFFETVAR	   k4:	  Acetyl	  (+42.01)	  
Rv2882c_frr	   2	   LVVIkPYEANQLR	   k5:	  Acetyl	  (+42.01)	  
Rv2882c_frr	   2	   TTHQYVTQIDELVkHK	   k14:	  Acetyl	  (+42.01)	  
Rv0363c_fba	   1	   DkLDSYVRPLLAISAQR	   k2:	  Acetyl	  (+42.01)	  
Rv0002_dnaN	   1	   ALPNkPVDVHVEGNR	   k5:	  Acetyl	  (+42.01)	  
Rv0489_gpm1	   1	   HYGALQGLDkAETK	   k10:	  Acetyl	  (+42.01)	  
Rv1463_Rv1463	   1	   YAESQHGGILLITHYTR	  
Rv3774_echA21	   1	   ELALTGkNIDAAR	   k7:	  Acetyl	  (+42.01)	  
Rv2986c_hupB	   2	   AELIDVLTQK	   	  
Rv2986c_hupB	   2	   AELIDVLTQkLGSDR	   k10:	  Acetyl	  (+42.01)	  
Rv2244_acpM	   4	   IPDEDLAGLR	   	  
Rv2244_acpM	   4	   TVGDVVAYIQK	   	  
Rv2244_acpM	   4	   TVGDVVAYIQK	   	  
Rv2244_acpM	   4	   YGVkIPDEDLAGLR	   k4:	  Acetyl	  (+42.01)	  
Rv2788_sirR	   1	   LAEQGLVDHEkYGAVTLTDSGR	   k11:	  Acetyl	  (+42.01)	  
Rv0641_rplA	   1	   mSKTSKAYRAAAAK	   m1:	  Oxidation	  (+15.99)	  
Rv3592_mhuD	   1	   INAIEVPAGAGPELEkR	   k16:	  Acetyl	  (+42.01)	  
Rv3457c_rpoA	   2	   TDFDkLILDVETK	   k5:	  Acetyl	  (+42.01)	  
Rv3457c_rpoA	   2	   TLVELFGLAR	   	  
Rv1308_atpA	   3	   GFAATGGGSVVPDEHVEALDEDKLAk	   k26:	  Acetyl	  (+42.01)	  
Rv1308_atpA	   3	   HVLIIFDDLTK	   	  
Rv1308_atpA	   3	   LTEVIkNFK	   k6:	  Acetyl	  (+42.01)	  
Rv3528c_Rv3528c	   1	   LLDLGEkHYFR	   k7:	  Acetyl	  (+42.01)	  
Rv0548c_menB	   1	   FkQTDADVGSFDGGYGSAYLAR	   k2:	  Acetyl	  (+42.01)	  
Rv2241_aceE	   2	   GYALGkHFEGR	   k6:	  Acetyl	  (+42.01)	  
Rv2241_aceE	   2	   TFkEVLR	   k3:	  Acetyl	  (+42.01)	  
Rv2476c_gdh	   2	   ELEALPSEkEIAR	   k9:	  Acetyl	  (+42.01)	  
Rv2476c_gdh	   2	   LLPkVLADVQR	   k4:	  Acetyl	  (+42.01)	  
Rv3396c_guaA	   1	   LLFkDEVR	   k4:	  Acetyl	  (+42.01)	  
Rv0462_lpdC	   5	   ALPNEDADVSkEIEK	   k11:	  Acetyl	  (+42.01)	  
Rv0462_lpdC	   5	   ALPNEDADVSKEIEkQFK	   k15:	  Acetyl	  (+42.01)	  
Rv0462_lpdC	   5	   DGVAQELkAEK	   k8:	  Acetyl	  (+42.01)	  
Rv0462_lpdC	   5	   NAELVHIFTkDAK	   k10:	  Acetyl	  (+42.01)	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Rv0462_lpdC	   5	   NEGYDVVVAkFPFTANAK	   k10:	  Acetyl	  (+42.01)	  
Rv0668_rpoC	   1	   LGYLLDLAPkDLEK	   k10:	  Acetyl	  (+42.01)	  
Rv3246c_mtrA	   2	   VEkDPENPTVVLTVR	   k3:	  Acetyl	  (+42.01)	  
Rv3246c_mtrA	   2	   VEkDPENPTVVLTVR	   k3:	  Acetyl	  (+42.01)	  
Rv3801c_fadD32	   1	   TGDYGTYFkDHLYIAGR	   k9:	  Acetyl	  (+42.01)	  
Rv3105c_prfB	   1	   VLQAkLLER	   k5:	  Acetyl	  (+42.01)	  
Rv0683_rpsG	   1	   TGTDPVITLkR	   k10:	  Acetyl	  (+42.01)	  
Rv2140c_TB18.6	   1	   YYVAVHAVKVEk	   k12:	  Acetyl	  (+42.01)	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Table 4.12. Peptides Identified by Anti-Acetyl-Lysine Enrichment from 
∆Rv1151 (mtCobB) Normoxia Trypsinized Lysate. 
Protein	  name	   Total	  
spectrum	  
count	  
Peptide	  sequence	   Variable	  modifications	  
identified	  by	  spectrum	  
Rv3033_Rv3033	   1	   NQVANIISDkLFQR	   k10:	  Acetyl	  (+42.01)	  
Rv0379_secE2	   1	   LEVSFkmR	   k6:	  Acetyl	  (+42.01),	  
m7:	  Oxidation	  (+15.99)	  
Rv1751_Rv1751	   1	   AGVQVTLLEkHGDFLR	   k10:	  Acetyl	  (+42.01)	  
Rv2220_glnA1	   1	   TPDDVFkLAK	   k7:	  Acetyl	  (+42.01)	  
Rv0384c_clpB	   1	   LQLQVSLPAK	   	  
Rv3648c_cspA	   2	   TLEENQkVEFEIGHSPK	   k7:	  Acetyl	  (+42.01)	  
Rv3648c_cspA	   2	   VEFEIGHSPkGPQATGVR	   k10:	  Acetyl	  (+42.01)	  
Rv1636_TB15.3	   3	   AADILkDESYK	   k6:	  Acetyl	  (+42.01)	  
Rv1636_TB15.3	   3	   VDVLIVHTT	   	  
Rv1636_TB15.3	   3	   VTGTAPIYEILHDAkER	   k15:	  Acetyl	  (+42.01)	  
Rv0580c_Rv0580c	   2	   SLLHTPLAGPLR	   	  
Rv0580c_Rv0580c	   2	   TQLmVVSFTGR	   m4:	  Oxidation	  (+15.99)	  
Rv3800c_pks13	   4	   DEVQQLHEHQkTQTAEEIAR	   k11:	  Acetyl	  (+42.01)	  
Rv3800c_pks13	   4	   GGYLkDIK	   k5:	  Acetyl	  (+42.01)	  
Rv3800c_pks13	   4	   TYLEAGQIDGFVR	   	  
Rv3800c_pks13	   4	   VPVFVFHPAGGSTVVYEPLLGR	  
Rv0632c_echA3	   1	   GGFELAYR	   	  
Rv1390_rpoZ	   1	   YALVIYAAK	   	  
Rv3401_Rv3401	   1	   FGLFHLLQASAR	   	  
Rv3592_mhuD	   2	   INAIEVPAGAGPELEkR	   k16:	  Acetyl	  (+42.01)	  
Rv3592_mhuD	   2	   INAIEVPAGAGPELEkR	   k16:	  Acetyl	  (+42.01)	  
Rv1310_atpD	   2	   TISLQPTDGLVR	   	  
Rv1310_atpD	   2	   VVDLLTPYVR	   	  
Rv3274c_fadE25	   1	   DDEGFTVGPkER	   k10:	  Acetyl	  (+42.01)	  
Rv2713_sthA	   1	   TQHVIGkEVDVVR	   k7:	  Acetyl	  (+42.01)	  
Rv3569c_hsaD	   1	   LSkFSVAPTR	   k3:	  Acetyl	  (+42.01)	  
Rv1037c_esxI	   1	   NFQVIYEQANAHGQK	   	  
Rv2504c_scoA	   1	   TVSSYVGENkEFAR	   k10:	  Acetyl	  (+42.01)	  
Rv2996c_serA1	   2	   AQGINLIIHYVDR	   	  
Rv2996c_serA1	   2	   AQGINLIIHYVDRPGALGK	  
Rv1144_Rv1144	   1	   DLASkLIR	   k5:	  Acetyl	  (+42.01)	  
Rv2385_mbtJ	   1	   AmTYVAQFIR	   m2:	  Oxidation	  (+15.99)	  
Rv3248c_sahH	   2	   TGNLVTkNSLTPDVR	   k7:	  Acetyl	  (+42.01)	  
Rv3248c_sahH	   2	   TGNLVTkNSLTPDVR	   k7:	  Acetyl	  (+42.01)	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Rv2203_Rv2203	   1	   GQVQGIAQLLFQR	   	  
Rv3224_Rv3224	   2	   DGANIALIAkTAEPHPK	   k10:	  Acetyl	  (+42.01)	  
Rv3224_Rv3224	   2	   TAEPHPkLPGTVFTAAK	   k7:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   10	   DAGQIAGLNVLR	   	  
Rv0350_dnaK	   10	   EIAAHNkLLGSFELTGIPPAPR	   k7:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   10	   FkGTSGIDLTK	   k2:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   10	   GTSGIDLTkDK	   k9:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   10	   IQEGSGLSkEDIDR	   k9:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   10	   IQEGSGLSkEDIDR	   k9:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   10	   IVNEPTAAALAYGLDKGEk	   k19:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   10	   NQAETLVYQTEkFVK	   k12:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   10	   qATkDAGQIAGLNVLR	   n-­‐term:	  Gln-­‐>pyro-­‐Glu	  
(-­‐17.03),	  k4:	  Acetyl	  
(+42.01)	  
Rv0350_dnaK	   10	   VPEDTLNkVDAAVAEAK	   k8:	  Acetyl	  (+42.01)	  
Rv2429_ahpD	   2	   AALPEYAkDIK	   k8:	  Acetyl	  (+42.01)	  
Rv2429_ahpD	   2	   DIkLNLSSITR	   k3:	  Acetyl	  (+42.01)	  
Rv0684_fusA1	   1	   ASAGHIYAVIGLK	   	  
Rv0896_gltA2	   2	   ILAkLGGDDSLLGIAK	   k4:	  Acetyl	  (+42.01)	  
Rv0896_gltA2	   2	   mFTVLFALGR	   m1:	  Oxidation	  (+15.99)	  
Rv0860_fadB	   2	   GYSEkLEAK	   k5:	  Acetyl	  (+42.01)	  
Rv0860_fadB	   2	   LEAkALER	   k4:	  Acetyl	  (+42.01)	  
Rv0821c_phoY2	   1	   mGALALHVAkIAR	   m1:	  Oxidation	  
(+15.99),	  k10:	  Acetyl	  
(+42.01)	  
Rv0282_eccA3	   2	   ADLDkFLDTNEGLR	   k5:	  Acetyl	  (+42.01)	  
Rv0282_eccA3	   2	   LVVIIAGYR	   	  
Rv3295_Rv3295	   1	   AFFAAVVkDEADR	   k8:	  Acetyl	  (+42.01)	  
Rv0569_Rv0569	   2	   FGAVQSAILHAR	   	  
Rv0569_Rv0569	   2	   GLIIEVR	   	  
Rv2753c_dapA	   1	   ALASHPNIVGVkDAK	   k12:	  Acetyl	  (+42.01)	  
Rv3850_Rv3850	   1	   DVETkQFVSAVTNR	   k5:	  Acetyl	  (+42.01)	  
Rv0933_pstB	   2	   LTVIIVTHNLAQAAR	   	  
Rv0933_pstB	   2	   LTVIIVTHNLAQAAR	   	  
Rv1023_eno	   1	   VAkYNQLLR	   k3:	  Acetyl	  (+42.01)	  
Rv0148_Rv0148	   1	   VALFGNDGANFDkPPSVQDVAAR	   k13:	  Acetyl	  (+42.01)	  
Rv1133c_metE	   1	   VLAELkEALGQGIPAR	   k6:	  Acetyl	  (+42.01)	  
Rv2783c_gpsI	   5	   DGLVHISkLGK	   k8:	  Acetyl	  (+42.01)	  
Rv2783c_gpsI	   5	   IDEIkTQVVQR	   k5:	  Acetyl	  (+42.01)	  
Rv2783c_gpsI	   5	   LRVEIADIDkR	   k10:	  Acetyl	  (+42.01)	  
Rv2783c_gpsI	   5	   VEDVVNVGDkLR	   k10:	  Acetyl	  (+42.01)	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Rv2783c_gpsI	   5	   VEIADIDkR	   k8:	  Acetyl	  (+42.01)	  
Rv2158c_murE	   1	   GQGFLALVDYAHkPEALR	   k13:	  Acetyl	  (+42.01)	  
Rv2509_Rv2509	   1	   GSGVHVTVLAPGPVR	   	  
Rv3628_ppa	   4	   DLEPGkFVK	   k6:	  Acetyl	  (+42.01)	  
Rv3628_ppa	   4	   HFFVHYkDLEPGK	   k7:	  Acetyl	  (+42.01)	  
Rv3628_ppa	   4	   HFFVHYkDLEPGK	   k7:	  Acetyl	  (+42.01)	  
Rv3628_ppa	   4	   HFFVHYkDLEPGK	   k7:	  Acetyl	  (+42.01)	  
Rv3029c_fixA	   3	   FPSFkGImAAK	   k5:	  Acetyl	  (+42.01),	  
m8:	  Oxidation	  (+15.99)	  
Rv3029c_fixA	   3	   FPSFkGImAAK	   k5:	  Acetyl	  (+42.01),	  
m8:	  Oxidation	  (+15.99)	  
Rv3029c_fixA	   3	   TNIVVLIK	   	  
Rv2185c_TB16.3	   1	   LIDGALkDLK	   k7:	  Acetyl	  (+42.01)	  
Rv1932_tpx	   1	   DLPFAQkR	   k7:	  Acetyl	  (+42.01)	  
Rv0818_Rv0818	   1	   GRPLDLTYkEFELLK	   k9:	  Acetyl	  (+42.01)	  
Rv3849_espR	   1	   AHGLPSAAQQkVLDR	   k11:	  Acetyl	  (+42.01)	  
Rv2031c_hspX	   6	   DGQLTIkAER	   k7:	  Acetyl	  (+42.01)	  
Rv2031c_hspX	   6	   GILTVSVAVSEGKPTEK	  
Rv2031c_hspX	   6	   GILTVSVAVSEGKPTEK	  
Rv2031c_hspX	   6	   SEFAYGSFVR	   	  
Rv2031c_hspX	   6	   TVSLPVGADEDDIK	   	  
Rv2031c_hspX	   6	   TVSLPVGADEDDIkATYDK	   k14:	  Acetyl	  (+42.01)	  
Rv2213_pepB	   1	   DLVNTPPSHLFPAEFAkR	   k17:	  Acetyl	  (+42.01)	  
Rv1617_pykA	   1	   qVDkSLLELAR	   n-­‐term:	  Gln-­‐>pyro-­‐Glu	  
(-­‐17.03),	  k4:	  Acetyl	  
(+42.01)	  
Rv1448c_tal	   1	   IVDRPNLFIkIPATK	   k10:	  Acetyl	  (+42.01)	  
Rv1925_fadD31	   2	   NIkYVGDLVAYR	   k3:	  Acetyl	  (+42.01)	  
Rv1925_fadD31	   2	   NIkYVGDLVAYR	   k3:	  Acetyl	  (+42.01)	  
Rv2626c_hrp1	   1	   HLPEHAIVQFVK	   	  
Rv3676_crp	   1	   LYIIISGK	   	  
Rv2839c_infB	   1	   VHELAkELGVTSK	   k6:	  Acetyl	  (+42.01)	  
Rv0652_rplL	   5	   EAkDLVDGAPKPLLEK	   k3:	  Acetyl	  (+42.01)	  
Rv0652_rplL	   5	   EAkDLVDGAPKPLLEK	   k3:	  Acetyl	  (+42.01)	  
Rv0652_rplL	   5	   EAkDLVDGAPKPLLEK	   k3:	  Acetyl	  (+42.01)	  
Rv0652_rplL	   5	   EIVSGLGLK	   	  
Rv0652_rplL	   5	   IGVIkVVR	   k5:	  Acetyl	  (+42.01)	  
Rv0655_mkl	   2	   AQAAILDDLEGTHkYAVHEIGQ	   k14:	  Acetyl	  (+42.01)	  
Rv0655_mkl	   2	   LALVGLGGDEKk	   k12:	  Acetyl	  (+42.01)	  
Rv0636_hadB	   1	   FTAVVPVPNDGkGAELVFNGR	   k12:	  Acetyl	  (+42.01)	  
Rv0155_pntAa	   1	   GGQTLIGFLAPR	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Rv1306_atpF	   2	   AEQQVASTLQTAHEQLkR	   k17:	  Acetyl	  (+42.01)	  
Rv1306_atpF	   2	   AEQQVASTLQTAHEQLkR	   k17:	  Acetyl	  (+42.01)	  
Rv2744c_35kd_ag	   1	   qLADIEkLQVNVR	   n-­‐term:	  Gln-­‐>pyro-­‐Glu	  
(-­‐17.03),	  k7:	  Acetyl	  
(+42.01)	  
Rv1201c_dapD	   2	   GPVTVYGVDkFPR	   k10:	  Acetyl	  (+42.01)	  
Rv1201c_dapD	   2	   RGPVTVYGVDkFPR	   k11:	  Acetyl	  (+42.01)	  
Rv1521_fadD25	   3	   DLLIVYGR	   	  
Rv1521_fadD25	   3	   IkDLLIVYGR	   k2:	  Acetyl	  (+42.01)	  
Rv1521_fadD25	   3	   LVAIIELKk	   k9:	  Acetyl	  (+42.01)	  
Rv0702_rplD	   1	   QVLVVIGR	   	  
Rv1629_polA	   1	   FTPEAVVEkYGLTPR	   k9:	  Acetyl	  (+42.01)	  
Rv1248c_Rv1248c	   1	   DFTEIkFR	   k6:	  Acetyl	  (+42.01)	  
Rv3868_eccA1	   1	   LVVIIAGYSSDIDR	   	  
Rv0685_tuf	   9	   GITINIAHVEYQTDK	   	  
Rv0685_tuf	   9	   GITINIAHVEYQTDKR	   	  
Rv0685_tuf	   9	   GQVVTKPGTTTPHTEFEGQVYILSkDEGGR	   k25:	  Acetyl	  (+42.01)	  
Rv0685_tuf	   9	   LLDQGQAGDNVGLLLR	  
Rv0685_tuf	   9	   LLDQGQAGDNVGLLLR	  
Rv0685_tuf	   9	   TTVTGVEmFR	   m8:	  Oxidation	  (+15.99)	  
Rv0685_tuf	   9	   VLHDkFPDLNETK	   k5:	  Acetyl	  (+42.01)	  
Rv0685_tuf	   9	   VLHDKFPDLNETkAFDQIDNAPEER	   k13:	  Acetyl	  (+42.01)	  
Rv0685_tuf	   9	   VSALkALEGDAK	   k5:	  Acetyl	  (+42.01)	  
Rv3520c_Rv3520c	   1	   ALkPITHPLR	   k3:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   25	   AGAATEVELkER	   k10:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   25	   AGAATEVELkER	   k10:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   25	   DETTIVEGAGDTDAIAGR	  
Rv0440_groEL2	   25	   DLLPLLEK	   	  
Rv0440_groEL2	   25	   EIELEDPYEkIGAELVK	   k10:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   25	   FDkGYISGYFVTDPER	   k3:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   25	   GLNALADAVK	   	  
Rv0440_groEL2	   25	   GTFkSVAVK	   k4:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   25	   GTFkSVAVK	   k4:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   25	   GYISGYFVTDPER	   	  
Rv0440_groEL2	   25	   IGAELVkEVAK	   k7:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   25	   KTDDVAGDGTTTATVLAQALVR	  
Rv0440_groEL2	   25	   kVVVTKDETTIVEGAGDTDAIAGR	   k1:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   25	   LAkLAGGVAVIK	   k3:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   25	   NVAAGANPLGLkR	   k12:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   25	   NVAAGANPLGLkR	   k12:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   25	   QEIENSDSDYDREkLQER	   k14:	  Acetyl	  (+42.01)	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Rv0440_groEL2	   25	   QEIENSDSDYDREkLQER	   k14:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   25	   QIAFNSGLEPGVVAEK	  
Rv0440_groEL2	   25	   QIAFNSGLEPGVVAEkVR	   k16:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   25	   qIAFNSGLEPGVVAEkVR	   n-­‐term:	  Gln-­‐>pyro-­‐Glu	  
(-­‐17.03),	  k16:	  Acetyl	  
(+42.01)	  
Rv0440_groEL2	   25	   QIAFNSGLEPGVVAEkVR	   k16:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   25	   VALEAPLK	   	  
Rv0440_groEL2	   25	   VTETLLKGAk	   k10:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   25	   VVVTkDETTIVEGAGDTDAIAGR	   k5:	  Acetyl	  (+42.01)	  
Rv3131_Rv3131	   1	   TVLTLAVR	   	  
Rv3246c_mtrA	   2	   VEkDPENPTVVLTVR	   k3:	  Acetyl	  (+42.01)	  
Rv3246c_mtrA	   2	   VEkDPENPTVVLTVR	   k3:	  Acetyl	  (+42.01)	  
Rv1388_mihF	   2	   GGTNLTQVLK	   	  
Rv1388_mihF	   2	   GGTNLTQVLkDAESDEVLGK	   k10:	  Acetyl	  (+42.01)	  
Rv0157_pntB	   1	   GVPVkYAIHPVAGR	   k5:	  Acetyl	  (+42.01)	  
Rv2145c_wag31	   1	   TYLESQLEELGQR	   	  
Rv0513_Rv0513	   1	   LAEIVkIYPEADGR	   k6:	  Acetyl	  (+42.01)	  
Rv3598c_lysS	   1	   GIADSLGLEkDPAIHDNR	   k10:	  Acetyl	  (+42.01)	  
Rv1658_argG	   1	   GFVYVHGLSSkLAAR	   k11:	  Acetyl	  (+42.01)	  
Rv3846_sodA	   2	   GANDAVAkLEEAR	   k8:	  Acetyl	  (+42.01)	  
Rv3846_sodA	   2	   GANDAVAkLEEAR	   k8:	  Acetyl	  (+42.01)	  
Rv1181_pks4	   1	   FAAAVQAALkDGYR	   k10:	  Acetyl	  (+42.01)	  
Rv1837c_glcB	   1	   GDLAAAVDkDGTAFLR	   k9:	  Acetyl	  (+42.01)	  
Rv0667_rpoB	   2	   STLEkDNTVGTDEALLDIYR	   k5:	  Acetyl	  (+42.01)	  
Rv0667_rpoB	   2	   STLEkDNTVGTDEALLDIYR	   k5:	  Acetyl	  (+42.01)	  
Rv3688c_Rv3688c	   1	   ELSDDEVIkVLAR	   k9:	  Acetyl	  (+42.01)	  
Rv0462_lpdC	   2	   ALPNEDADVSkEIEK	   k11:	  Acetyl	  (+42.01)	  
Rv0462_lpdC	   2	   VAGVHFLmkK	   m8:	  Oxidation	  
(+15.99),	  k9:	  Acetyl	  
(+42.01)	  
Rv3581c_ispF	   2	   HVVVLITQHGYR	   	  
Rv3581c_ispF	   2	   HVVVLITQHGYR	   	  
Rv3418c_groES	   3	   RIPLDVAEGDTVIYSkYGGTEIK	   k16:	  Acetyl	  (+42.01)	  
Rv3418c_groES	   3	   RIPLDVAEGDTVIYSkYGGTEIK	   k16:	  Acetyl	  (+42.01)	  
Rv3418c_groES	   3	   VNIkPLEDK	   k4:	  Acetyl	  (+42.01)	  
Rv0815c_cysA2	   1	   VkLLDGGR	   k2:	  Acetyl	  (+42.01)	  
Rv3028c_fixB	   1	   AAVDSGYYPGQFQVGQTGK	  
Rv2889c_tsf	   3	   AEGKPEQALPkIVEGR	   k11:	  Acetyl	  (+42.01)	  
Rv2889c_tsf	   3	   GDDAAAAHAVALQIAALR	  
Rv2889c_tsf	   3	   IGEkLELR	   k4:	  Acetyl	  (+42.01)	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Rv0873_fadE10	   1	   TEAFLVkLR	   k7:	  Acetyl	  (+42.01)	  
Rv0951_sucC	   2	   AGGVkYAATPQDAYEHAK	   k5:	  Acetyl	  (+42.01)	  
Rv0951_sucC	   2	   VPVNAVkGVDLDFAR	   k7:	  Acetyl	  (+42.01)	  
Rv0831c_Rv0831c	   2	   AQVSSIVGLER	   	  
Rv0831c_Rv0831c	   2	   ELkHLLINDLPIER	   k3:	  Acetyl	  (+42.01)	  
Rv0884c_serC	   1	   SLHLTYGEFSAkFASAVSK	   k12:	  Acetyl	  (+42.01)	  
Rv0009_ppiA	   1	   TVANFVGLAQGTK	   	  
Rv3417c_groEL1	   1	   LAkLAGGVAVIK	   k3:	  Acetyl	  (+42.01)	  
Rv2882c_frr	   1	   DLDkTTHQYVTQIDELVK	   k4:	  Acetyl	  (+42.01)	  
Rv0231_fadE4	   2	   GVEkDTFFETVAR	   k4:	  Acetyl	  (+42.01)	  
Rv0231_fadE4	   2	   GVEkDTFFETVAR	   k4:	  Acetyl	  (+42.01)	  
Rv0363c_fba	   2	   DkLDSYVRPLLAISAQR	   k2:	  Acetyl	  (+42.01)	  
Rv0363c_fba	   2	   LRPDILAQGQQVAAAK	  
Rv0002_dnaN	   1	   ALPNkPVDVHVEGNR	   k5:	  Acetyl	  (+42.01)	  
Rv1488_Rv1488	   1	   NVVGGmTLEQTLTSR	   m6:	  Oxidation	  (+15.99)	  
Rv0489_gpm1	   1	   HYGALQGLDkAETK	   k10:	  Acetyl	  (+42.01)	  
Rv1463_Rv1463	   1	   YAESQHGGILLITHYTR	  
Rv1436_gap	   1	   GLmTTIHAYTQDQNLQDGPHkDLR	   m3:	  Oxidation	  
(+15.99),	  k21:	  Acetyl	  
(+42.01)	  
Rv0066c_icd2	   1	   IFYkDAFAK	   k4:	  Acetyl	  (+42.01)	  
Rv2244_acpM	   4	   IPDEDLAGLR	   	  
Rv2244_acpM	   4	   TVGDVVAYIQK	   	  
Rv2244_acpM	   4	   TVGDVVAYIQK	   	  
Rv2244_acpM	   4	   YGVkIPDEDLAGLR	   k4:	  Acetyl	  (+42.01)	  
Rv3804c_fbpA	   1	   VQFQSGGANSPALYLLDGLR	  
Rv1886c_fbpB	   1	   VQFQSGGNNSPAVYLLDGLR	  
Rv1379_pyrR	   1	   IAHQIIEkTALDDPVGPDAPR	   k8:	  Acetyl	  (+42.01)	  
Rv3457c_rpoA	   2	   NFGQkSIDEVK	   k5:	  Acetyl	  (+42.01)	  
Rv3457c_rpoA	   2	   TLVELFGLAR	   	  
Rv1308_atpA	   6	   AISLLLR	   	  
Rv1308_atpA	   6	   ALELQAPSVVHR	   	  
Rv1308_atpA	   6	   HVLIIFDDLTK	   	  
Rv1308_atpA	   6	   HVLIIFDDLTK	   	  
Rv1308_atpA	   6	   LTEVIkNFK	   k6:	  Acetyl	  (+42.01)	  
Rv1308_atpA	   6	   TGEVLSVPVGDGFLGR	  
Rv0005_gyrB	   1	   LLKDkDPNLTGDDIR	   k5:	  Acetyl	  (+42.01)	  
Rv2241_aceE	   2	   GYALGkHFEGR	   k6:	  Acetyl	  (+42.01)	  
Rv2241_aceE	   2	   TFkEVLR	   k3:	  Acetyl	  (+42.01)	  
Rv2476c_gdh	   5	   ASGQkDLATLSVAAR	   k5:	  Acetyl	  (+42.01)	  
Rv2476c_gdh	   5	   ASGQkDLATLSVAAR	   k5:	  Acetyl	  (+42.01)	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Rv2476c_gdh	   5	   ELEALPSEkEIAR	   k9:	  Acetyl	  (+42.01)	  
Rv2476c_gdh	   5	   LLPkVLADVQR	   k4:	  Acetyl	  (+42.01)	  
Rv2476c_gdh	   5	   LTDDDkLLVLAQAR	   k6:	  Acetyl	  (+42.01)	  
Rv3396c_guaA	   1	   LLFkDEVR	   k4:	  Acetyl	  (+42.01)	  
Rv3858c_gltD	   1	   ADPGGFLkYTHR	   k8:	  Acetyl	  (+42.01)	  
Rv0718_rpsH	   1	   LkANIAQILK	   k2:	  Acetyl	  (+42.01)	  
Rv3801c_fadD32	   2	   TGDYGTYFK	   	  
Rv3801c_fadD32	   2	   TGDYGTYFkDHLYIAGR	   k9:	  Acetyl	  (+42.01)	  
Rv3105c_prfB	   1	   VLQAkLLER	   k5:	  Acetyl	  (+42.01)	  
Rv2468c_Rv2468c	   1	   FAIYLGDLGR	   	  
Rv0716_rplE	   1	   SIAQFkLR	   k6:	  Acetyl	  (+42.01)	  
Rv1872c_lldD2	   2	   AIEILQTGVIR	   	  
Rv1872c_lldD2	   2	   DLAPLLQFNRPQFDTSkR	   k17:	  Acetyl	  (+42.01)	  
Rv0683_rpsG	   1	   TGTDPVITLkR	   k10:	  Acetyl	  (+42.01)	  
Rv2159c_Rv2159c	   1	   mKFVNHIEPVAPR	   m1:	  Oxidation	  
(+15.99),	  n-­‐term:	  
Acetyl	  (+42.01)	  
Rv2188c_pimB	   1	   kGQDTLVTALPSIR	   k1:	  Acetyl	  (+42.01)	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Table 4.13. Peptides Identified by Anti-Acetyl-Lysine Enrichment from 
∆Rv1151 (mtCobB) Hypoxia Trypsinized Lysate. 
Protein	  name	   Total	  
spectrum	  
count	  
Peptide	  sequence	   Variable	  modifications	  identified	  
by	  spectrum	  
Rv1308_atpA	   4	   GFAATGGGSVVPDEHVEALDED
KLAk	  
k26:	  Acetyl	  (+42.01)	  
Rv1308_atpA	   4	   HVLIIFDDLTK	   	  
Rv1308_atpA	   4	   LTEVIkNFK	   k6:	  Acetyl	  (+42.01)	  
Rv1308_atpA	   4	   TAVcVDTILNQR	   c4:	  Carbamidomethyl	  (+57.02)	  
Rv2940c_mas	   1	   LLTLGWQQR	   	  
Rv2462c_tig	   1	   YGQAVAESDVQPLGRPNIEVTK	  
Rv2145c_wag31	   2	   GSAAPVDSNADAGGFDQFNR	  
Rv2145c_wag31	   2	   TYLESQLEELGQR	   	  
Rv2220_glnA1	   2	   HYIGGLLHHAPSLLAFTNPTVNSYK	  
Rv2220_glnA1	   2	   SVFDDGLAFDGSSIR	   	  
Rv0384c_clpB	   1	   LQLQVSLPAK	   	  
Rv3699_Rv3699	   1	   AAVSkYWK	   k5:	  Acetyl	  (+42.01)	  
Rv0147_Rv0147	   1	   ITAALTkFR	   k7:	  Acetyl	  (+42.01)	  
Rv3029c_fixA	   2	   AVEEALQIR	   	  
Rv3029c_fixA	   2	   TNIVVLIK	   	  
Rv3800c_pks13	   4	   HSVYFTHGIR	   	  
Rv3800c_pks13	   4	   NWVGkAVGK	   k5:	  Acetyl	  (+42.01)	  
Rv3800c_pks13	   4	   TRGGYLkDIK	   k7:	  Acetyl	  (+42.01)	  
Rv3800c_pks13	   4	   YIKPGGEPIHDVEYWkK	   k16:	  Acetyl	  (+42.01)	  
Rv0957_purH	   1	   AGVTLYLTGAR	   	  
Rv1656_argF	   1	   ALLVWLLER	   	  
Rv0632c_echA3	   2	   GGFELAYR	   	  
Rv0632c_echA3	   2	   SAYQQATGLAK	   	  
Rv0704_rplB	   1	   SAGSSIQLLGK	   	  
Rv3592_mhuD	   2	   AHAVENSPGFLGFQLLRPVK	   	  
Rv3592_mhuD	   2	   INAIEVPAGAGPELEkR	   k16:	  Acetyl	  (+42.01)	  
Rv1310_atpD	   3	   FTQAGSEVSTLLGR	   	  
Rv1310_atpD	   3	   GVEVIDTGR	   	  
Rv1310_atpD	   3	   TISLQPTDGLVR	   	  
Rv3569c_hsaD	   1	   LSkFSVAPTR	   k3:	  Acetyl	  (+42.01)	  
Rv2391_sirA	   1	   DWGIAkFR	   k6:	  Acetyl	  (+42.01)	  
Rv2958c_Rv2958c	   1	   LSLSVSAR	   	  
Rv2996c_serA1	   2	   AQGINLIIHYVDRPGALGK	   	  
Rv2996c_serA1	   2	   TKPGVIIVNAAR	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Rv2385_mbtJ	   1	   AmTYVAQFIR	   m2:	  Oxidation	  (+15.99)	  
Rv0244c_fadE5	   1	   GLSLYFVPK	   	  
Rv1437_pgk	   1	   SVANLkDLLAEGVSGR	   k6:	  Acetyl	  (+42.01)	  
Rv1390_rpoZ	   1	   YALVIYAAK	   	  
Rv1827_garA	   1	   LVFLTGPK	   	  
Rv0859_fadA	   1	   LKPAFEGLAALGGFDDVALQkYH
WVEK	  
k21:	  Acetyl	  (+42.01)	  
Rv0810c_Rv0810c	   1	   ELkYSSPQTDFQR	   k3:	  Acetyl	  (+42.01)	  
Rv3283_sseA	   1	   SSHTWFVLTHLLGK	   	  
Rv0350_dnaK	   10	   AALGGSDISAIK	   	  
Rv0350_dnaK	   10	   DAGQIAGLNVLR	   	  
Rv0350_dnaK	   10	   IQEGSGLSkEDIDR	   k9:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   10	   ITQDLLDR	   	  
Rv0350_dnaK	   10	   KYTAPEISAR	   	  
Rv0350_dnaK	   10	   NQAETLVYQTEK	   	  
Rv0350_dnaK	   10	   NQAETLVYQTEKFVk	   k15:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   10	   NQAETLVYQTEkFVK	   k12:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   10	   VVDWLVDKFk	   k10:	  Acetyl	  (+42.01)	  
Rv0350_dnaK	   10	   YTAPEISAR	   	  
Rv0896_gltA2	   2	   LPGWIAHWR	   	  
Rv0896_gltA2	   2	   VYkNYDPR	   k3:	  Acetyl	  (+42.01)	  
Rv3489_Rv3489	   1	   SDHGEIGDVEPLADSTASQAR	  
Rv2429_ahpD	   2	   AALPEYAkDIK	   k8:	  Acetyl	  (+42.01)	  
Rv2429_ahpD	   2	   DIkLNLSSITR	   k3:	  Acetyl	  (+42.01)	  
Rv0489_gpm1	   1	   HYGALQGLDkAETK	   k10:	  Acetyl	  (+42.01)	  
Rv3747_Rv3747	   1	   LNVQGGVLSR	   	  
Rv3874_esxB	   2	   TDAATLAQEAGNFER	   	  
Rv3874_esxB	   2	   TQIDQVESTAGSLQGQWR	   	  
Rv0860_fadB	   7	   ANPDGAGVQPWDKk	   k14:	  Acetyl	  (+42.01)	  
Rv0860_fadB	   7	   GAGFYEYADGK	   	  
Rv0860_fadB	   7	   GYSEkLEAK	   k5:	  Acetyl	  (+42.01)	  
Rv0860_fadB	   7	   LEAkALER	   k4:	  Acetyl	  (+42.01)	  
Rv0860_fadB	   7	   LVAEkDSITGVVVASAK	   k5:	  Acetyl	  (+42.01)	  
Rv0860_fadB	   7	   LVAEkDSITGVVVASAK	   k5:	  Acetyl	  (+42.01)	  
Rv0860_fadB	   7	   TFFAGGDVK	   	  
Rv3028c_fixB	   1	   AAVDSGYYPGQFQVGQTGK	  
Rv0282_eccA3	   1	   LVVIIAGYR	   	  
Rv1483_fabG1	   1	   GIGLAIAQR	   	  
Rv0041_leuS	   1	   FVYPGPDGEVEVFQEFGkIGK	   k18:	  Acetyl	  (+42.01)	  
Rv2115c_mpa	   1	   EQLENAVGSHAPTR	   	  
Rv0247c_Rv0247c	   1	   LQQTQTPDLAVR	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Rv2986c_hupB	   2	   AELIDVLTQK	   	  
Rv2986c_hupB	   2	   AELIDVLTQkLGSDR	   k10:	  Acetyl	  (+42.01)	  
Rv0854_Rv0854	   1	   SQDGkYELTPK	   k5:	  Acetyl	  (+42.01)	  
Rv0569_Rv0569	   2	   FGAVQSAILHAR	   	  
Rv0569_Rv0569	   2	   GLIIEVR	   	  
Rv2524c_fas	   1	   GSQYAIAGTVR	   	  
Rv2785c_rpsO	   1	   GLLLLVGR	   	  
Rv3566c_nat	   2	   VASWYASTHPASkFVTGLTAAVI
TDDAR	  
k13:	  Acetyl	  (+42.01)	  
Rv3566c_nat	   2	   VASWYASTHPASkFVTGLTAAVI
TDDAR	  
k13:	  Acetyl	  (+42.01)	  
Rv0652_rplL	   3	   EAkDLVDGAPKPLLEK	   k3:	  Acetyl	  (+42.01)	  
Rv0652_rplL	   3	   EAkDLVDGAPKPLLEK	   k3:	  Acetyl	  (+42.01)	  
Rv0652_rplL	   3	   EIVSGLGLK	   	  
Rv0433_Rv0433	   1	   WAEFEGFVYDQKk	   k13:	  Acetyl	  (+42.01)	  
Rv0148_Rv0148	   2	   VALFGNDGANFDkPPSVQDVAA
R	  
k13:	  Acetyl	  (+42.01)	  
Rv0148_Rv0148	   2	   VHLYGGYHVLR	   	  
Rv0467_icl1	   1	   SAEQIQQEWDTNPR	   	  
Rv1133c_metE	   5	   EALGQGIPARPVIIGPITFLLLSK	  
Rv1133c_metE	   5	   SWLAFGAEK	   	  
Rv1133c_metE	   5	   TLVAGVVDGR	   	  
Rv1133c_metE	   5	   WAVGAFR	   	  
Rv1133c_metE	   5	   WFDTNYHYLVPEIGPSTTFTLHPGK	  
Rv1630_rpsA	   4	   AWGTIEALKEkDEAVK	   k11:	  Acetyl	  (+42.01)	  
Rv1630_rpsA	   4	   AWLEQTQSEVR	   	  
Rv1630_rpsA	   4	   GTVIEVVK	   	  
Rv1630_rpsA	   4	   RAWLEQTQSEVR	   	  
Rv0905_echA6	   1	   VVAPDAFFQFPTSkYGLALDNW
SIR	  
k14:	  Acetyl	  (+42.01)	  
Rv2783c_gpsI	   2	   DGLVHISkLGK	   k8:	  Acetyl	  (+42.01)	  
Rv2783c_gpsI	   2	   VEIADIDkR	   k8:	  Acetyl	  (+42.01)	  
Rv0824c_desA1	   1	   SVDPVELEkLR	   k9:	  Acetyl	  (+42.01)	  
Rv3628_ppa	   2	   DLEPGkFVK	   k6:	  Acetyl	  (+42.01)	  
Rv3628_ppa	   2	   HFFVHYkDLEPGK	   k7:	  Acetyl	  (+42.01)	  
Rv2460c_clpP2	   1	   ILTAEEAkDYGIIDTVLEYR	   k8:	  Acetyl	  (+42.01)	  
Rv0707_rpsC	   1	   AAGGEEAAPDAAAPVEAQSTES	  
Rv1886c_fbpB	   1	   VQFQSGGNNSPAVYLLDGLR	  
Rv2299c_htpG	   1	   DGQQQIFYATGETR	   	  
Rv0054_ssb	   1	   QTGEWkDGEALFLR	   k6:	  Acetyl	  (+42.01)	  
Rv3001c_ilvC	   1	   VGVIGYGSQGHAHSLSLR	   	  
Rv2031c_hspX	   5	   GILTVSVAVSEGKPTEK	   	  
  180 
Rv2031c_hspX	   5	   SEFAYGSFVR	   	  
Rv2031c_hspX	   5	   TEQkDFDGRSEFAYGSFVR	   k4:	  Acetyl	  (+42.01)	  
Rv2031c_hspX	   5	   TVSLPVGADEDDIKATYDK	   	  
Rv2031c_hspX	   5	   TVSLPVGADEDDIkATYDK	   k14:	  Acetyl	  (+42.01)	  
Rv2780_ald	   1	   HGQILFTFLHLAASR	   	  
Rv0155_pntAa	   1	   GGQTLIGFLAPR	   	  
Rv2699c_Rv2699c	   1	   RTETDDVSEDSLEELkAR	   k16:	  Acetyl	  (+42.01)	  
Rv0248c_Rv0248c	   2	   GQYAETEEEADQWLkDNDSAR	   k15:	  Acetyl	  (+42.01)	  
Rv0248c_Rv0248c	   2	   HSYDVVVIGAGGAGLR	   	  
Rv2467_pepN	   1	   FAVTQSGAAPGAGETR	   	  
Rv3596c_clpC1	   1	   SQVEEIIGQGQQAPSGHIPFTPR	  
Rv1658_argG	   1	   GFVYVHGLSSkLAAR	   k11:	  Acetyl	  (+42.01)	  
Rv3418c_groES	   13	   EKPQEGTVVAVGPGR	   	  
Rv3418c_groES	   13	   EKPQEGTVVAVGPGRWDEDGEK	  
Rv3418c_groES	   13	   ILVQANEAETTTASGLVIPDTAK	  
Rv3418c_groES	   13	   IPLDVAEGDTVIYSkYGGTEIK	   k15:	  Acetyl	  (+42.01)	  
Rv3418c_groES	   13	   RIPLDVAEGDTVIYSk	   k16:	  Acetyl	  (+42.01)	  
Rv3418c_groES	   13	   RIPLDVAEGDTVIYSK	   	  
Rv3418c_groES	   13	   RIPLDVAEGDTVIYSkYGGTEIK	   k16:	  Acetyl	  (+42.01)	  
Rv3418c_groES	   13	   VNIKPLEDK	   	  
Rv3418c_groES	   13	   VNIKPLEDkILVQANEAETTTASG
LVIPDTAK	  
k9:	  Acetyl	  (+42.01)	  
Rv3418c_groES	   13	   WDEDGEkRIPLDVAEGDTVIYSK	   k7:	  Acetyl	  (+42.01)	  
Rv3418c_groES	   13	   WDEDGEkRIPLDVAEGDTVIYSK	   k7:	  Acetyl	  (+42.01)	  
Rv3418c_groES	   13	   YNGEEYLILSAR	   	  
Rv3418c_groES	   13	   YNGEEYLILSAR	   	  
Rv1629_polA	   1	   FTPEAVVEkYGLTPR	   k9:	  Acetyl	  (+42.01)	  
Rv1240_mdh	   2	   ALNAVAADDVR	   	  
Rv1240_mdh	   2	   GASSAASAASATIDAAR	   	  
Rv1521_fadD25	   2	   DLLIVYGR	   	  
Rv1521_fadD25	   2	   SAAHGHPDILYLQYTSGSTR	   	  
Rv0379_secE2	   1	   SVYkVIDIIGTSPTSWEQAAAEAV
QR	  
k4:	  Acetyl	  (+42.01)	  
Rv3676_crp	   1	   LYIIISGK	   	  
Rv2839c_infB	   1	   GASLSDFADK	   	  
Rv0639_nusG	   1	   SKPGDWYVVHSYAGYENK	   	  
Rv3875_esxA	   1	   LAAAWGGSGSEAYQGVQQK	  
Rv1391_dfp	   1	   RkGcDLLVVNAVGEGR	   k2:	  Acetyl	  (+42.01),	  c4:	  
Carbamidomethyl	  (+57.02)	  
Rv0636_hadB	   1	   GAELVFNGR	   	  
Rv0046c_ino1	   1	   SEHQSLPAPEASTEVR	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Rv0951_sucC	   1	   AGGVkYAATPQDAYEHAK	   k5:	  Acetyl	  (+42.01)	  
Rv1201c_dapD	   1	   RGPVTVYGVDkFPR	   k11:	  Acetyl	  (+42.01)	  
Rv3852_hns	   1	   SAPPKPAEAPVSLQQR	   	  
Rv0702_rplD	   1	   QVLVVIGR	   	  
Rv1248c_Rv1248c	   1	   DFTEIkFR	   k6:	  Acetyl	  (+42.01)	  
Rv0009_ppiA	   1	   TVANFVGLAQGTK	   	  
Rv0296c_Rv0296c	   3	   ENLLIVHWHDLGR	   	  
Rv0296c_Rv0296c	   3	   ENLLIVHWHDLGR	   	  
Rv0296c_Rv0296c	   3	   ENLLIVHWHDLGR	   	  
Rv0706_rplV	   1	   TSHITVVVESR	   	  
Rv1925_fadD31	   2	   NIkYVGDLVAYR	   k3:	  Acetyl	  (+42.01)	  
Rv1925_fadD31	   2	   NIkYVGDLVAYR	   k3:	  Acetyl	  (+42.01)	  
Rv1596_nadC	   2	   ALQkYAVR	   k4:	  Acetyl	  (+42.01)	  
Rv1596_nadC	   2	   LGLGDAALIkDNHVAAAGSVVD
ALR	  
k10:	  Acetyl	  (+42.01)	  
Rv0685_tuf	   12	   AFDQIDNAPEER	   	  
Rv0685_tuf	   12	   ELLAAQEFDEDAPVVR	   	  
Rv0685_tuf	   12	   GITINIAHVEYQTDK	   	  
Rv0685_tuf	   12	   GITINIAHVEYQTDKR	   	  
Rv0685_tuf	   12	   GITINIAHVEYQTDKR	   	  
Rv0685_tuf	   12	   HTPFFNNYR	   	  
Rv0685_tuf	   12	   HTPFFNNYRPQFYFR	   	  
Rv0685_tuf	   12	   LLDQGQAGDNVGLLLR	   	  
Rv0685_tuf	   12	   PGTTTPHTEFEGQVYILSkDEGG
R	  
k19:	  Acetyl	  (+42.01)	  
Rv0685_tuf	   12	   TTLTAAITK	   	  
Rv0685_tuf	   12	   VLHDkFPDLNETK	   k5:	  Acetyl	  (+42.01)	  
Rv0685_tuf	   12	   VLHDkFPDLNETK	   k5:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   AGAATEVELkER	   k10:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   AGAATEVELkER	   k10:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   AGAATEVELkERK	   k10:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   DETTIVEGAGDTDAIAGR	   	  
Rv0440_groEL2	   33	   DETTIVEGAGDTDAIAGR	   	  
Rv0440_groEL2	   33	   DETTIVEGAGDTDAIAGR	   	  
Rv0440_groEL2	   33	   EIELEDPYEkIGAELVK	   k10:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   FDkGYISGYFVTDPER	   k3:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   GLNALADAVK	   	  
Rv0440_groEL2	   33	   GTFkSVAVK	   k4:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   GYISGYFVTDPER	   	  
Rv0440_groEL2	   33	   KTDDVAGDGTTTATVLAQALVR	  
Rv0440_groEL2	   33	   KVVVTkDETTIVEGAGDTDAIAG k6:	  Acetyl	  (+42.01)	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Rv0440_groEL2	   33	   LAGGVAVIK	   	  
Rv0440_groEL2	   33	   LAkLAGGVAVIK	   k3:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   NVAAGANPLGLK	   	  
Rv0440_groEL2	   33	   NVAAGANPLGLkR	   k12:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   QEIENSDSDYDREkLQER	   k14:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   qEIENSDSDYDREkLQER	   n-­‐term:	  Gln-­‐>pyro-­‐Glu	  (-­‐17.03),	  
k14:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   qEIENSDSDYDREkLQER	   n-­‐term:	  Gln-­‐>pyro-­‐Glu	  (-­‐17.03),	  
k14:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   QIAFNSGLEPGVVAEK	   	  
Rv0440_groEL2	   33	   qIAFNSGLEPGVVAEK	   n-­‐term:	  Gln-­‐>pyro-­‐Glu	  (-­‐17.03)	  
Rv0440_groEL2	   33	   qIAFNSGLEPGVVAEkVR	   n-­‐term:	  Gln-­‐>pyro-­‐Glu	  (-­‐17.03),	  
k16:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   qIAFNSGLEPGVVAEkVR	   n-­‐term:	  Gln-­‐>pyro-­‐Glu	  (-­‐17.03),	  
k16:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   QIAFNSGLEPGVVAEkVR	   k16:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   QIAFNSGLEPGVVAEkVR	   k16:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   SALQNAASIAGLFLTTEAVVADKPEK	  
Rv0440_groEL2	   33	   TDDVAGDGTTTATVLAQALVR	  
Rv0440_groEL2	   33	   VALEAPLK	   	  
Rv0440_groEL2	   33	   VSTVkDLLPLLEK	   k5:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   VTETLLK	   	  
Rv0440_groEL2	   33	   VTETLLkGAK	   k7:	  Acetyl	  (+42.01)	  
Rv0440_groEL2	   33	   VVVTkDETTIVEGAGDTDAIAGR	   k5:	  Acetyl	  (+42.01)	  
Rv3648c_cspA	   2	   TLEENQkVEFEIGHSPK	   k7:	  Acetyl	  (+42.01)	  
Rv3648c_cspA	   2	   VEFEIGHSPK	   	  
Rv3246c_mtrA	   1	   VEkDPENPTVVLTVR	   k3:	  Acetyl	  (+42.01)	  
Rv2246_kasB	   1	   YAINNSFGFGGHNVAIAFGR	  
Rv0157_pntB	   1	   GVPVkYAIHPVAGR	   k5:	  Acetyl	  (+42.01)	  
Rv2454c_Rv2454c	   1	   FPYYLETYGFHSIHGR	   	  
Rv3846_sodA	   1	   GANDAVAkLEEAR	   k8:	  Acetyl	  (+42.01)	  
Rv3270_ctpC	   2	   ASEWVDkLR	   k7:	  Acetyl	  (+42.01)	  
Rv3270_ctpC	   2	   ASEWVDkLRR	   k7:	  Acetyl	  (+42.01)	  
Rv3281_accE5	   1	   VSGTNEVSDGNETNNPAPVSR	  
Rv1015c_rplY	   1	   TIQHADLLVVR	   	  
Rv1837c_glcB	   2	   DELQAQIDkWHR	   k9:	  Acetyl	  (+42.01)	  
Rv1837c_glcB	   2	   GDLAAAVDkDGTAFLR	   k9:	  Acetyl	  (+42.01)	  
Rv0667_rpoB	   2	   GENIPEPGIPESFK	   	  
Rv0667_rpoB	   2	   GTFIINGTER	   	  
Rv1643_rplT	   1	   EQQLHSLNYAYR	   	  
Rv3581c_ispF	   1	   HVVVLITQHGYR	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Rv3274c_fadE25	   4	   DDEGFTVGPkER	   k10:	  Acetyl	  (+42.01)	  
Rv3274c_fadE25	   4	   EIAPHAAEVDEkAR	   k12:	  Acetyl	  (+42.01)	  
Rv3274c_fadE25	   4	   GSPTTELYFENcR	   c12:	  Carbamidomethyl	  (+57.02)	  
Rv3274c_fadE25	   4	   ITQIYEGTNQIQR	   	  
Rv0815c_cysA2	   4	   DFVDAQQFSkLLSER	   k10:	  Acetyl	  (+42.01)	  
Rv0815c_cysA2	   4	   SDEELAkLYADAGLDNSK	   k7:	  Acetyl	  (+42.01)	  
Rv0815c_cysA2	   4	   SSHTWFVLR	   	  
Rv0815c_cysA2	   4	   SSHTWFVLR	   	  
Rv1098c_fum	   1	   NILESFkLLTNVSR	   k7:	  Acetyl	  (+42.01)	  
Rv2971_Rv2971	   1	   TPAQVLLR	   	  
Rv3858c_gltD	   1	   ADPGGFLkYTHR	   k8:	  Acetyl	  (+42.01)	  
Rv2889c_tsf	   1	   AEGKPEQALPkIVEGR	   k11:	  Acetyl	  (+42.01)	  
Rv0873_fadE10	   1	   TEAFLVkLR	   k7:	  Acetyl	  (+42.01)	  
Rv2703_sigA	   2	   AmADQARTIR	   m2:	  Oxidation	  (+15.99)	  
Rv2703_sigA	   2	   AVEkFDYTK	   k4:	  Acetyl	  (+42.01)	  
Rv0831c_Rv0831c	   1	   AQVSSIVGLER	   	  
Rv0211_pckA	   3	   GNDWYFR	   	  
Rv0211_pckA	   3	   VFFVNWFR	   	  
Rv0211_pckA	   3	   VVFTDGSEEEFQR	   	  
Rv3417c_groEL1	   6	   AEIDKSDSDWDREkLGER	   k14:	  Acetyl	  (+42.01)	  
Rv3417c_groEL1	   6	   AEIDKSDSDWDREkLGER	   k14:	  Acetyl	  (+42.01)	  
Rv3417c_groEL1	   6	   EVGLEVLGSAR	   	  
Rv3417c_groEL1	   6	   LAGGVAVIK	   	  
Rv3417c_groEL1	   6	   LAkLAGGVAVIK	   k3:	  Acetyl	  (+42.01)	  
Rv3417c_groEL1	   6	   SDSDWDREkLGER	   k9:	  Acetyl	  (+42.01)	  
Rv0281_Rv0281	   1	   TkYFDEYFR	   k2:	  Acetyl	  (+42.01)	  
Rv0363c_fba	   1	   DkLDSYVRPLLAISAQR	   k2:	  Acetyl	  (+42.01)	  
Rv0002_dnaN	   1	   LLDAEFPkFR	   k8:	  Acetyl	  (+42.01)	  
Rv3692_moxR2	   2	   GATALLGTAR	   	  
Rv3692_moxR2	   2	   GHVLLEGVPGVAK	   	  
Rv1463_Rv1463	   3	   YAESQHGGILLITHYTR	   	  
Rv1463_Rv1463	   3	   YAESQHGGILLITHYTR	   	  
Rv1463_Rv1463	   3	   YIHPEYVHVFVGGR	   	  
Rv1636_TB15.3	   5	   AADILkDESYK	   k6:	  Acetyl	  (+42.01)	  
Rv1636_TB15.3	   5	   LIIASAYLPQHEDAR	   	  
Rv1636_TB15.3	   5	   LLGSVPANVSR	   	  
Rv1636_TB15.3	   5	   VDVLIVHTT	   	  
Rv1636_TB15.3	   5	   VTGTAPIYEILHDAkER	   k15:	  Acetyl	  (+42.01)	  
Rv0407_fgd1	   1	   GASIYDVPDGGVPVYIAAGGPAV
AkYAGR	  
k25:	  Acetyl	  (+42.01)	  
Rv3710_leuA	   2	   AIVHFYNSTSILQR	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Rv3710_leuA	   2	   cVEQAAkYPGTQWR	   c1:	  Carbamidomethyl	  (+57.02),	  
k7:	  Acetyl	  (+42.01)	  
Rv1479_moxR1	   2	   GHVLLEGVPGVAK	   	  
Rv1479_moxR1	   2	   SWVAFGASPR	   	  
Rv2954c_Rv2954c	   1	   HFHSIFYLR	   	  
Rv2244_acpM	   5	   IESENPDAVANVQAR	   	  
Rv2244_acpM	   5	   IESENPDAVANVQAR	   	  
Rv2244_acpM	   5	   IPDEDLAGLR	   	  
Rv2244_acpM	   5	   LEEENPEAAQALR	   	  
Rv2244_acpM	   5	   TVGDVVAYIQK	   	  
Rv0688_Rv0688	   1	   EFYDEkDIALR	   k6:	  Acetyl	  (+42.01)	  
Rv2711_ideR	   1	   LDQSGPTVSQTVSR	   	  
Rv3248c_sahH	   4	   GVPVFAWK	   	  
Rv3248c_sahH	   4	   GVTEETTTGVLR	   	  
Rv3248c_sahH	   4	   HSLIDGINR	   	  
Rv3248c_sahH	   4	   VLIcGYGDVGK	   c4:	  Carbamidomethyl	  (+57.02)	  
Rv3457c_rpoA	   4	   GYVPAVQNR	   	  
Rv3457c_rpoA	   4	   LHQLGLSLK	   	  
Rv3457c_rpoA	   4	   NFGQkSIDEVK	   k5:	  Acetyl	  (+42.01)	  
Rv3457c_rpoA	   4	   TLVELFGLAR	   	  
Rv2605c_tesB2	   1	   ASQQQVWLR	   	  
Rv0701_rplC	   1	   VNKPLTGQYTAAGVNPR	   	  
Rv2241_aceE	   2	   GYALGkHFEGR	   k6:	  Acetyl	  (+42.01)	  
Rv2241_aceE	   2	   TFkEVLR	   k3:	  Acetyl	  (+42.01)	  
Rv2476c_gdh	   1	   ASGQkDLATLSVAAR	   k5:	  Acetyl	  (+42.01)	  
Rv3396c_guaA	   1	   LLFkDEVR	   k4:	  Acetyl	  (+42.01)	  
Rv1475c_acn	   2	   GTLLLGVR	   	  
Rv1475c_acn	   2	   NYADVFkGDDRWR	   k7:	  Acetyl	  (+42.01)	  
Rv0154c_fadE2	   1	   AAWTIDQHGNkEAR	   k11:	  Acetyl	  (+42.01)	  
Rv0566c_Rv0566c	   1	   AAVDVFKEk	   k9:	  Acetyl	  (+42.01)	  
Rv0462_lpdC	   2	   ALPNEDADVSKEIEkQFK	   k15:	  Acetyl	  (+42.01)	  
Rv0462_lpdC	   2	   NEGYDVVVAkFPFTANAK	   k10:	  Acetyl	  (+42.01)	  
Rv0668_rpoC	   5	   DAGFYWATR	   	  
Rv0668_rpoC	   5	   DGLFcEkIFGPTR	   c5:	  Carbamidomethyl	  (+57.02),	  
k7:	  Acetyl	  (+42.01)	  
Rv0668_rpoC	   5	   DWEcYcGkYK	   c4:	  Carbamidomethyl	  (+57.02),	  
c6:	  Carbamidomethyl	  (+57.02),	  
k8:	  Acetyl	  (+42.01)	  
Rv0668_rpoC	   5	   LGYLLDLAPKDLEk	   k14:	  Acetyl	  (+42.01)	  
Rv0668_rpoC	   5	   TLKPEkDGLFcEK	   k6:	  Acetyl	  (+42.01),	  c11:	  
Carbamidomethyl	  (+57.02)	  
Rv3597c_lsr2	   1	   GRIPADVIDAYHAAT	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Rv3801c_fadD32	   1	   TGDYGTYFkDHLYIAGR	   k9:	  Acetyl	  (+42.01)	  
Rv2468c_Rv2468c	   1	   FAIYLGDLGR	   	  
Rv0716_rplE	   1	   SIAQFkLR	   k6:	  Acetyl	  (+42.01)	  
Rv0683_rpsG	   2	   TGTDPVITLkR	   k10:	  Acetyl	  (+42.01)	  
Rv0683_rpsG	   2	   WLVGYSR	   	  
Rv1002c_Rv1002c	   1	   QYQVQRPWLGTVR	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